WO2024044848A1 - Indazole derivatives as serotonergic agents useful for the treatment of disorders related thereto - Google Patents
Indazole derivatives as serotonergic agents useful for the treatment of disorders related thereto Download PDFInfo
- Publication number
- WO2024044848A1 WO2024044848A1 PCT/CA2023/051144 CA2023051144W WO2024044848A1 WO 2024044848 A1 WO2024044848 A1 WO 2024044848A1 CA 2023051144 W CA2023051144 W CA 2023051144W WO 2024044848 A1 WO2024044848 A1 WO 2024044848A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- independently selected
- compounds
- halo
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 157
- 208000035475 disorder Diseases 0.000 title claims abstract description 86
- 238000011282 treatment Methods 0.000 title claims description 69
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 title abstract 2
- 239000003762 serotonin receptor affecting agent Substances 0.000 title description 2
- 201000010099 disease Diseases 0.000 claims abstract description 71
- 238000000034 method Methods 0.000 claims abstract description 61
- 230000004913 activation Effects 0.000 claims abstract description 52
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims abstract description 48
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 43
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 36
- 208000020016 psychiatric disease Diseases 0.000 claims abstract description 27
- 208000015114 central nervous system disease Diseases 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 430
- 229910052731 fluorine Inorganic materials 0.000 claims description 118
- 229910052805 deuterium Inorganic materials 0.000 claims description 101
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 99
- 150000003839 salts Chemical class 0.000 claims description 87
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 77
- 125000005843 halogen group Chemical group 0.000 claims description 75
- 229910052801 chlorine Inorganic materials 0.000 claims description 68
- 125000001153 fluoro group Chemical group F* 0.000 claims description 68
- 229910052739 hydrogen Inorganic materials 0.000 claims description 65
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 57
- 239000012453 solvate Substances 0.000 claims description 48
- 239000000460 chlorine Substances 0.000 claims description 47
- 229910052760 oxygen Inorganic materials 0.000 claims description 43
- 229940002612 prodrug Drugs 0.000 claims description 42
- 239000000651 prodrug Substances 0.000 claims description 42
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 40
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 241000282414 Homo sapiens Species 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 37
- 150000001975 deuterium Chemical group 0.000 claims description 36
- 125000006712 (C1-C4) deuteroalkyl group Chemical group 0.000 claims description 33
- 125000004429 atom Chemical group 0.000 claims description 33
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 33
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 229910052717 sulfur Inorganic materials 0.000 claims description 30
- 229910020008 S(O) Inorganic materials 0.000 claims description 29
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 28
- 208000012902 Nervous system disease Diseases 0.000 claims description 27
- 229910052799 carbon Inorganic materials 0.000 claims description 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 26
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 25
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- 208000024891 symptom Diseases 0.000 claims description 23
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 21
- 229930195729 fatty acid Natural products 0.000 claims description 21
- 239000000194 fatty acid Substances 0.000 claims description 21
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 20
- 150000004665 fatty acids Chemical class 0.000 claims description 20
- 208000019901 Anxiety disease Diseases 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 19
- 208000025966 Neurological disease Diseases 0.000 claims description 18
- 125000003342 alkenyl group Chemical group 0.000 claims description 18
- 230000036506 anxiety Effects 0.000 claims description 16
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 14
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 14
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 13
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 13
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 231100000871 behavioral problem Toxicity 0.000 claims description 11
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims description 10
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 claims description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims description 10
- 125000000739 C2-C30 alkenyl group Chemical group 0.000 claims description 10
- 229940125797 compound 12 Drugs 0.000 claims description 10
- 239000011737 fluorine Substances 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 8
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 7
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 7
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 6
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 201000000980 schizophrenia Diseases 0.000 claims description 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 5
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims description 5
- 241000282465 Canis Species 0.000 claims description 5
- 235000021297 Eicosadienoic acid Nutrition 0.000 claims description 5
- 241000282324 Felis Species 0.000 claims description 5
- 229940126142 compound 16 Drugs 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 5
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 208000019116 sleep disease Diseases 0.000 claims description 5
- 208000011117 substance-related disease Diseases 0.000 claims description 5
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 4
- 206010012335 Dependence Diseases 0.000 claims description 4
- 208000030814 Eating disease Diseases 0.000 claims description 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 235000014632 disordered eating Nutrition 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 239000002539 nanocarrier Substances 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 3
- 208000019022 Mood disease Diseases 0.000 claims description 3
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims description 3
- 206010013663 drug dependence Diseases 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 208000022925 sleep disturbance Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 2
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 2
- 208000009575 Angelman syndrome Diseases 0.000 claims description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- 208000014912 Central Nervous System Infections Diseases 0.000 claims description 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 2
- 208000019749 Eye movement disease Diseases 0.000 claims description 2
- 208000026097 Factitious disease Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 206010057342 Onychophagia Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010036631 Presenile dementia Diseases 0.000 claims description 2
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 2
- 206010039966 Senile dementia Diseases 0.000 claims description 2
- 208000023906 Sexual and Gender disease Diseases 0.000 claims description 2
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 claims description 2
- 206010048327 Supranuclear palsy Diseases 0.000 claims description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 230000016571 aggressive behavior Effects 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 208000014679 binge eating disease Diseases 0.000 claims description 2
- 230000000669 biting effect Effects 0.000 claims description 2
- 208000027688 depersonalization disease Diseases 0.000 claims description 2
- 208000018459 dissociative disease Diseases 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 230000005032 impulse control Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 239000000693 micelle Substances 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 208000012268 mitochondrial disease Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 239000007908 nanoemulsion Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 208000028780 ocular motility disease Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 229940001470 psychoactive drug Drugs 0.000 claims description 2
- 239000004089 psychotropic agent Substances 0.000 claims description 2
- 230000003938 response to stress Effects 0.000 claims description 2
- 210000001525 retina Anatomy 0.000 claims description 2
- 238000006748 scratching Methods 0.000 claims description 2
- 230000002393 scratching effect Effects 0.000 claims description 2
- 230000035882 stress Effects 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 208000002271 trichotillomania Diseases 0.000 claims description 2
- XSXIVVZCUAHUJO-AVQMFFATSA-N (11e,14e)-icosa-11,14-dienoic acid Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCCC(O)=O XSXIVVZCUAHUJO-AVQMFFATSA-N 0.000 claims 2
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 208000009999 tuberous sclerosis Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 23
- 230000008569 process Effects 0.000 abstract description 9
- -1 C1-4fluoroalkyl Chemical group 0.000 description 115
- 210000004027 cell Anatomy 0.000 description 73
- 238000006243 chemical reaction Methods 0.000 description 71
- QVDSEJDULKLHCG-UHFFFAOYSA-N psilocybin Chemical compound C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 description 66
- 239000000243 solution Substances 0.000 description 58
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 46
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 42
- 230000001337 psychedelic effect Effects 0.000 description 38
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 36
- 125000006239 protecting group Chemical group 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 28
- 239000002904 solvent Substances 0.000 description 28
- 229910001868 water Inorganic materials 0.000 description 27
- 238000003786 synthesis reaction Methods 0.000 description 26
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 25
- GRVDJDISBSALJP-FIBGUPNXSA-N trideuterio($l^{1}-oxidanyl)methane Chemical compound [2H]C([2H])([2H])[O] GRVDJDISBSALJP-FIBGUPNXSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 241000700159 Rattus Species 0.000 description 22
- SPCIYGNTAMCTRO-UHFFFAOYSA-N psilocin Chemical compound C1=CC(O)=C2C(CCN(C)C)=CNC2=C1 SPCIYGNTAMCTRO-UHFFFAOYSA-N 0.000 description 22
- 239000003196 psychodysleptic agent Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 102000017911 HTR1A Human genes 0.000 description 19
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 19
- 238000003556 assay Methods 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 17
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 17
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 16
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 15
- 208000004547 Hallucinations Diseases 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 229910017711 NHRa Inorganic materials 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 101000783617 Homo sapiens 5-hydroxytryptamine receptor 2A Proteins 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- 210000003169 central nervous system Anatomy 0.000 description 13
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 12
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
- 239000012131 assay buffer Substances 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 12
- 101000822895 Homo sapiens 5-hydroxytryptamine receptor 1A Proteins 0.000 description 11
- 239000000556 agonist Substances 0.000 description 11
- 239000006143 cell culture medium Substances 0.000 description 11
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 230000009466 transformation Effects 0.000 description 10
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 230000003213 activating effect Effects 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- HNCVRGCNKZVUSU-SECBINFHSA-N tert-butyl (2r)-2-(methylsulfonyloxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1COS(C)(=O)=O HNCVRGCNKZVUSU-SECBINFHSA-N 0.000 description 9
- 239000007832 Na2SO4 Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000004743 Polypropylene Substances 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- 125000002009 alkene group Chemical group 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 230000003400 hallucinatory effect Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 210000001853 liver microsome Anatomy 0.000 description 8
- 229920001155 polypropylene Polymers 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 230000000862 serotonergic effect Effects 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 7
- 208000026251 Opioid-Related disease Diseases 0.000 description 7
- 239000000443 aerosol Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 150000002148 esters Chemical group 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000003653 radioligand binding assay Methods 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 238000000844 transformation Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 101150015707 HTR1A gene Proteins 0.000 description 6
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 6
- 229920002873 Polyethylenimine Polymers 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- 230000008484 agonism Effects 0.000 description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
- 239000000935 antidepressant agent Substances 0.000 description 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 230000009429 distress Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 6
- 229940097277 hygromycin b Drugs 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Chemical group O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 229960005322 streptomycin Drugs 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 5
- 206010012239 Delusion Diseases 0.000 description 5
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000001430 anti-depressive effect Effects 0.000 description 5
- 239000000164 antipsychotic agent Substances 0.000 description 5
- 229940005529 antipsychotics Drugs 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000007405 data analysis Methods 0.000 description 5
- 231100000868 delusion Toxicity 0.000 description 5
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 5
- 239000003292 glue Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 238000001671 psychotherapy Methods 0.000 description 5
- 238000013207 serial dilution Methods 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000012384 transportation and delivery Methods 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- CYEQSOYROKGJDA-UHFFFAOYSA-N 6-methoxy-1h-indazole Chemical compound COC1=CC=C2C=NNC2=C1 CYEQSOYROKGJDA-UHFFFAOYSA-N 0.000 description 4
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 4
- 208000007848 Alcoholism Diseases 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 description 4
- 101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- MDIGAZPGKJFIAH-UHFFFAOYSA-N Serotonin hydrochloride Chemical compound Cl.C1=C(O)C=C2C(CCN)=CNC2=C1 MDIGAZPGKJFIAH-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 239000003693 atypical antipsychotic agent Substances 0.000 description 4
- 229940127236 atypical antipsychotics Drugs 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 229960001259 diclofenac Drugs 0.000 description 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- XMHIUKTWLZUKEX-UHFFFAOYSA-N hexacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O XMHIUKTWLZUKEX-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 4
- 229960003081 probenecid Drugs 0.000 description 4
- 230000007958 sleep Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- XSXIVVZCUAHUJO-HZJYTTRNSA-N (11Z,14Z)-icosadienoic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCCC(O)=O XSXIVVZCUAHUJO-HZJYTTRNSA-N 0.000 description 3
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 3
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 3
- 108091005479 5-HT2 receptors Proteins 0.000 description 3
- CFMZDEQEVCDMRN-UHFFFAOYSA-N 6-fluoro-1h-indazole Chemical compound FC1=CC=C2C=NNC2=C1 CFMZDEQEVCDMRN-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 101150104779 HTR2A gene Proteins 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229910010084 LiAlH4 Inorganic materials 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 3
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 229960004538 alprazolam Drugs 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 150000007514 bases Chemical class 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 229940108924 conjugated linoleic acid Drugs 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000000380 hallucinogen Substances 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000000155 isotopic effect Effects 0.000 description 3
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229940057917 medium chain triglycerides Drugs 0.000 description 3
- 230000004630 mental health Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002385 psychotomimetic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229910052701 rubidium Inorganic materials 0.000 description 3
- NNNVXFKZMRGJPM-KHPPLWFESA-N sapienic acid Chemical compound CCCCCCCCC\C=C/CCCCC(O)=O NNNVXFKZMRGJPM-KHPPLWFESA-N 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 3
- UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- VOLGAXAGEUPBDM-UHFFFAOYSA-N $l^{1}-oxidanylethane Chemical compound CC[O] VOLGAXAGEUPBDM-UHFFFAOYSA-N 0.000 description 2
- SZQQHKQCCBDXCG-BAHYSTIISA-N (2e,4e,6e)-hexadeca-2,4,6-trienoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C(O)=O SZQQHKQCCBDXCG-BAHYSTIISA-N 0.000 description 2
- HPSWUFMMLKGKDS-DNKOKRCQSA-N (2e,4e,6e,8e,10e,12e)-tetracosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O HPSWUFMMLKGKDS-DNKOKRCQSA-N 0.000 description 2
- JXGVXCZADZNAMJ-LLVKDONJSA-N (2r)-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@H]1CCCN1C(=O)OCC1=CC=CC=C1 JXGVXCZADZNAMJ-LLVKDONJSA-N 0.000 description 2
- KXVFBCSUGDNXQF-DZDBOGACSA-N (2z,4z,6z,8z,10z)-tetracosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C=C/C(O)=O KXVFBCSUGDNXQF-DZDBOGACSA-N 0.000 description 2
- AVKOENOBFIYBSA-WMPRHZDHSA-N (4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O AVKOENOBFIYBSA-WMPRHZDHSA-N 0.000 description 2
- DQGMPXYVZZCNDQ-KBPWROHVSA-N (8E,10E,12Z)-octadecatrienoic acid Chemical compound CCCCC\C=C/C=C/C=C/CCCCCCC(O)=O DQGMPXYVZZCNDQ-KBPWROHVSA-N 0.000 description 2
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 description 2
- MMJZTSLHOIGZPU-DOFZRALJSA-N (9Z,12Z,15Z,18Z)-tetracosatetraenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O MMJZTSLHOIGZPU-DOFZRALJSA-N 0.000 description 2
- NPTIBOCVSPURCS-JLNKQSITSA-N (9Z,12Z,15Z,18Z,21Z)-tetracosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O NPTIBOCVSPURCS-JLNKQSITSA-N 0.000 description 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 2
- IQDGSYLLQPDQDV-TXHXQZCNSA-N 1,1,1-trideuterio-n-(trideuteriomethyl)methanamine;hydrochloride Chemical compound Cl.[2H]C([2H])([2H])NC([2H])([2H])[2H] IQDGSYLLQPDQDV-TXHXQZCNSA-N 0.000 description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- GBWMWHHLQDBPFP-UHFFFAOYSA-N 2-(thian-2-yloxy)thiane Chemical compound S1CCCCC1OC1SCCCC1 GBWMWHHLQDBPFP-UHFFFAOYSA-N 0.000 description 2
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 2
- OQOCQFSPEWCSDO-JLNKQSITSA-N 6Z,9Z,12Z,15Z,18Z-Heneicosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O OQOCQFSPEWCSDO-JLNKQSITSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 235000021357 Behenic acid Nutrition 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000006561 Cluster Headache Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 2
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000021353 Lignoceric acid Nutrition 0.000 description 2
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 229910003204 NH2 Inorganic materials 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010057852 Nicotine dependence Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 2
- 241000720974 Protium Species 0.000 description 2
- 241001237914 Psilocybe Species 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 208000025569 Tobacco Use disease Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000004479 aerosol dispenser Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000000049 anti-anxiety effect Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229940116226 behenic acid Drugs 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000007177 brain activity Effects 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- 125000005879 dioxolanyl group Chemical group 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 2
- PRHHYVQTPBEDFE-UHFFFAOYSA-N eicosatrienoic acid Natural products CCCCCC=CCC=CCCCCC=CCCCC(O)=O PRHHYVQTPBEDFE-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- OQOCQFSPEWCSDO-UHFFFAOYSA-N heneicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCC(O)=O OQOCQFSPEWCSDO-UHFFFAOYSA-N 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 102000044222 human HTR2A Human genes 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 229960005417 ketanserin Drugs 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 229960001632 labetalol Drugs 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 239000000472 muscarinic agonist Substances 0.000 description 2
- 239000003149 muscarinic antagonist Substances 0.000 description 2
- 235000021288 n-6 DPA Nutrition 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 230000003227 neuromodulating effect Effects 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000181 nicotinic agonist Substances 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 2
- 229940033080 omega-6 fatty acid Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000003891 oxalate salts Chemical class 0.000 description 2
- 238000002638 palliative care Methods 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 229960000697 propantheline Drugs 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 229910052705 radium Inorganic materials 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000002399 serotonin 2A agonist Substances 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- BFFLLBPMZCIGRM-MRVPVSSYSA-N tert-butyl (2r)-2-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1CO BFFLLBPMZCIGRM-MRVPVSSYSA-N 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical group C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- GKJZMAHZJGSBKD-NMMTYZSQSA-N (10E,12Z)-octadecadienoic acid Chemical compound CCCCC\C=C/C=C/CCCCCCCCC(O)=O GKJZMAHZJGSBKD-NMMTYZSQSA-N 0.000 description 1
- HVGRZDASOHMCSK-HZJYTTRNSA-N (13Z,16Z)-docosadienoic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCCCCC(O)=O HVGRZDASOHMCSK-HZJYTTRNSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- KRVOJOCLBAAKSJ-RDTXWAMCSA-N (2R,3R)-nemonapride Chemical compound C1=C(Cl)C(NC)=CC(OC)=C1C(=O)N[C@H]1[C@@H](C)N(CC=2C=CC=CC=2)CC1 KRVOJOCLBAAKSJ-RDTXWAMCSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BBWMTEYXFFWPIF-CJBMEHDJSA-N (2e,4e,6e)-icosa-2,4,6-trienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C=C\C(O)=O BBWMTEYXFFWPIF-CJBMEHDJSA-N 0.000 description 1
- JXGVXCZADZNAMJ-NSHDSACASA-N (2s)-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1=CC=CC=C1 JXGVXCZADZNAMJ-NSHDSACASA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- VENRYLMOFDSSDJ-WMPRHZDHSA-N (6Z,9Z,12Z,15Z,18Z)-tetracosapentaenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O VENRYLMOFDSSDJ-WMPRHZDHSA-N 0.000 description 1
- YHGJECVSSKXFCJ-KUBAVDMBSA-N (6Z,9Z,12Z,15Z,18Z,21Z)-tetracosahexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O YHGJECVSSKXFCJ-KUBAVDMBSA-N 0.000 description 1
- TWSWSIQAPQLDBP-CGRWFSSPSA-N (7e,10e,13e,16e)-docosa-7,10,13,16-tetraenoic acid Chemical compound CCCCC\C=C\C\C=C\C\C=C\C\C=C\CCCCCC(O)=O TWSWSIQAPQLDBP-CGRWFSSPSA-N 0.000 description 1
- OYHQOLUKZRVURQ-KQHSAVHASA-N (9Z,12E)-octadecadienoic acid Chemical compound CCCCC\C=C\C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-KQHSAVHASA-N 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 1
- HVGRZDASOHMCSK-UHFFFAOYSA-N (Z,Z)-13,16-docosadienoic acid Natural products CCCCCC=CCC=CCCCCCCCCCCCC(O)=O HVGRZDASOHMCSK-UHFFFAOYSA-N 0.000 description 1
- PXUIZULXJVRBPC-UHFFFAOYSA-N 1'-[3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl]hexahydro-2H-spiro[imidazo[1,2-a]pyridine-3,4'-piperidin]-2-one Chemical compound C12=CC(Cl)=CC=C2CCC2=CC=CC=C2N1CCCN1CCC2(C(NC3CCCCN32)=O)CC1 PXUIZULXJVRBPC-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- DKMFBWQBDIGMHM-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)-1-butanone Chemical compound C1CC(C)CCN1CCCC(=O)C1=CC=C(F)C=C1 DKMFBWQBDIGMHM-UHFFFAOYSA-N 0.000 description 1
- MDLAAYDRRZXJIF-UHFFFAOYSA-N 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol Chemical compound C1CC(O)(C=2C=C(C(Cl)=CC=2)C(F)(F)F)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 MDLAAYDRRZXJIF-UHFFFAOYSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FEBOTPHFXYHVPL-UHFFFAOYSA-N 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl]-1H-benzimidazol-2-one Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 FEBOTPHFXYHVPL-UHFFFAOYSA-N 0.000 description 1
- GUJRSXAPGDDABA-NSHDSACASA-N 3-bromo-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2,6-dimethoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC GUJRSXAPGDDABA-NSHDSACASA-N 0.000 description 1
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
- WCIBOXFOUGQLFC-UHFFFAOYSA-N 4-[4-(4-fluorobenzoyl)piperidin-1-yl]-1-(4-fluorophenyl)butan-1-one Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(C(=O)C=2C=CC(F)=CC=2)CC1 WCIBOXFOUGQLFC-UHFFFAOYSA-N 0.000 description 1
- 102000035038 5-HT1 receptors Human genes 0.000 description 1
- 108091005478 5-HT1 receptors Proteins 0.000 description 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- QOYHHIBFXOOADH-UHFFFAOYSA-N 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 QOYHHIBFXOOADH-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- AHANXAKGNAKFSK-UHFFFAOYSA-N Bishomo-a-linolenic acid Natural products CCC=CCC=CCC=CCCCCCCCCCC(O)=O AHANXAKGNAKFSK-UHFFFAOYSA-N 0.000 description 1
- XVGOZDAJGBALKS-UHFFFAOYSA-N Blonanserin Chemical compound C1CN(CC)CCN1C1=CC(C=2C=CC(F)=CC=2)=C(CCCCCC2)C2=N1 XVGOZDAJGBALKS-UHFFFAOYSA-N 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 208000000003 Breakthrough pain Diseases 0.000 description 1
- RKLNONIVDFXQRX-UHFFFAOYSA-N Bromperidol Chemical compound C1CC(O)(C=2C=CC(Br)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 RKLNONIVDFXQRX-UHFFFAOYSA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- 208000011597 CGF1 Diseases 0.000 description 1
- 101150038243 CLOCK gene Proteins 0.000 description 1
- CTAOSMMOOBZDEK-UHFFFAOYSA-N CN(C)C.C1(CCCCC1)NC1CCCCC1 Chemical compound CN(C)C.C1(CCCCC1)NC1CCCCC1 CTAOSMMOOBZDEK-UHFFFAOYSA-N 0.000 description 1
- DQGMPXYVZZCNDQ-UVZPLDOLSA-N Calendinsaeure Natural products CCCCCC=C/C=C/C=C/CCCCCCC(=O)O DQGMPXYVZZCNDQ-UVZPLDOLSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- KAAZGXDPUNNEFN-UHFFFAOYSA-N Clotiapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2SC2=CC=C(Cl)C=C12 KAAZGXDPUNNEFN-UHFFFAOYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
- 208000025967 Dissociative Identity disease Diseases 0.000 description 1
- 235000021292 Docosatetraenoic acid Nutrition 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 206010066392 Fear of death Diseases 0.000 description 1
- 208000001836 Firesetting Behavior Diseases 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000004230 Gender Dysphoria Diseases 0.000 description 1
- 208000029810 Gender identity disease Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019070 Hallucination, auditory Diseases 0.000 description 1
- 206010019075 Hallucination, visual Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000003698 Heroin Dependence Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- XSXIVVZCUAHUJO-UHFFFAOYSA-N Homo-gamma-linoleic acid Natural products CCCCCC=CCC=CCCCCCCCCCC(O)=O XSXIVVZCUAHUJO-UHFFFAOYSA-N 0.000 description 1
- 101150013372 Htr2c gene Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- RLJFTICUTYVZDG-UHFFFAOYSA-N Methiothepine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2CC1N1CCN(C)CC1 RLJFTICUTYVZDG-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- JTVPZMFULRWINT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC JTVPZMFULRWINT-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- XCWPUUGSGHNIDZ-UHFFFAOYSA-N Oxypertine Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(C)=C1CCN(CC1)CCN1C1=CC=CC=C1 XCWPUUGSGHNIDZ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 206010033888 Paraphilia Diseases 0.000 description 1
- 206010034158 Pathological gambling Diseases 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000012545 Psychophysiologic disease Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- UNRHXEPDKXPRTM-UHFFFAOYSA-N Sultopride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=CC=C1OC UNRHXEPDKXPRTM-UHFFFAOYSA-N 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 206010043087 Tachyphylaxis Diseases 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
- 206010043903 Tobacco abuse Diseases 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 235000021322 Vaccenic acid Nutrition 0.000 description 1
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 description 1
- PBHFNBQPZCRWQP-QUCCMNQESA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-phenylcarbamate Chemical compound CN([C@@H]1[C@@](C2=C3)(C)CCN1C)C2=CC=C3OC(=O)NC1=CC=CC=C1 PBHFNBQPZCRWQP-QUCCMNQESA-N 0.000 description 1
- QOKMIHKIMQNRES-UHFFFAOYSA-L [Cl-].[Cl-].[Cr++]Cc1ccccc1 Chemical compound [Cl-].[Cl-].[Cr++]Cc1ccccc1 QOKMIHKIMQNRES-UHFFFAOYSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960000276 acetophenazine Drugs 0.000 description 1
- WNTYBHLDCKXEOT-UHFFFAOYSA-N acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000012826 adjustment disease Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- TWSWSIQAPQLDBP-UHFFFAOYSA-N adrenic acid Natural products CCCCCC=CCC=CCC=CCC=CCCCCCC(O)=O TWSWSIQAPQLDBP-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- HQPCSDADVLFHHO-LTKCOYKYSA-N all-cis-8,11,14,17-icosatetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HQPCSDADVLFHHO-LTKCOYKYSA-N 0.000 description 1
- TWSWSIQAPQLDBP-DOFZRALJSA-N all-cis-docosa-7,10,13,16-tetraenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O TWSWSIQAPQLDBP-DOFZRALJSA-N 0.000 description 1
- JIWBIWFOSCKQMA-LTKCOYKYSA-N all-cis-octadeca-6,9,12,15-tetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O JIWBIWFOSCKQMA-LTKCOYKYSA-N 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960003036 amisulpride Drugs 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 208000024823 antisocial personality disease Diseases 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005245 asenapine Drugs 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002430 atomoxetine Drugs 0.000 description 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229960002507 benperidol Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229950002871 blonanserin Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 description 1
- 229960001210 brexpiprazole Drugs 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229960004037 bromperidol Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 229960000608 butaperazine Drugs 0.000 description 1
- DVLBYTMYSMAKHP-UHFFFAOYSA-N butaperazine Chemical compound C12=CC(C(=O)CCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 DVLBYTMYSMAKHP-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 229950009852 carfenazine Drugs 0.000 description 1
- XZSMZRXAEFNJCU-UHFFFAOYSA-N carfenazine Chemical compound C12=CC(C(=O)CC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 XZSMZRXAEFNJCU-UHFFFAOYSA-N 0.000 description 1
- 229960005123 cariprazine Drugs 0.000 description 1
- KPWSJANDNDDRMB-QAQDUYKDSA-N cariprazine Chemical compound C1C[C@@H](NC(=O)N(C)C)CC[C@@H]1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 KPWSJANDNDDRMB-QAQDUYKDSA-N 0.000 description 1
- 229960000700 carpipramine Drugs 0.000 description 1
- NWPJLRSCSQHPJV-UHFFFAOYSA-N carpipramine Chemical compound C1CN(CCCN2C3=CC=CC=C3CCC3=CC=CC=C32)CCC1(C(=O)N)N1CCCCC1 NWPJLRSCSQHPJV-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960003030 chlorproethazine Drugs 0.000 description 1
- DBOUGBAQLIXZLV-UHFFFAOYSA-N chlorproethazine Chemical compound C1=C(Cl)C=C2N(CCCN(CC)CC)C3=CC=CC=C3SC2=C1 DBOUGBAQLIXZLV-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001552 chlorprothixene Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229950001534 clocapramine Drugs 0.000 description 1
- QAZKXHSIKKNOHH-UHFFFAOYSA-N clocapramine Chemical compound C1CN(CCCN2C3=CC(Cl)=CC=C3CCC3=CC=CC=C32)CCC1(C(=O)N)N1CCCCC1 QAZKXHSIKKNOHH-UHFFFAOYSA-N 0.000 description 1
- 229960001184 clopenthixol Drugs 0.000 description 1
- XRYLGRGAWQSVQW-UHFFFAOYSA-N clorotepine Chemical compound C1CN(C)CCN1C1C2=CC(Cl)=CC=C2SC2=CC=CC=C2C1 XRYLGRGAWQSVQW-UHFFFAOYSA-N 0.000 description 1
- 229950011192 clorotepine Drugs 0.000 description 1
- 229960003864 clotiapine Drugs 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000010492 cognitive-emotional process Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960004278 cyamemazine Drugs 0.000 description 1
- SLFGIOIONGJGRT-UHFFFAOYSA-N cyamemazine Chemical compound C1=C(C#N)C=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 SLFGIOIONGJGRT-UHFFFAOYSA-N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000005345 deuteroalkyl group Chemical group 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical class CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005303 dithiazolyl group Chemical group S1SNC(=C1)* 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 229960005146 dixyrazine Drugs 0.000 description 1
- MSYUMPGNGDNTIQ-UHFFFAOYSA-N dixyrazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC(C)CN1CCN(CCOCCO)CC1 MSYUMPGNGDNTIQ-UHFFFAOYSA-N 0.000 description 1
- QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 1
- CVCXSNONTRFSEH-UHFFFAOYSA-N docosa-2,4-dienoic acid Chemical compound CCCCCCCCCCCCCCCCCC=CC=CC(O)=O CVCXSNONTRFSEH-UHFFFAOYSA-N 0.000 description 1
- KFEVDPWXEVUUMW-UHFFFAOYSA-N docosanoic acid Natural products CCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 KFEVDPWXEVUUMW-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960005220 fluanisone Drugs 0.000 description 1
- IRYFCWPNDIUQOW-UHFFFAOYSA-N fluanisone Chemical compound COC1=CC=CC=C1N1CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 IRYFCWPNDIUQOW-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002419 flupentixol Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960003532 fluspirilene Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229960003162 iloperidone Drugs 0.000 description 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 150000002473 indoazoles Chemical class 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 206010023461 kleptomania Diseases 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229950008108 lenperone Drugs 0.000 description 1
- 229960004145 levosulpiride Drugs 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229960000423 loxapine Drugs 0.000 description 1
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960001432 lurasidone Drugs 0.000 description 1
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002582 magnetoencephalography Methods 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229960001861 melperone Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 229960000300 mesoridazine Drugs 0.000 description 1
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229940042053 methotrimeprazine Drugs 0.000 description 1
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229950006793 metitepine Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960004938 molindone Drugs 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- 229960000758 moperone Drugs 0.000 description 1
- AGAHNABIDCTLHW-UHFFFAOYSA-N moperone Chemical compound C1=CC(C)=CC=C1C1(O)CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 AGAHNABIDCTLHW-UHFFFAOYSA-N 0.000 description 1
- 229960003894 mosapramine Drugs 0.000 description 1
- 208000027881 multiple personality disease Diseases 0.000 description 1
- 239000000359 muscarinic M1 receptor agonist Substances 0.000 description 1
- 239000003683 muscarinic M2 receptor antagonist Substances 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- YWWVWXASSLXJHU-WAYWQWQTSA-N myristoleic acid Chemical compound CCCC\C=C/CCCCCCCC(O)=O YWWVWXASSLXJHU-WAYWQWQTSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229950011108 nemonapride Drugs 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 201000000988 opioid abuse Diseases 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960002841 oxypertine Drugs 0.000 description 1
- 229960001057 paliperidone Drugs 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000024817 paranoid personality disease Diseases 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960004505 penfluridol Drugs 0.000 description 1
- 229960002195 perazine Drugs 0.000 description 1
- WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 1
- 229960000769 periciazine Drugs 0.000 description 1
- LUALIOATIOESLM-UHFFFAOYSA-N periciazine Chemical compound C1CC(O)CCN1CCCN1C2=CC(C#N)=CC=C2SC2=CC=CC=C21 LUALIOATIOESLM-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229950004193 perospirone Drugs 0.000 description 1
- GTAIPSDXDDTGBZ-OYRHEFFESA-N perospirone Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCN3C(=O)[C@@H]4CCCC[C@@H]4C3=O)=NSCC2=C1 GTAIPSDXDDTGBZ-OYRHEFFESA-N 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000000272 proprioceptive effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 201000004645 pyromania Diseases 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000000029 referred pain Diseases 0.000 description 1
- 229960003448 remoxipride Drugs 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 1
- 229960000652 sertindole Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000004039 social cognition Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000000956 solid--liquid extraction Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 229950010000 sulforidazine Drugs 0.000 description 1
- FLGCRGJDQJIJAW-UHFFFAOYSA-N sulforidazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)(=O)=O)=CC=C2SC2=CC=CC=C21 FLGCRGJDQJIJAW-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 229960004724 sultopride Drugs 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- QZZGJDVWLFXDLK-UHFFFAOYSA-N tetracosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(O)=O QZZGJDVWLFXDLK-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000004589 thienofuryl group Chemical group O1C(=CC2=C1C=CS2)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001730 thiiranyl group Chemical group 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- ZCAGUOCUDGWENZ-UHFFFAOYSA-N thiomorpholinyl sulfoxide group Chemical group N1(CCSCC1)S(=O)N1CCSCC1 ZCAGUOCUDGWENZ-UHFFFAOYSA-N 0.000 description 1
- 229960004728 thiopropazate Drugs 0.000 description 1
- AIUHRQHVWSUTGJ-UHFFFAOYSA-N thiopropazate Chemical compound C1CN(CCOC(=O)C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 AIUHRQHVWSUTGJ-UHFFFAOYSA-N 0.000 description 1
- 229960003397 thioproperazine Drugs 0.000 description 1
- VZYCZNZBPPHOFY-UHFFFAOYSA-N thioproperazine Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 VZYCZNZBPPHOFY-UHFFFAOYSA-N 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960005344 tiapride Drugs 0.000 description 1
- 229950000809 timiperone Drugs 0.000 description 1
- YDLQKLWVKKFPII-UHFFFAOYSA-N timiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(N2C(NC3=CC=CC=C32)=S)CC1 YDLQKLWVKKFPII-UHFFFAOYSA-N 0.000 description 1
- 229960005013 tiotixene Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- LKOVPWSSZFDYPG-WUKNDPDISA-N trans-octadec-2-enoic acid Chemical compound CCCCCCCCCCCCCCC\C=C\C(O)=O LKOVPWSSZFDYPG-WUKNDPDISA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000018726 traumatic encephalopathy Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- WCYWZMWISLQXQU-FIBGUPNXSA-N trideuteriomethane Chemical compound [2H][C]([2H])[2H] WCYWZMWISLQXQU-FIBGUPNXSA-N 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
- 229960002341 trifluperidol Drugs 0.000 description 1
- GPMXUUPHFNMNDH-UHFFFAOYSA-N trifluperidol Chemical compound C1CC(O)(C=2C=C(C=CC=2)C(F)(F)F)CCN1CCCC(=O)C1=CC=C(F)C=C1 GPMXUUPHFNMNDH-UHFFFAOYSA-N 0.000 description 1
- 229960003904 triflupromazine Drugs 0.000 description 1
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- RYJXBGGBZJGVQF-UHFFFAOYSA-N veralipride Chemical compound COC1=CC(S(N)(=O)=O)=CC(C(=O)NCC2N(CCC2)CC=C)=C1OC RYJXBGGBZJGVQF-UHFFFAOYSA-N 0.000 description 1
- 229960001968 veralipride Drugs 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1
- 229960004496 zotepine Drugs 0.000 description 1
- 229960004141 zuclopenthixol Drugs 0.000 description 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Definitions
- Mental health disorders refer to a wide range of disorders that include, but are not limited to, depressive disorders, anxiety and panic disorders, schizophrenia, eating disorders, substance misuse disorders, post-traumatic stress disorder, attention deficit/hyperactivity disorder and obsessive-compulsive disorder.
- Many mental health disorders, as well as neurological disorders are impacted by alterations, dysfunction, degeneration, and/or damage to the brain’s serotonergic system, which may explain, in part, common endophenotypes and comorbidities among neuropsychiatric and neurological diseases.
- the field of psychedelic neuroscience has witnessed a recent renaissance following decades of restricted research due to their legal status.
- Psychedelics are powerful psychoactive substances that alter perception and mood and affect numerous cognitive processes.
- Psychedelics have both rapid onset and persisting effects long after their acute effects, which includes changes in mood and brain function. Long lasting effects may result from their unique receptor affinities, which affect neurotransmission via neuromodulatory systems that serve to modulate brain activity, i.e., neuroplasticity, and promote cell survival, are neuroprotective, and modulate brain neuroimmune systems.
- psychedelic drugs may potentially provide the next-generation of neurotherapeutics, where treatment resistant psychiatric and neurological diseases, e.g., depression, post-traumatic stress disorder, dementia and addiction, may become treatable with attenuated pharmacological risk profiles.
- treatment resistant psychiatric and neurological diseases e.g., depression, post-traumatic stress disorder, dementia and addiction
- attenuated pharmacological risk profiles e.g., depression, post-traumatic stress disorder, dementia and addiction
- psychedelic drugs are dangerous, from a physiologic safety standpoint, they are one of the safest known classes of CNS drugs.
- Preliminary data show that psychedelic administration in humans results in a unique profile of effects and potential adverse reactions that need to be appropriately addressed to maximize safety.
- psilocybin In humans as well as other mammals, psilocybin is transformed into the active metabolite psilocin, or 4-hydroxy-N,N-dimethyltryptamine. It is likely that psilocin partially or wholly produces most of the subjective and physiological effects of psilocybin in humans and non-human animals. Recently, human psilocybin research confirmed the 5- HT2A activity of psilocybin and psilocin, and provides some support for indirect effects on dopamine through 5-HT2A activity and possible activity at other serotonin receptors. In fact, the most consistent finding for involvement of other receptors in the actions of psychedelics is the 5-HT1A receptor.
- 5-HT1A receptors are colocalized with 5-HT2A receptors on cortical pyramidal cells [Mart ⁇ n-Ruiz et al. J Neurosci. 2001, 21(24):9856–986], where the two receptor types have opposing functional effects [Araneda et al. Neuroscience 1991, 40(2):399–412].
- 5-HT2A receptor plays an important role in emotional responses and is an important target to be considered in the actions of 5-HT2A agonist psychedelics.
- 5-HT2A agonists produce hallucinogenic effects in humans, and rodents generalize from one 5-HT2A agonist to others, as between psilocybin and LSD [Aghajanian et al., Eur J Pharmacol., 1999, 367(2-3):197–206; Nichols at al., J Neurochem., 2004, 90(3):576–584].
- Psilocybin has a stronger affinity for the human 5-HT2A receptor than for the rat receptor and it has a lower K(i) for both 5-HT2A and 5-HT2C receptors than LSD. Moreover, results from a series of drug-discrimination studies in rats found that 5HT2A antagonists, and not 5-HT1A antagonists, prevented rats from recognizing psilocybin [Winter et al., Pharmacol Biochem Behav., 2007, 87(4):472–480]. Daily doses of LSD and psilocybin reduce 5-HT2 receptor density in rat brain.
- 5-HT2A agonism is widely recognized as the primary action of classic psychedelic agents
- psilocybin has lesser affinity for a wide range of other pre- and post-synaptic serotonin and dopamine receptors, as well as the serotonin reuptake transporter [Tyls et al., Eur. Neuropsychopharmacol., 2014, 24(3):342–356].
- Psilocybin activates 5-HT1A receptors, which may contribute to antidepressant/anti-anxiety effects.
- Depression and anxiety are two of the most common psychiatric disorders worldwide.
- Depression is a multifaceted condition characterized by episodes of mood disturbances alongside other symptoms such as anhedonia, psychomotor complaints, feelings of guilt, attentional deficits and suicidal tendencies, all of which can range in severity.
- anxiety disorders are a collective of etiologically complex disorders characterized by intense psychosocial distress and other symptoms depending on the subtype.
- Anxiety associated with life-threatening disease is the only anxiety subtype that has been studied in terms of psychedelic-assisted therapy.
- Pharmacological and psychosocial interventions are commonly used to manage this type of anxiety, but their efficacy is mixed and limited such that they often fail to provide satisfactory emotional relief.
- psychedelic-assisted therapy may represent a promising alternative for patients with depression and anxiety that are ineffectively managed by conventional methods.
- the psychedelic treatment model consists of administering the orally-active drug to induce a mystical experience lasting 4-9 h depending on the psychedelic [Halberstadt, Behav Brain Res., 2015, 277:99-120; Nichols, Pharmacol Rev., 2016, 68(2): 264-355]. This enables participants to work through and integrate difficult feelings and situations, leading to enduring anti-depressant and anxiolytic effects.
- Classical psychedelics like psilocybin and LSD are being studied as potential candidates.
- Psychedelic treatment is generally well-tolerated with no persisting adverse effects. Regarding their mechanisms of action, they mediate their main therapeutic effects biochemically via serotonin receptor agonism, and psychologically by generating meaningful psycho-spiritual experiences that contribute to mental flexibility. Given the limited success rates of current treatments for anxiety and mood disorders, and considering the high morbidity associated with these conditions, there is potential for psychedelics to provide symptom relief in patients inadequately managed by conventional methods.
- this approach may be particularly well suited for managing cognitive deficits and preventing neurodegeneration.
- subpopulations of low attentive and low motivated rats demonstrate improved performance on 5 choice serial reaction time and progressive ratio tasks, respectively, following doses of psilocybin below the threshold for eliciting the classical wet dog shake behavioral response associated with hallucinogenic doses (Blumstock et al., WO 2020/157569 A1, Higgins et al., Front.
- 5HT2A agonists also show similar neuroprotective and increased neuroplasticity effects (neuroplastogens) and reduced neuroinflammation, which could be beneficial in both neurodegenerative and neurodevelopmental diseases and chronic disorders
- Neuroplastogens neuroplasticity effects
- This repeated, lower, dose paradigm may extend the utility of these compounds to additional indications and may prove useful for wellness applications.
- Psychosis is often referred to as an abnormal state of mind that is characterized by hallucinatory experiences, delusional thinking, and disordered thoughts. Moreover, this state is accompanied by impairments in social cognition, inappropriate emotional expressions, and playful behavior. Most often, psychosis develops as part of a psychiatric disorder, of which, it represents an integral part of schizophrenia. It corresponds to the mostflorid phase of the illness. The veryfirst manifestation of psychosis in a patient is referred to as first-episode psychosis. It reflects a critical transitional stage toward the chronic establishment of the disease, that is presumably mediated by progressive structural and functional abnormalities seen in diagnosed patients. [ACS Chem.
- the present application includes compounds of Formula I: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R 1 is selected from H, halo, NH 2 , C 1-6 alkyl, C 1-6 alkoxyl, NH(C 1-6 alkyl) and N(C 1-6 alkyl) 2 ; Q is selected from Q1, Q2, Q3, Q4, Q5 and Q6: (Q1), (Q2), (Q3), (Q4) (Q5) and (Q6) is a single bond or a double bond provided that when in Q1 is a double bond then R 8 and R 14 are not present, when in Q2 is a double bond then R 16 and R 24 are not present, and when in Q6 is a double bond then R 53 and R 62 are not present; R 2 and R 5 are independently selected from H, halo, OH, C 1-6 alkyl and C 1-6 alkoxy; one or both of R 3 and R 4 is independently selected from H, halo,
- the compound of Formula I is defined as follows: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R 1 is H; Q is selected from Q1, Q2, Q3, Q4, Q5 and Q6: (Q1), (Q2) (Q3), (Q4) (Q5) and (Q6); is a single bond or a double bond provided that when in Q1 is a double bond then R 8 and R 14 are not present, when in Q2 is a double bond then R 16 and R 24 are not present, and when in Q6 is a double bond then R 53 and R 62 are not present; R 2 and R 5 are independently selected from H, D and F; one or both of R 3 and R 4 is selected from H, C 1-4 alkoxy, C 1-4 fluoralkoxy and C 1- 4 deuteroalkoxy, or R 3 and R 4 are linked together to form O-(CH 2 ) 1-2 O; R 7 , R 8 , R 9 , R 10 , R 12 , R
- the present application also includes a compound selected from compound 12 and compound 16, (12) (16) or a pharmaceutically acceptable salt, solvate and/or prodrug thereof.
- the compounds of the application are used as medicaments.
- the application also includes a compound of the application for use as a medicament.
- the present application also includes a method of treating psychosis or psychotic symptoms comprising administering a therapeutically effective amount of one or more compounds of the application to a subject in need thereof.
- the present application also includes a method of treating a mental illness comprising administering a therapeutically effective amount of one or more compounds of the application to a subject in need thereof.
- the present application also includes a method of treating a central nervous system (CNS) disease, disorder or condition and/or neurological disease, disorder or condition comprising administering a therapeutically effective amount of one or more compounds of the application to a subject in need thereof.
- CNS central nervous system
- the application additionally provides a process for the preparation of compounds of the application. General and specific processes are discussed in more detail below and set forth in the examples below. [0031] Other features and advantages of the present application will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating embodiments of the application are given by way of illustration only and the scope of the claims should not be limited by these embodiments but should be given the broadest interpretation consistent with the description as a whole.
- composition(s) of the application or “composition(s) of the present application” and the like as used herein refers to a composition, such a pharmaceutical composition, comprising one or more compounds of the application.
- composition(s) of the application or “composition(s) of the present application” and the like as used herein refers to a composition, such a pharmaceutical composition, comprising one or more compounds of the application.
- the term “and/or” as used herein means that the listed items are present, or used, individually or in combination. In effect, this term means that "at least one of or “one or more” of the listed items is used or present.
- the term “and/or” with respect to pharmaceutically acceptable salts, solvates and/or prodrugs thereof means that the compounds of the application exist as individual salts, solvates and prodrugs, as well as a combination of, for example, a salt of a solvate of a compound of the application.
- suitable means that the selection of the particular compound or conditions would depend on the specific synthetic manipulation to be performed, the identity of the molecule(s) to be transformed and/or the specific use for the compound, but the selection would be well within the skill of a person trained in the art. All process/method steps described herein are to be conducted under conditions sufficient to provide the product shown. A person skilled in the art would understand that all reaction conditions, including, for example, reaction solvent, reaction time, reaction temperature, reaction pressure, reactant ratio and whether or not the reaction should be performed under an anhydrous or inert atmosphere, can be varied to optimize the yield of the desired product and it is within their skill to do so.
- solvate means a compound, or a salt and/or prodrug of a compound, wherein molecules of a suitable solvent are incorporated in the crystal lattice.
- prodrug means a compound, or salt and/or prodrug of a compound, that, after administration, is converted into an active drug.
- alkyl as used herein, whether it is used alone or as part of another group, means straight or branched chain, saturated alkyl groups. The number of carbon atoms that are possible in the referenced alkyl group are indicated by the prefix “C n1-n2 ”.
- C 1 - 6 alkyl (or “C 1 -C 6 alkyl”) means an alkyl group having 1, 2, 3, 4, 5, or 6 carbon atoms.
- alkenyl as used herein, whether it is used alone or as part of another group, means straight or branched chain, saturated alkenyl groups containing at least one double bond. The number of carbon atoms that are possible in the referenced alkenyl group are indicated by the prefix “C n1-n2 ”.
- C 2-6 alkyl (or “C 2 -C 6 alkyl”) means an alkenyl group having 2, 3, 4, 5, or 6 carbon atoms.
- alkenylene as used herein, whether it is used alone or as part of another group, means a straight or branched chain, unsaturated alkylene group, that is, an unsaturated carbon chain that contains substituents on two of its ends and at least one double bond.
- the number of carbon atoms that are possible in the referenced alkenylene group are indicated by the prefix “C n1-n2 ”.
- C 2-6 alkenylene means an alkenylene group having 2, 3, 4, 5 or 6 carbon atoms.
- alkoxy as used herein, alone or in combination, includes an alkyl group connected to an oxygen-connecting atom.
- cycloalkyl as used herein, whether it is used alone or as part of another group, means a saturated carbocyclic group containing from 3 to 6 carbon atoms and one or more rings. The number of carbon atoms that are possible in the referenced cycloalkyl group are indicated by the numerical prefix “C n1-n2 ”.
- C3- 6cycloalkyl means a cycloalkyl group having 3, 4, 5 or 6 carbon atoms.
- heterocycloalkyl refers to cyclic groups containing at least one non-aromatic ring containing from 3 to 6 atoms in which one or more of the atoms are a heteromoiety selected from O, S, S(O), SO 2 , NH, NC 1-6 alkyl and N and the remaining atoms are C.
- Heterocycloalkyl groups are either saturated or unsaturated (i.e. contain one or more double bonds).
- heterocycloalkyl group contains the prefix C n1-n2 or “n1 to n2” this prefix indicates the number of carbon atoms in the corresponding carbocyclic group, in which one or more, suitably 1 to 4, of the ring atoms is replaced with a heteromoeity as [0052]
- aryl as used herein, whether it is used alone or as part of another group, refers to carbocyclic groups containing at least one aromatic ring and contains from 6 to 10 carbon atoms.
- heteroaryl refers to cyclic groups containing at least one heteroaromatic ring containing 5-6 atoms in which one or more of the atoms are a heteroatom selected from O, S and N and the remaining atoms are C.
- a heteroaryl group contains the prefix C n1-n2 this prefix indicates the number of carbon atoms in the corresponding carbocyclic group, in which one or more, suitably 1 to 4, of the ring atoms is replaced with a heteroatom as defined above.
- halogen refers to a halogen atom and includes fluoro, chloro, bromo and iodo.
- haloalkyl refers to an alkyl group as defined above in which one or more of the available hydrogen atoms have been replaced with a halogen.
- C 1-6 haloalkyl refers to a C 1 to C 6 linear or branched alkyl group as defined above with one or more halogen substituents.
- deuteroalkyl refers to an alkyl group as defined above in which one or more of the available hydrogen atoms have been replaced with a deuterium.
- C 1-6 deuteroalkyl refers to a C 1 to C 6 linear or branched alkyl group as defined above with one or more deuterium substituents.
- available refers to atoms that would be known to a person skilled in the art to be capable of replacement by a substituent.
- one or more item includes a single item selected from the list as well as mixtures of two or more items selected from the list.
- alternative isotope thereof refers to an isotope of an element that is other than the isotope that is most abundant in nature.
- the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature.
- the present application is meant to include all suitable isotopic variations of the compounds of general Formula I and pharmaceutically acceptable salts, solvates and/or prodrugs thereof.
- different isotopic forms of hydrogen (H) include protium ( 1 H), deuterium ( 2 H) and tritium ( 3 H). Protium is the predominant hydrogen isotope found in nature.
- the term “compound” refers to the compound and, in certain embodiments, to the extent they are stable, any hydrate or solvate thereof.
- a hydrate is the compound complexed with water and a solvate is the compound complexed with a solvent, which may be an organic solvent or an inorganic solvent.
- a “stable” compound is a compound that can be prepared and isolated and whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein (e.g., therapeutic administration to a subject).
- the compounds of the present application are limited to stable compounds embraced by general Formula (I), or pharmaceutically acceptable salts, solvates and/or prodrugs thereof.
- the term “pharmaceutically acceptable” means compatible with the treatment of subjects.
- pharmaceutically acceptable carrier means a non-toxic solvent, dispersant, excipient, adjuvant or other material which is mixed with the active ingredient in order to permit the formation of a pharmaceutical composition, i.e., a dosage form capable of administration to a subject.
- pharmaceutically acceptable salt means either an acid addition salt or a base addition salt which is suitable for, or compatible with, the treatment of subjects.
- An acid addition salt suitable for, or compatible with, the treatment of subjects is any non-toxic organic or inorganic acid addition salt of any basic compound.
- a base addition salt suitable for, or compatible with, the treatment of subjects is any non-toxic organic or inorganic base addition salt of any acidic compound.
- protecting group or "PG” and the like as used herein refers to a chemical moiety which protects or masks a reactive portion of a molecule to prevent side reactions in those reactive portions of the molecule, while manipulating or reacting a different portion of the molecule. After the manipulation or reaction is complete, the protecting group is removed under conditions that do not degrade or decompose the remaining portions of the molecule. The selection of a suitable protecting group can be made by a person skilled in the art.
- treating means an approach for obtaining beneficial or desired results, including clinical results.
- beneficial or desired clinical results include, but are not limited to alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease and remission (whether partial or total), whether detectable or undetectable.
- Treating and “treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment.
- Treatment as used herein also include prophylactic treatment.
- a subject with early neurological disease can be treated to prevent progression, or alternatively a subject in remission can be treated with a compound or composition of the application to prevent recurrence.
- Treatment methods comprise administering to a subject a therapeutically effective amount of one or more of the compounds of the application and optionally consist of a single administration, or alliteratively comprise a series of administrations..
- the term "effective amount” or "therapeutically effective amount” means an amount of one or more compounds of the application that is effective, at dosages and for periods of time necessary to achieve the desired result.
- an effective amount is an amount that, for example, increases said activation compared to the activation without administration of the one or more compounds.
- “Palliating” a disease, disorder or condition means that the extent and/or undesirable clinical manifestations of a disease, disorder or condition are lessened and/or time course of the progression is slowed or lengthened, as compared to not treating the disorder.
- administered means administration of a therapeutically effective amount of one or more compounds or compositions of the application to a cell, tissue, organ or subject.
- prevention or “prophylaxis”, or synonym thereto, as used herein refers to a reduction in the risk or probability of a patient becoming afflicted with a disease, disorder or condition or manifesting a symptom associated with a disease, disorder or condition.
- the "disease, disorder or condition” as used herein refers to a disease, disorder or condition treated or treatable by activation of a serotonin receptor, for example 5-HT 2A and particularly using a serotonin receptor agonist such as one or more compounds of the application herein described.
- the disease, disorder or condition may also be treated or treatable via alternative mechanisms, for example by modulation, deactivation, antagonism or reverse agonism of a serotonin receptor, including 5-HT 2A and/or 5-HT 1A .
- the term “treating a disease, disorder or condition by activation of a serotonin receptor” as used herein means that the disease, disorder or condition to be treated is affected by, modulated by and/or has some biological basis, either direct or indirect, that includes serotonergic activity, in particular increases in serotonergic activity. These diseases respond favourably when serotonergic activity associated with the disease, disorder or condition is modulated, for example agonized, by one or more of the compounds or compositions of the application.
- activation includes agonism, partial agonist and positive allosteric modulation of a serotonin receptor.
- the terms “5-HT 1A ” and “5-HT 2A ” are used herein mean the 5-HT 1A and 5- HT 2A receptor subtypes of the 5-HT serotonin receptor, respectively.
- the term “therapeutic agent” as used herein refers to any drug or active agent that has a pharmacological effect when administered to a subject. II.
- Compounds includes compounds of Formula I: or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein:
- R 1 is selected from H, halo, NH 2 , C 1-6 alkyl, C 1-6 alkoxyl, NH( C 1-6 alkyl) and N( C 1-6 alkyl) 2 ;
- Q is selected from Q1 , Q2, Q3, Q4, Q5 and Q6:
- - is a single bond or a double bond provided that when - in Q1 is a double bond then R 8 and R 14 are not present, when in Q2 is a double bond then R 16 and R 24 are not present, and when in Q6 is a double bond then R 53 and R 62 are not present;
- R 2 and R 5 are independently selected from H, OH, halo, C 1-6 alkyl and C 1-6 alkoxy; one or both of R 3 and R 4 is independently selected from H, halo, C 1-6 alkyl and C 1-6 alkoxy, or
- R 3 and R 4 are linked together to form O-(CH 2 ) 1-2 O, or one of R 3 and R 4 is selected from X-L-A and the other of R 3 and R 4 is selected from H, halo, C 1-6 alkyl and C 1-6 alkoxy;
- X is selected from a direct bond, O, C(O), NR a , NR a C(O), C(O)NR a , OC(O), C(O)O, OC(O)O, NR a C(O)O, OC(O)NR a and NR a C(O)NR a ;
- L is selected from a direct bond, C 1-6 alkylene, C 2-6 alkenylene, C 1-6 alkyleneO, C 2-
- substituted in the context of “substituted with a fluorine atom or chlorine atom” or “substituted with alternate isotope thereof” or “ substituted with deuterium” means any hydrogen can be replaced with a fluorine atom or chlorine atom, or any atom can be replaced with alternate isotope thereof, such as deuterium. Accordingly, in some embodiments, all available hydrogen atoms are optionally and independently replaced with a fluorine atom or chlorine atom and all available atoms are optionally replaced with alternate isotope thereof. In some embodiments, all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium.
- R 2 , R 3 , R 4 , R 5 , R 25 , R 26 , R 27 , R 28 , R 29 and R 30 is D or comprises D.
- at least one of R 2 , R 3 , R 4 , R 5 is alkyl substituted with one or more fluorine and/or chlorine atoms.
- at least three of R 2 , R 3 , R 4 , R 5 are not H.
- R 3 and R 4 are linked together to form O-(CH 2 ) 1-2 O.
- one of R 3 and R 4 is selected from X-L-A and the other of R 3 and R 4 is selected from H, halo, C 1-6 alkyl and C 1-6 alkoxy; and A is not H, C 1- 6 alkyl or C 2-6 alkenyl;
- R 7 -R 14 or R 31 - R 40 respectively are not all H, when one of R 3 and R 4 is halo and the other of R 3 and R 4 is H.
- all available atoms are optionally replaced with alternate isotope thereof, all available hydrogen atoms in a group are optionally replaced with deuterium.
- Q is Q1, , and is a single bond and the compound of Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 and R 14 are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof, provided R 7 -R 14 are not all H, when one of R 3 and R 4 is halo and the other of R 3 and R 4 is H.
- Q is Q1, , and is a double bond and the compound of Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , R 9 , R 10 , R 11 , R 12 and R 13 are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof.
- Q is Q2, , and is a single bond and the compound of Formula I has the following structure: I Or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 and R 24 are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof.
- Q is Q2, , and is a double bond and the compound of Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 15 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 and R 23 are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof.
- Q is Q3,
- the compound of Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 25 , R 26 , R 27 , R 28 , R 29 and R 30 are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof, provided at least one of R 2 , R 3 , R 4 , R 5 , R 25 , R 26 , R 27 , R 28 , R 29 and R 30 is D or comprises D, or at least one of R 2 , R 3 , R 4 , R 5 is alkyl substituted with one or more fluorine and/or chlorine R 3 and R 4 are linked together to form O-(CH 2 ) 1-2 O; or one of R 3 and R 4
- Q is Q4, , and the compound of Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 and R 40 are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof, provided R 2 , R 5 , R 31 - R 40 are not all H, when one of R 3 and R 4 is halo and the other of R 3 and R 4 is H.
- Q is Q5
- the compound of Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 41 , R 42 , R 43 , R 44 , R 45 , R 46 , R 47 , R 48 , R 49 , R 50 , R 51 and R 52 are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof.
- Q is Q6, , and is a single bond and the compound of Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 53 , R 54 , R 55 , R 56 , R 57 , R 58 , R 59 , R 60 , R 61 and R 62 are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate [0097]
- Q is Q6, , and is a double bond and the compound of Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 54 , R 55 , R 56 , R 57 ,
- R 1 , R 2 , R 4 and R 5 are all H and the compound Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R 3 and Q are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof, provided when Q is Q3; at least one of R 2 , R 3 , R 4 , R 5 , R 25 , R 26 , R 27 , R 28 , R 29 and R 30 is D or comprises D, or R 3 is alkyl substituted with one or more fluorine and/or chlorine atoms; or when Q is Q3; R 3 is X-L-A and A is not H, C 1-6 alkyl or C 2-6 alkenyl, or when Q is Q1 or Q4 then R 7 -R 14 or R 31 - R 40 respectively are not
- R 1 , R 2 , R 3 and R 5 are all H and the compound Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R 4 and Q are as defined for Formula I, and wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof, provided when Q is Q3; at least one of R 2 , R 3 , R 4 , R 5 , R 25 , R 26 , R 27 , R 28 , R 29 and R 30 is D or comprises D, or R 4 is alkyl substituted with one or more fluorine and/or chlorine atoms; or when Q is Q3; R 4 is X-L-A and A is not H, C 1-6 alkyl or C 2-6 alkenyl; when Q is Q1 or Q4 then R 7 -R 14 or R 31 - R 40 respectively are
- R 1 , R 2 and R 5 are all H and the compound Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R 3 , R 4 and Q are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof, provided when Q is Q3; at least one of R 2 , R 3 , R 4 , R 5 , R 25 , R 26 , R 27 , R 28 , R 29 and R 30 is D or comprises D, or at least one of R 3 and R 4 is alkyl substituted with one or more fluorine and/or chlorine atoms; or when Q is Q3; R 3 and R 4 are linked together to form O-(CH 2 ) 1-2 O; or when Q is Q3; one of R 3 and R 4 is selected from X-L-A and the other of R
- R 1 is H and R 2 , R 3 , R 4 and R 5 are all D and the compound of Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: Q is as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof.
- R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , R 31 , R 32 , R 33 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , R 42 , R 43 , R 45 , R 46 , R 47 , R 48 , R 49 , R 50 , R 51 , R 52 , R 53 , R 54 , R 55 , R 57 , R 58 , R 59 , R 60 , R 61 and R 62 are independently selected from H, D, F, Cl, C 1-6 alkyl, C 1-6 fluoroalkyl and C 1-6 deuteroalkyl.
- R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , R 31 , R 32 , R 33 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , R 42 , R 43 , R 45 , R 46 , R 47 , R 48 , R 49 , R 50 , R 51 , R 52 , R 53 , R 54 , R 55 , R 57 , R 58 , R 59 , R 60 , R 61 and R 62 are independently selected from H and D.
- R 8 , R 9 , R 10 , R 11 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 21 , R 22 , R 23 , R 24 , R 30 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 40 , R 41 , R 42 , R 43 , R 44 , R 45 , R 46 , R 47 , R 48 , R 49 , R 50 , R 52 , R 53 , R 54 , R 55 , R 56 and R 57 are independently selected from H and D.
- R 25 , R 26 , R 27 and R 28 are independently selected from H and D. In some embodiments, R 25 , R 26 , R 27 and R 28 are H. In some embodiments, R 25 , R 26 , R 27 and R 28 are D. In some embodiments, R 25 and R 26 are H and R 27 and R 28 are D. In some embodiments, R 25 and R 26 are D and R 27 and R 28 are H. [00105] In some embodiments, when Q is (Q4) or (Q5), the stereochemistry at the carbon to which R 33 or R 43 is bonded is either R or S. Therefore in some embodiments, Q4 is or and Q5 is or .
- the stereochemistry at the carbon to which R 33 or R 43 is bonded is R. In some embodiments, the stereochemistry at the carbon to which R 33 or R 43 is bonded is S. [00107] In some embodiments, when Q is (Q1), (Q2) or (Q6) and is a single bond, the stereochemistry at the carbon to which R 14 , R 24 or R 53 is bonded is either R or S. Therefore in some embodiments, Q1 is or , Q2 is or , and Q6 is or . [00108] In some embodiments, the stereochemistry at the carbon to which R 14 , R 24 or R 53 is bonded is R. In some embodiments, the stereochemistry at the carbon to which R 14 , R 24 or R 53 is bonded is S. [00109] In some embodiments Q is selected from one of the following groups:
- R 11 , R 19 , R 29 , R 30 , R 34 , R 44 and R 56 are independently selected from H, D, C 1-6 alkyl, C 1-6 fluoroalkyl, C 1-6 deuteroalkyl and C(O)-A’.
- R 11 , R 19 , R 29 , R 30 , R 34 , R 44 and R 56 are independently selected from H, C 1-4 alkyl, C 1-4 fluoroalkyl, C 1-4 deuteroalkyl and C(O)-A’.
- R 11 , R 19 , R 29 , R 30 , R 34 , R 44 and R 56 are independently selected from H, C 1-4 alkyl, C 1-4 fluoroalkyl and C 1-4 deuteroalkyl. In some embodiments, R 11 , R 19 , R 29 , R 30 , R 34 , R 44 and R 56 are independently selected from H, CH 3 , CD 3 , CD 2 H, CF 2 H and CF 3 . In some embodiments, R 11 , R 19 , R 29 , R 30 , R 34 , R 44 and R 56 are independently selected from H, CH 3 and CD 3 .
- R 11 , R 19 , R 29 , R 30 , R 34 , R 44 and R 56 are independently selected from CH 3 and CD 3 .
- Q is selected from one of the following groups: , wherein R 34 is selected from H, D, C 1-6 alkyl, C 1-6 fluoroalkyl, C 1-6 deuteroalkyl and C(O)-A’. and C(O)-A’.
- R 34 is selected from H, C 1-4 alkyl, C 1-4 fluoroalkyl and C 1-4 deuteroalkyl.
- R 34 is selected from H, CH 3 , CD 3 , CD 2 H, CF 2 H and CF 3 .
- R 34 is selected from H, CH 3 and CD 3 . In some embodiments, R 34 is selected from CH 3 and CD 3 .
- R 29 and R 30 together with the N atom to which they are bound, form a 3- to 6-membered heterocyclic ring which optionally comprises one or two additional heteromoieties independently selected from O, N and NR 64 and which is optionally substituted with one or more substituents independently selected from halo, OH, C 1-4 alkyl and OC 1-4 alkyl.
- R 11 , R 19 , R 29 , R 30 , R 34 , R 44 and R 56 are independently selected from C(O)-A’.
- one of R 29 and R 30 is C(O)-A’ and the other is selected from H and C 1-6 alkyl. In some embodiments, one of R 29 and R 30 is C(O)-A’ and the other is selected from H and C 1-4 alkyl. [00114] In some embodiments, A' is selected from Y, O-Y and O-C 1-2 alkylene-O- C(O)-Y, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom.
- A' is selected from Y, O-Y and O-C 1 alkylene-O-C(O)-Y, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom.
- Y is C 10-25 alkyl, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom.
- Y is C 13-21 alkyl, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom.
- Y is C 10-25 alkenyl, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom.
- Y' is C 13-21 alkenyl, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom.
- Y is C 10-25 alkenyl and comprises 1, 2, 3, 4, 5 or 6 double bonds.
- the alkyl or alkene group of Y is an alkyl or alkenyl group present in a fatty acid, wherein all available H atoms are optionally substituted with deuterium.
- Y is an alkenyl group present in a fatty acid, wherein all available H atoms are optionally substituted with deuterium.
- the fatty acid is an omega-6 fatty acid (ie an unsaturated or polyunsaturated fatty acid wherein the double bond that is closest to the methyl end of the molecule is located at carbon numbered 6 starting from the end methyl group) or an omega-3 fatty acid (i.e. an unsaturated or polyunsaturated fatty acid wherein the double bond that is closest to the methyl end of the molecule is located at carbon numbered 3 starting from the end methyl group), wherein all available H atoms are optionally substituted with deuterium.
- Y is an alkyl group present in a fatty acid wherein all available H atoms are optionally substituted with deuterium.
- the alkyl or alkene group of Y is an alkyl or alkene group present in a fatty acid selected from the list of fatty acids in Table 1 : Table 1 Common Name Lipid Number Chemical Name linoleic acid (LA) 18:2 (n-6) all-cis-9,12- octadecadienoic acid, rumenic acid 18:2 (n-6) 9Z,11E-octadecadienoic (conjugated linoleic acid) acid, conjugated linoleic acid 18:2 (n-6) 10E,12Z-octadecadienoic acid, conjugated linoleic acid 18:2 (n-6) 9Z,12E-octadecadienoic acid, gamma-linolenic acid (GLA) 18
- the alkene group of Y is an alkyl or alkenyl group present in linoleic acid, eicosadienoic acid and docosahexanoic acid.
- Y is the alkyl or alkenyl group of a fatty acid wherein 1-10, 2-8, 2-6 or 2-4 H atoms are substituted with deuterium.
- A' is Y. [00122] In some embodiments, A' is -O-Y. [00123] In some embodiments, A' is -O-C 3 alkylene-O-C(O)-Y. [00124] In some embodiments, R 1 is selected from H, halo, NH 2 , C 1-4 alkyl, C 1- 4 alkoxy, NH(C 1-4 alkyl) and N(C 1-4 alkyl) 2 .
- R 1 is selected from H, D, Cl, F, NH 2 , C 1-4 alkyl, C 1-4 alkoxy, C 1-4 fluoroalkyl, C 1-4 deuteroalkyl, NH(C 1-4 alkyl), NH(C 1 - 4deuteroalkyl), NH(C 1-4 flouroalkyl), N(C 1-4 alkyl) 2 , N(C 1-4 fluoroalkyl) 2 , N(C 1-4 deuteroalkyl) 2 , N(C 1-4 fluoroalkyl)(C 1-4 alkyl), N(C 1-4 fluoroalkyl)(C 1-4 deuteroalkyl) and N(C 1-4 deuteroalkyl)(C 1 - 4alkyl).
- R 1 is selected from H, D, Cl, F, NH 2 , C 1-2 alkyl, C 1-2 alkoxy, C 1 - 2fluoroalkyl, C 1-2 deuteroalkyl, NH(C 1-2 alkyl), NH(C 1-2 deuteroalkyl), NH(C 1-2 flouroalkyl), N(C 1-2 alkyl) 2 , N(C 1-2 fluoroalkyl) 2 , N(C 1-2 deuteroalkyl) 2 , N(C 1-2 fluoroalkyl)(C 1-2 alkyl), N(C 1- 2 fluoroalkyl)(C 1-2 deuteroalkyl) and N(C 1-2 deuteroalkyl)(C 1-2 alkyl).
- R 1 is selected from H, D, Cl, F, OH, C 1-2 alkyl, C 1-2 alkoxy, C 1-2 fluoroalkyl and C 1-2 deuteroalkyl. In some embodiments R 1 is selected from H, D, F, NH 2 , CH 3 , CF 2 H, CD 2 H, CH 3 O, CF 3 , CD 3 , NH(CH 3 ), NH(CD 3 ), NH(CF 3 ), N(CH 3 ) 2 , N(CF 3 ) 2 and N(CD 3 ) 2 .
- R 1 is selected from H, D, F, NH 2 , CH 3 , CF 2 H, CD 2 H, CH 3 O, CF 3 and CD 3 . In some embodiments R 1 is selected from H, D, F, CH 3 , CF 2 H, CD 2 H, CH 3 O, CF 3 and CD 3 . In some embodiments, R 1 is selected from H and D. In some embodiments, R 1 is D. In some embodiments R 1 is H.
- R 2 and R 5 are independently selected from H, D, Cl, F, OH, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 fluoroalkoxy, C 1-4 deuteroalkoxy, C 1-4 fluoroalkyl and C 1- 4deuteroalkyl. In some embodiments, R 2 and R 5 are independently selected from H, D, Cl, F, OH, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 fluoroalkyl and C 1-4 deuteroalkyl.
- R 2 and R 5 are independently selected from H, D, Cl, F, OH, C 1-2 alkyl, C 1-2 alkoxy, C 1- 2 fluoroalkoxy, C 1-2 deuteroalkoxy, C 1-2 fluoroalkyl and C 1-2 deuteroalkyl.
- R 2 and R 5 are independently selected from H, D, Cl, F, OH, C 1-2 alkyl, C 1 - lk C fl lk l d C d t lk l I b di t R d R independently selected from H, D, F, OH, CH 3 , CH 3 O, CF 2 HO, CD 2 HO, CF 3 O, CD 3 O, CF 2 H, CD 2 H, CF 3 and CD 3 .
- R 2 and R 5 are independently selected from H, D, F, OH, CH 3 , CF 2 H, CD 2 H, CH 3 O, CF 3 and CD 3 .
- R 2 and R 5 are independently selected from H, D, F, OH, CH 3 , CH 3 O, CF 2 HO, CF 3 O and CD 3 O. In some embodiments, R 2 and R 5 are independently selected from H and D. In some embodiments, at least one of R 2 and R 5 is D. In some embodiments, each of R 2 and R 5 are D. In some embodiments, each of R 2 and R 5 are H.
- R 3 and R 4 is independently selected from H, D, F, Cl, C 1-6 alkyl, C 1-6 fluoroalkyl, C 1-6 deuteroalkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy and C 1-6 deuteroalkoxy. In some embodiments both of R 3 and R 4 are independently selected from H, D, F, Cl, C 1-4 alkyl, C 1-4 fluoroalkyl, C 1-4 deuteroalkyl, C 1-4 alkoxy, C 1-4 fluoroalkoxy and C 1-4 deuteroalkoxy.
- R 3 and R 4 is independently selected from H, D, F, Cl, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , CH(CH 3 )2, CF 3 , CF 2 H, CH 2 CF 2 H, CH2CF 3 , CH 2 CFH 2 , CH(CF 3 ) 2 , CD 3 , CH(CH 3 )2O, CH 3 CH 2 CH 2 O, CH 3 CH2O, CH 3 O, CF 3 O, CHF 2 O, CF 2 HCH 2 O, CF 3 CH2O, (CF 3 )2CHO, and CD 3 O.
- R 3 and R 4 is independently selected from H, D, F, Cl, CH 3 , CH(CH 3 )2, CF 3 , CF 2 H, CD 3 , CH(CH 3 ) 2 O, CH 3 O, CF 3 O, CHF 2 O, and CD 3 O.
- both of R 3 and R 4 are independently selected from H, D, F, Cl, C 1-6 alkyl, C 1-6 fluoroalkyl, C 1-6 deuteroalkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy and C1- 6deuteroalkoxy.
- both of R 3 and R 4 are independently selected from D, F, Cl, C 1-6 alkyl, C 1-6 fluoroalkyl, C 1-6 deuteroalkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy and C1- 6deuteroalkoxy.
- both of R 3 and R 4 are independently selected from H, D, F, Cl, C 1-4 alkyl, C 1-4 fluoroalkyl, C 1-4 deuteroalkyl, C 1-4 alkoxy, C 1-4 fluoroalkoxy and C1- 4deuteroalkoxy.
- both of R 3 and R 4 are independently selected from H, D, F, Cl, CH 3 , CH(CH 3 )2, CF 3 , CF2H, CD 3 , CH(CH 3 ) 2 O, CH 3 O, CF 3 O, CHF 2 O, and CD 3 O.
- both of R 3 and R 4 are independently selected from D, F, Cl, CH 3 , CH(CH 3 )2, CF 3 , CF 2 H, CD 3 , CH(CH 3 ) 2 O, CH 3 O, CF 3 O, CHF 2 O, and CD 3 O. In some embodiments both of R 3 and R 4 are independently selected from CH 3 O, CF 3 O, CHF 2 O, and CD 3 O. In some embodiments both of R 3 and R 4 are CD 3 O or both of R 3 and R 4 are CH 3 O.
- R 3 is H or D and R 4 is selected from H, D, F, Cl, C 1- 6 alkyl, C 1-6 fluoroalkyl, C 1-6 deuteroalkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy and C 1-6 deuteroalkoxy.
- R 3 is H or D and R 4 is selected from H, D, F, Cl, C 1-4 alkyl, C 1- 4fluoroalkyl, C 1-4 deuteroalkyl, C 1-4 alkoxy, C 1-4 fluoroalkoxy and C 1-4 deuteroalkoxy.
- R 3 is H or D and R 4 is selected from H, D, F, Cl, CH(CH 3 ) 2 , CH 3 , CF 3 , CF 2 H, CD 3 , CH(CH 3 ) 2 O CH 3 O, CF 3 O, CHF 2 O, and CD 3 O.
- R 3 is H or D and R 4 is selected from D, F, Cl, CH 3 , CH(CH 3 ) 2 , CF 3 , CF 2 H, CD 3 , CH(CH 3 ) 2 O, CH 3 O, CF 3 O, CHF 2 O, and CD 3 O.
- R 3 is H or D and R 4 is selected from CH(CH 3 ) 2 O CH 3 O, CF 3 O, CHF 2 O, and CD 3 O. In some embodiments, R 3 is H and R 4 is selected from CH 3 O and CD 3 O. [00129] In some embodiments, R 4 is H or D and R 3 is selected from H, D, F, Cl, C 1- 6 alkyl, C 1-6 fluoroalkyl, C 1-6 deuteroalkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy and C 1-6 deuteroalkoxy.
- R 4 is H or D and R 3 is selected from H, D, F, Cl, C 1-4 alkyl, C 1- 4fluoroalkyl, C 1-4 deuteroalkyl, C 1-4 alkoxy, C 1-4 fluoroalkoxy and C 1-4 deuteroalkoxy.
- R 4 is H or D and R 3 is selected from D, F, Cl, CH 3 , CH(CH 3 )2, CF 3 , CF2H, CD 3 , CH(CH 3 )2O, CH 3 O, CF 3 O, CHF2O, and CD 3 O.
- R 4 is H or D and R 3 is selected from CH(CH 3 )2O CH 3 O, CF 3 O, CHF2O, and CD 3 O. In some embodiments, R 4 is H and R 3 is selected from CH 3 O and CD 3 O. [00130] In some embodiments, R 2 , R 3 , R 4 and R 5 are selected from D, F, Cl, CH 3 , CH(CH 3 )2, CF 3 , CF2H, CD 3 , CH(CH 3 )2O CH 3 O, CF 3 O, CHF2O, and CD 3 O.
- R 2 , R 3 , R 4 and R 5 are all H or In some embodiments, R 2 , R 3 , R 4 and R 5 are all D. In some embodiments R 2 , R 3 , R 4 and R 5 are selected from CH(CH 3 )2O CH 3 O, CF 3 O, CHF2O, and CD 3 O. In some embodiments, two of R 2 , R 3 , R 4 and R 5 are selected from H or D and the remaining of R 2 , R 3 , R 4 and R 5 are selected from CH(CH 3 )2O CH 3 O, CF 3 O, CHF2O, and CD 3 O.
- two of R 2 , R 3 , R 4 and R 5 are selected from H or D and the remaining of R 2 , R 3 , R 4 and R 5 are selected from CH 3 O and CD 3 O.
- one of R 2 , R 3 , R 4 and R 5 is selected from H or D and the remaining of R 2 , R 3 , R 4 and R 5 are selected from CH(CH 3 )2O CH 3 O, CF 3 O, CHF2O, and CD 3 O.
- one of R 3 , R 4 R 5 and R 6 is selected from H or D and the remaining of R 2 , R 3 , R 4 and R 5 are selected from CH 3 O and CD 3 O.
- R 3 and R 4 are linked together to form O-CH2O.
- one of R 3 and R 4 is selected from X-L-A and the other of R 3 and R 4 is selected from H, halo, C 1-6 alkyl and C 1-6 alkoxy.
- X is a direct bond and one of R 3 and R 4 is selected from L-A and the other of R 3 and R 4 is selected from H, halo, C 1-6 alkyl and C 1-6 alkoxy.
- X is selected from O, C(O), NR a , NR a C(O), C(O)NR a , OC(O), C(O)O, OC(O)O, NR a C(O)O, OC(O)NR a and NR a C(O)NR a .
- X is selected from O, C(O), OC(O), C(O)O and OC(O)O.
- X is selected from O, OC(O) d C(O)O I b di t X i O I b di t X i l t d from OC(O) and C(O)O.
- X is selected from O, NR a , NR a C(O), C(O)NR a , NR a C(O)O, OC(O)NR a and NR a C(O)NR a . In some embodiments, X is selected from NR a C(O), C(O)NR a , NR a C(O)O, OC(O)NR a and NR a C(O)NR a . In some embodiments, X is selected from NR a C(O), and C(O)NR a .
- X is selected from NR a C(O)O, OC(O)NR a and NR a C(O)NR a . In some embodiments, X is selected from O, OC(O), C(O)O, NR a C(O), and C(O)NR a .
- L is selected from a direct bond, C 1-4 alkylene, C 2- 4 alkenylene, C 1-4 alkyleneO, C 2-4 alkenyleneO, C 1-4 alkyleneC(O), C 2-4 alkenyleneC(O) C 1- 4alkyleneNR b C(O), C2-4alkenyleneNR b C(O), C 1-4 alkyleneC(O)NR b , C2- 4alkenyleneC(O)NR b , C 1-4 alkyleneOC(O), C2-4alkenyleneOC(O), C 1-4 alkyleneC(O)O, C2- 4alkenyleneC(O)O, C 1-4 alkyleneOC(O)NR b , C2-4alkenyleneOC(O)NR b , C1- 4alkyleneNR b C(O)O C2-4alkenyleneNR b C(O)O, C 1-4 alkyleneOC(O)O, C2- 4alkenyleneOC(O)O, C1- 4al
- L is selected from a direct bond, C 1-2 alkylene, C2-4alkenylene, C 1-2 alkyleneO, C2-4alkenyleneO, C 1-2 alkyleneC(O), C2-4alkenyleneC(O) C 1-2 alkyleneNR b C(O), C2- 4alkenyleneNR b C(O), C 1-2 alkyleneC(O)NR b , C2-4alkenyleneC(O)NR b , C 1-2 alkyleneOC(O), C2-4alkenyleneOC(O), C 1-2 alkyleneC(O)O, C2-4alkenyleneC(O)O, C 1-2 alkyleneOC(O)NR b , C2-4alkenyleneOC(O)NR b , C 1-2 alkyleneNR b C(O)O C2-4alkenyleneNR b , C1- 2alkyleneOC(O)O, C2-4alkenyleneOC(O)O, C 1-2 alkylene
- L is selected from a direct bond, C1- 2alkylene, C 1-2 alkyleneO, C 1-2 alkyleneC(O), C 1-2 alkyleneNR b C(O), C 1-2 alkyleneC(O)NR b , C 1-2 alkyleneOC(O), C 1-2 alkyleneC(O)O, C 1-2 alkyleneOC(O)NR b , C 1-2 alkyleneNR b C(O)O, C 1-2 alkyleneOC(O)O, and C 1-2 alkyleneNR b C(O)NR b .
- L is selected from a direct bond, CH2, CF2, CD2, CH2-O, CF2-O, CD2-O, CH2-C(O), CF2-C(O), CD2-C(O), CH2-NR b C(O), CD2-NR b C(O), CF2-NR b C(O), CH2-C(O)NR b , CF2-C(O)NR b , CD2-C(O)NR b , CH2-OC(O), CD2-OC(O), CF2-OC(O), CH2-C(O)O, CF2-C(O)O, CD2-C(O)O, CH2- OC(O)NR b , CD2-OC(O)NR b , CF2-OC(O)NR b , CH2-NR b C(O)O, CF2-NR b C(O)O, CD2- NR b C(O)O, CH2-NR b C(O)O, CH2-NR b C(O)O, CH2-NR b C(O
- X is a direct bond and L is a direct bond and one of R 3 and R 4 is selected from A and the other of R 3 and R 4 is selected from H, halo, C 1-4 alkyl and C 1-4 alkoxy.
- X is selected from O, OC(O), C(O)O, NR a C(O), and C(O)NR a and one of R 3 and R 4 is selected from O-C 1-2 alkylene-A, O-C 1-2 alkyleneO-A, O- C 1-2 alkyleneC(O)-A, O-C 1-2 alkyleneNR b C(O)-A, O-C 1-2 alkyleneC(O)NR b -A, O-C 1- 2 alkyleneOC(O)-A, O-C 1-2 alkyleneC(O)O-A, O-C 1-2 alkyleneOC(O)NR b -A, O-C 1- 2 alkyleneNR b C(O)O-A, O-C 1-2 alkyleneOC(O)O-A, O-C 1-2 alkyleneNR b C(O)NR b -A, OC(O)- C 1-2 alkylene-A, OC(O)- C 1-2 alkylene
- X is selected from O, OC(O), C(O)O, NR a C(O), and C(O)NR a and one of R 3 and R 4 is selected from O-C 1-2 alkylene-A, O-C 1-2 alkyleneO-A, O-C 1-2 alkyleneC(O)-A, O-C1- 2alkyleneNR b C(O)-A, O-C 1-2 alkyleneC(O)NR b -A, O-C 1-2 alkyleneOC(O)-A, O-C1- 2alkyleneC(O)O-A, O-C 1-2 alkyleneOC(O)NR b -A, O-C 1-2 alkyleneNR b C(O)O-A, O-C1- 2alkyleneOC(O)O-A, O-C 1-2 alkyleneNR b C(O)O-A, O-C1- 2alkyleneOC(O)O-A, O-C 1-2 alkyleneNR
- the other of R 3 and R 4 is selected from H, F, Cl, C1- 4alkyl, C 1-4 haloalkyl, C 1-4 deuteroalkyl and C 1-4 alkoxy wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom.
- R 3 and R 4 is selected from D, F, Cl, CH 3 , CH(CH 3 )2, CF 3 , CF2H, CD 3 , CH(CH 3 )2O, CH 3 O, CF 3 O, CHF2O, and CD 3 O wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. and the other of R 3 and R 4 is H or D.
- R 3 is X-L-A and R 4 is selected from H, halo, C 1-6 alkyl and C 1-6 alkoxy.
- R 4 is X-L-A and R 3 is selected from H, halo, C1- 6alkyl and C 1-6 alkoxy.
- R a is selected from H and C 1-4 alkyl.
- R b is selected from H, C 1-4 alkyl, and A'.
- A is H, and one of R 3 and R 4 is selected OH, C(O)H, NHR a , NHR a C(O), C(O)NHR a , OC(O)H, C(O)OH, OC(O)OH, NR a C(O)OH, OC(O)NHR a , NHR a C(O)NR a , X-C 1-4 alkylene, X-C2-4alkenylene, X-C 1-4 alkyleneOH, X-C2-4alkenyleneOH, X-C 1-4 alkyleneC(O)H, X-C2-4alkenyleneC(O)H, X-C 1-4 alkyleneNR b C(O)H, X-C2- 4alkenyleneNR b C(O)H, X-C 1-4 alkyleneC(O)NHR b , X-C2-4alkenyleneC(O)NHR b
- A is H, and one of R 3 and R 4 is selected OH, C(O)H, NHR a , NHR a C(O), C(O)NHR a , OC(O)H, C(O)OH, OC(O)OH, NR a C(O)OH, OC(O)NHR a , NHR a C(O)NR a , X-C 1-2 alkylene, X-C 2-4 alkenylene, X-C 1-2 alkyleneOH, X-C 2- 4 alkenyleneOH, X-C 1-2 alkyleneC(O)H, X-C 2-4 alkenyleneC(O)H, X-C 1-2 alkyleneNR b C(O)H, X-C 2-4 alkenyleneNR b C(O)H, X-C 2-4 alkenyleneNR b C(O)H, X-C 1-2 alkyleneC(O)NHR b , X-
- A is H and X is a direct bond. Therefore, in some embodiments, and one of R 3 and R 4 is selected from C 1-4 alkyl, C2-4alkenyl, C 1-4 alkyleneOH, C 2-6 alkenyleneOH, C 1-4 alkyleneC(O)H, C2-4alkenyleneC(O)H, C 1-4 alkyleneNR b C(O)H, C2- 4alkenyleneNR b C(O)H, C 1-4 alkyleneC(O)NHR b , C2-4alkenyleneC(O)NHR b , C1- 4alkyleneOC(O)H, C2-4alkenyleneOC(O)H, C 1-4 alkyleneC(O)OH, C2-4alkenyleneC(O)H, C1- 4alkyleneOC(O)NHR b , C 2-6 alkenyleneOC(O)NHR b , C 1-4 alkyleneNR b C(O)OH,
- A is H and X is selected from O, C(O), NR a , NR a C(O), C(O)NR a , OC(O), C(O)O, OC(O)O, NR a C(O)O, OC(O)NR a and NR a C(O)NR a .
- A is H and X is selected from O, C(O), OC(O), C(O)O and OC(O)O.
- A is H and X is selected from O, OC(O) and C(O)O.
- A is H and X is O.
- A is H and X is selected from OC(O) and C(O)O. In some embodiments, A is H and X is selected from NR a , NR a C(O), C(O)NR a , NR a C(O)O, OC(O)NR a and NR a C(O)NR a . In some embodiments, A is H and X is selected from NR a C(O), C(O)NR a , NR a C(O)O, OC(O)NR a and NR a C(O)NR a . In some embodiments, A is H and X is selected from NR a C(O), and C(O)NR a .
- A is H and X is selected from NR a C(O)O, OC(O)NR a and NR a C(O)NR a .
- A is H, and L is a direct bond, and one of R 3 and R 4 is selected from X-H.
- R 3 and R 4 is selected from OH, C(O)H, NHR a , NHR a C(O), C(O)NHR a , OC(O)H, C(O)OH, OC(O)OH, NR a C(O)OH, OC(O)NHR a and NHR a C(O)NR a , wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom.
- R b is selected from H and C 1-4 alkyl, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom.
- one of R 3 and R 4 is selected from A, O-A, C(O)-A, C(O)-A, C(O)O-A, C 1-4 alkylene-A, C 1-4 alkylene-C(O)-A, C 1-4 alkylene-C(O)O-A, O-C 1- 4 alkylene-A, O-C 1-4 alkylene-C(O)-A, and O-C 1-4 alkylene-C(O)O-A and the other of R 3 and R 4 is selected from H, halo, C 1-6 alkyl and C 1-6 alkoxy, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom.
- one of R 3 and R 4 is selected from A, O-A, C(O)-A, C(O)-A, and C(O)O-A and the other of R 3 and R 4 is selected from H, halo, C 1-6 alkyl and C1- 6alkoxy, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom.
- one of R 3 and R 4 is A.
- one of R 3 and R 4 is O-A.
- one of R 3 and R 4 is C(O)-A.
- one of R 3 and R 4 is C(O)O-A.
- one of R 3 and R 4 is selected from C 1-4 alkylene-A, C1- 4alkylene-C(O)-A, C 1-4 alkylene-C(O)O-A, O-C 1-4 alkylene-A, O-C 1-4 alkylene-C(O)-A, and O- C 1-4 alkylene-C(O)O-A and the other of R 3 and R 4 is selected from H, halo, C 1-6 alkyl and C1- 6alkoxy, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom.
- one of R 3 and R 4 is C1- 4alkylene-A.
- one of R 3 and R 4 is C 1-4 alkylene-C(O)-A. In some embodiments, one of R 3 and R 4 is C 1-4 alkylene-C(O)O-A. In some embodiments, one of R 3 and R 4 is O-C 1-4 alkylene-A. In some embodiments, one of R 3 and R 4 is O-C 1-4 alkylene- C(O)-A. In some embodiments, one of R 3 and R 4 is O-C 1-4 alkylene-C(O)O-A.
- one of R 3 and R 4 is selected from A, O-A, C(O)-A, C(O)O-A, C 1-4 alkylene-A, C 1-4 alkylene-C(O)-A, C 1-4 alkylene-C(O)O-A, O-C 1-4 alkylene-A, O-C 1-4 alkylene-C(O)-A, and O-C 1-4 alkylene-C(O)O-A and the other of R 3 and R 4 is selected from H, F, Cl, C 1-4 alkyl and C 1-4 alkoxy, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom.
- one of R 3 and R 4 is selected from A, O-A, C(O)-A, C(O)O-A, C 1-4 alkylene- A, C 1-4 alkylene-C(O)-A, C 1-4 alkylene-C(O)O-A, O-C 1-4 alkylene-A, O-C 1-4 alkylene-C(O)-A, and O-C 1-4 alkylene-C(O)O-A and the other of R 3 and R 4 is selected from H, F, Cl, C 1-4 alkyl, C h l lk l C d t lk l d C lk h i il bl h d t optionally and independently substituted with a fluorine atom or deuterium atom.
- one of R 3 and R 4 is selected from A, O-A, C(O)-A, C(O)O-A, C 1-2 alkylene- A, C 1-2 alkylene-C(O)-A, C 1-2 alkylene-C(O)O-A, O-C 1-2 alkylene-A, O-C 1-2 alkylene-C(O)-A, and O-C 1-2 alkylene-C(O)O-A and the other of R 3 and R 4 is selected from D, F, Cl, CH 3 , CH(CH 3 ) 2 , CF 3 , CF 2 H, CD 3 , CH(CH 3 ) 2 O, CH 3 O, CF 3 O, CHF 2 O, and CD 3 O wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom.
- one of R 3 and R 4 is selected from A, O-A, C(O)- A, C(O)O-A, C 1-2 alkylene-A, C 1-2 alkylene-C(O)-A, C 1-2 alkylene-C(O)O-A, O-C 1-2 alkylene-A, O-C 1-2 alkylene-C(O)-A, and O-C 1-2 alkylene-C(O)O-A and the other of R 3 and R 4 is H or D, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom.
- one of R 3 and R 4 is selected from A, O-A, C(O)-A, C(O)O-A, CH2-A, CD2-A, CF2-A, CH2-C(O)-A, CF2-C(O)-A, CD2-C(O)-A, CH2-C(O)O-A, CD2-C(O)O-A, CF2-C(O)O-A, O-CH2A, O-CF2A,O-CD2A, O-CH2-C(O)-A, O- CD2-C(O)-A, O-CF2-C(O)-A, O- CH2-C(O)O-A, O- CF2-C(O)O-A, and O- CD2-C(O)O-A and the other of R 3 and R 4 is H or D.
- R 3 is selected from A, O-A, C(O)-A, C(O)O-A, C1- 2alkylene-A, C 1-2 alkylene-C(O)-A, C 1-2 alkylene-C(O)O-A, O-C 1-2 alkylene-A, O-C 1-2 alkylene- C(O)-A, and O-C 1-2 alkylene-C(O)O-A and O-C 1-2 alkylene-A and R 4 is H or D, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom.
- R 3 is selected from A, O-A, C(O)-A, C(O)O-A, CH2-A, CD2-A, CF2-A, CH2-C(O)-A, CF2-C(O)-A, CD2-C(O)-A, CH2-C(O)O-A, CD2-C(O)O- A, CF2-C(O)O-A, O-CH2A, O-CF2A, O-CD2A O-CH2-C(O)-A, O-CD2-C(O)-A, O-CF2-C(O)- A, O- CH2-C(O)O-A, O- CF2-C(O)O-A, and O- CD2-C(O)O-A, and R 4 is H or D.
- R 4 is selected from A, O-A, C(O)-A, C(O)O-A, C 1-2 alkylene-A, C 1-2 alkylene- C(O)-A, C 1-2 alkylene-C(O)O-A, O-C 1-2 alkylene-A, O-C 1-2 alkylene-C(O)-A, and O-C1- 2alkylene-C(O)O-A and O-C 1-2 alkylene-A and R 3 is H or D, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom.
- R 4 is selected from A, O-A, C(O)-A, C(O)O-A, CH2-A, CD2-A, CF2- A, CH2-C(O)-A, CF2-C(O)-A, CD2-C(O)-A, CH2-C(O)O-A, CD2-C(O)O-A, CF2-C(O)O-A, O- CH2A, O-CF2A, O-CD2A O-CH2-C(O)-A, O-CD2-C(O)-A, O-CF2-C(O)-A, O- CH2-C(O)O-A, O- CF 2 -C(O)O-A, and O- CD 2 -C(O)O-A, and R 3 is H or D.
- A is selected from C 1-30 alkyl, C 2-30 alkenyl, phenyl, C 3 - 6cycloalkyl, 3- to 6-membered heterocycloalkyl comprising 1 to 3 heteromoeities independently selected from O, S, S(O), SO 2 , N and NR 64 and 5- to 6-membered heteroaryl wherein the phenyl, C 3 - 10 cycloalkyl, 3- to 6-membered heterocycloalkyl and 5- to 6- membered heteroaryl are optionally substituted with one or two substituents independently selected from F, Cl, OH, C 1-4 alkyl, C 1-4 deuteroalkyl, C 1-4 fluoroalkyl, OC 1-4 alkyl, OC 1- 4 deuteroalkyl and OC 1-4 fluoroalkyl, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom.
- A is selected from C 1-30 alkyl, C 2-30 alkenyl, phenyl, C 3 - 6 cycloalkyl, 3- to 6-membered heterocycloalkyl comprising 1 to 3 heteromoeities independently selected from O, S, S(O), SO 2 , N and NR 63 and 5- to 6-membered heteroaryl comprising 1 to 3 heteromoeities independently selected from O, S, S(O), SO2, N and NR 53 , wherein the phenyl, C3- 10cycloalkyl, 3- to 6-membered heterocycloalkyl and 5- to 6-membered heteroaryl are optionally substituted with one or two substituents independently selected from F, Cl, OH, C 1-4 alkyl, C 1-4 deuteroalkyl, C 1-4 fluoroalkyl, OC 1-4 alkyl, OC 1-4 deuteroalkyl and OC1- 4fluoroalkyl.
- A is selected from phenyl, C3-6cycloalkyl, 3- to 6- membered heterocycloalkyl comprising 1 to 3 heteromoeities independently selected from O, S, S(O), SO2, N and NR 53 and 5- to 6-membered heteroaryl comprising 1 to 3 heteromoeities independently selected from O, S, S(O), SO2, N and NR 63 , wherein the phenyl, C3-10cycloalkyl, 3- to 6-membered heterocycloalkyl and 5- to 6-membered heteroaryl are optionally substituted with one or two substituents independently selected from F, Cl, OH, C 1-4 alkyl, C 1-4 deuteroalkyl, C 1-4 fluoroalkyl, OC 1-4 alkyl, OC 1-4 deuteroalkyl and OC 1-4 fluoroalkyl.
- A is selected from phenyl, C3-6cycloalkyl, 5- to 6- membered heterocycloalkyl comprising 1 to 2 heteromoeities independently selected from O, S, S(O), SO2, N and NR 63 and 5- to 6-membered heteroaryl comprising 1 to 3 heteromoeities independently selected from O, S, S(O), SO2, N and NR 63 , wherein the phenyl, C3-10cycloalkyl, 3- to 6-membered heterocycloalkyl and 5- to 6-membered heteroaryl are optionally substituted with one or two substituents independently selected from F, Cl, OH, C 1-4 alkyl, C 1-4 deuteroalkyl, C 1-4 fluoroalkyl, OC 1-4 alkyl, OC 1-4 deuteroalkyl and OC 1-4 fluoroalkyl.
- the C3-6cycloalkyl in A is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
- the C3-6cycloalkyl in A is cyclopropyl which is optionally substituted with one or two substituents independently selected from F, Cl, C 1-4 alkyl, C 1-4 deuteroalkyl, C 1-4 fluoroalkyl, OC 1-4 alkyl, OC 1-4 deuteroalkyl and OC 1-4 fluoroalkyl.
- the 3- to 6-membered heterocycloalkyl comprising 1 to 3 heteromoeities independently selected from O, S, S(O), SO 2 , N and NR 64 in A is selected from aziridinyl, oxiranyl, thiiranyl, oxaxiridinyl, dioxiranyl, azetidinyl, oxetanyl, theitanyl, diazetidinyl, dioxetanyl, dithietanyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, isoxthiolidinyl, thiazolidinyl, isothiazolidinyl, dioxolanyl, dithiolanyl, piperidinyl, triazolyl, furazanyl, oxadiazolyl, thiadiazolyl
- the 3- to 6-membered heterocycloalkyl comprising 1 to 3 heteromoeities independently selected from O, S, S(O), SO2, N and NR 64 in A are selected from tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, dioxolanyl, , piperidinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothiopyranyl oxide, tetrahydrothiopyranyl dioxide, dihydropyranyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl, each of which are optionally substituted with one or two substituents independently selected from F, C, C1- 4alkyl, C 1-4 deuteroalkyl,
- the 5- to 6-membered heteroaryl in A is selected from furyl, imidazolyl, isothiazolyl, thiazolyl, pyridyl, pyrazinyl, pyrazolyl, pyrrolyl, thienofuryl, triazolyl and thienyl, each of which are optionally substituted with one or two substituents independently selected from F, C, C 1-4 alkyl, C 1-4 deuteroalkyl, C 1-4 fluoroalkyl, OC 1-4 alkyl, OC 1-4 deuteroalkyl and OC 1-4 fluoroalkyl.
- the 5- to 6- membered heteroaryl in A is selected from furyl, isothiazolyl, thiazolyl, pyridyl and pyrrolyl, each of which are optionally substituted with one or two substituents independently selected from F, C, C 1-4 alkyl, C 1-4 deuteroalkyl, C 1-4 fluoroalkyl, OC 1-4 alkyl, OC 1-4 deuteroalkyl and OC 1-4 fluoroalkyl.
- the phenyl, C3-10cycloalkyl, 3- to 6-membered heterocycloalkyl and 5- to 6-membered heteroaryl in A are optionally substituted with one or two substituents independently selected from F, Cl, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , CH(CH 3 ) 2 , CF 3 , CF 2 H, CH 2 CF 2 H, CH 2 CF 3 , CH 2 CFH 2 , CH(CF 3 ) 2 , CD 3 , CH(CH 3 ) 2 O, CH 3 CH2CH2O, CH 3 CH2O, CH 3 O, CF 3 O, CHF2O, CF2HCH2O, CF 3 CH2O, (CF 3 )2CHO, and CD 3 O.
- A is selected from C 1-30 alkyl and C 2-30 alkenyl wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom.
- A is C 10-25 alkyl, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom.
- A is C 13-21 alkyl, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom.
- A is C 10-25 alkenyl, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom. In some embodiments, A is C 13-21 alkenyl, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom. In some embodiments, A is C 10-25 alkenyl and comprises 1, 2, 3, 4, 5 or 6 double bonds. [00160] In some embodiments, the alkyl or alkene group of A is an alkyl or alkenyl group present in a fatty acid, wherein all available H atoms are optionally substituted with deuterium.
- A is an alkenyl group present in a fatty acid, wherein all available H atoms are optionally substituted with deuterium.
- the fatty acid is an omega-6 fatty acid (i.e. an unsaturated or polyunsaturated fatty acid wherein the double bond that is closest to the methyl end of the molecule is located at carbon numbered 6 starting from the end methyl group) or an omega-3 fatty acid (i.e. an unsaturated or polyunsaturated fatty acid wherein the double bond that is closest to the methyl end of the molecule is located at carbon numbered 3 starting from the end methyl group), wherein all available H atoms are optionally substituted with deuterium.
- A is an alkyl group present in a fatty acid wherein all available H atoms are optionally substituted with deuterium.
- the alkyl or alkene group of A is an alkyl or alkene group present in a fatty acid selected from the list of fatty acids in Table 1 wherein all available H atoms are optionally substituted with deuterium.
- the alkene group of A is an alkyl or alkenyl group present in linoleic acid, eicosadienoic acid or decosahexanoic acid.
- A when A is the alkyl or alkenyl group of a fatty acid wherein 1-10, 2-8, 2-6 or 2-4 H atoms are substituted with deuterium.
- R 63 and R 64 are independently selected from H, D, C 1-4 alkyl, C 1-4 fluoroalkyl and C 1-4 deuteroalkyl. In some embodiments, R 63 and R 64 are independently selected from H, D, CH 3 , CF 3 and CD 3 . In some embodiments, R 63 and R 64 are independently selected from H and D.
- the compound of Formula I is defined as follows: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R 1 is H; Q is selected from Q1, Q2, Q3, Q4, Q5 and Q6: (Q1), (Q2), (Q3), (Q4) (Q5), and (Q6) is a single bond or a double bond provided that when in Q1 is a double bond then R 8 and R 14 are not present, when in Q2 is a double bond then R 16 and R 24 are not present, and when in Q6 is a double bond then R 53 and R 62 are not present; R 2 and R 5 are independently selected from H, D and F; one or both of R 3 and R 4 is selected from H, C 1-4 alkoxy, C 1-4 fluoralkoxy and C 1- 4 deuteroalkoxy or R 3 and R 4 are linked together to form O-(CH 2 ) 1-2 O; R 7 , R 8 , R 9 , R 10 , R 12 , R
- the compound of Formula I is defined as follows: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, R 1 is selected from H, halo, NH 2 , C 1-6 alkyl, C 1-6 alkoxyl, NH(C 1-6 alkyl) and N(C 1-6 alkyl) 2 ; Q is selected from Q1, Q2, Q3, Q4, Q5 and Q6: (Q1), (Q2), (Q3), (Q4), (Q5) and (Q6) is a single bond or a double bond provided that when in Q1 is a double bond then R 8 and R 14 are not present, when in Q2 is a double bond then R 16 and R 24 are not present and when in Q6 is a double bond then R 53 and R 62 are not present; R 2 and R 5 are independently selected from H, halo, OH, C 1-6 alkyl and C 1-6 alkoxy; one or both of R 3 and R 4 is independently selected from H, halo,
- one of R 11 , R 19 , R 29 , R 30 R 34 , R 44 and R 56 is C(O)-A’.
- one of R 3 and R 4 is selected from A, O-A, C(O)-A, C(O)O-A, C1- 4alkylene-A, C 1-4 alkylene-C(O)-A, C 1-4 alkylene-C(O)O-A, O-C 1-4 alkylene-A, O-C 1-4 alkylene- C(O)-A and O-C 1-4 alkylene-C(O)O-A.
- the compounds of Formula I are selected from the compounds listed below, or a pharmaceutically acceptable salt, solvate and/or prodrug thereof: Compound I.D. Chemical Structures I-1 I-2 I-46 (R)-I-47 (R)-I-48 (R)-I-49 (R)-I-50 (R)-I-51 (R)-I-52 (S)-I-53 (R)-I-53 (R)-I-54 (R)-I-55 (R)-I-56 (R)-I-57 (S)-I-57 (R)-I-58 (R)-I-59 (R)-I-60 (R)-I-61 (R)-I-62 (R)-I-63 (R)-I-64 (R)-I-65 (R)-I-66 (R)-I-67 (R)-I-68 (R)-I-69 (R)-I-70 (R)-I-71 (R)-I-72 (R)-
- the present application also includes a compound selected from compound 12 and compound 16, 12 and 16 or a pharmaceutically acceptable salt, solvate and/or prodrug thereof.
- the pharmaceutically acceptable salt is an acid addition salt or a base addition salt. The selection of a suitable salt may be made by a person skilled in the art.
- Suitable salts include acid addition salts that may, for example, be formed by mixing a solution of a compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid. Additionally, acids that are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.) and Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley VCH; S. Berge et al, Journal of Pharmaceutical Sciences 197766(1) 1-19; P. Gould, International J.
- An acid addition salt suitable for, or compatible with, the treatment of subjects is any non-toxic organic or inorganic acid addition salt of any basic compound.
- Basic compounds that form an acid addition salt include, for example, compounds comprising an amine group
- Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric, nitric and phosphoric acids, as well as acidic metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate.
- organic acids which form suitable salts include mono-, di- and tricarboxylic acids.
- organic acids are, for example, acetic, trifluoroacetic, propionic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, mandelic, salicylic, 2- phenoxybenzoic, p-toluenesulfonic acid and other sulfonic acids such as methanesulfonic acid, ethanesulfonic acid and 2-hydroxyethanesulfonic acid.
- exemplary acid addition salts also include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates (“mesylates”), naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates) and the like.
- the mono- or di-acid salts are formed and such salts exist in either a hydrated, solvated or substantially anhydrous form.
- acid addition salts are more soluble in water and various hydrophilic organic solvents and generally demonstrate higher melting points in comparison to their free base forms.
- the selection criteria for the appropriate salt will be known to one skilled in the art.
- Other non-pharmaceutically acceptable salts such as but not limited to oxalates may be used, for example in the isolation of compounds of the application for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.
- a base addition salt suitable for, or compatible with, the treatment of subjects is any non-toxic organic or inorganic base addition salt of any acidic compound.
- Acidic compounds that form a basic addition salt include, for example, compounds comprising a carboxylic acid group.
- Illustrative inorganic bases which form suitable salts include lithium, sodium, potassium, calcium, magnesium or barium hydroxide as well as ammonia.
- Illustrative organic bases which form suitable salts include aliphatic, alicyclic or aromatic organic amines such as isopropylamine, methylamine, trimethylamine, picoline, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2- diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like.
- Exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine dicyclohexylamine choline and caffeine
- the selection of the appropriate salt may be useful, for example, so that an ester functionality, if any, elsewhere in a compound is not hydrolyzed.
- the selection criteria for the appropriate salt will be known to one skilled in the art.
- exemplary basic salts also include ammonium salts, alkali metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamine, Abutyl amine, choline and salts with amino acids such as arginine, lysine and the like.
- alkali metal salts such as sodium, lithium and potassium salts
- alkaline earth metal salts such as calcium and magnesium salts
- salts with organic bases for example, organic amines
- organic bases for example, organic amines
- alkali metal salts such as sodium, lithium and potassium salts
- alkaline earth metal salts such as calcium and magnesium salts
- salts with organic bases for example, organic amines
- organic bases for example, organic amines
- amino acids such as arginine, lysine and the like.
- Basic nitrogen containing groups may be quarternized with agents such as lower alkyl halides (e.g., methyl, ethyl and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl and dibutyl sulfates), long chain halides (e.g., decyl, lauryl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides) and others.
- lower alkyl halides e.g., methyl, ethyl and butyl chlorides, bromides and iodides
- dialkyl sulfates e.g., dimethyl, diethyl and dibutyl sulfates
- long chain halides e.g., decyl, lauryl and stearyl chlorides,
- Compounds carrying an acidic moiety can be mixed with suitable pharmaceutically acceptable salts to provide, for example, alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts) and salts formed with suitable organic ligands such as quaternary ammonium salts.
- suitable pharmaceutically acceptable salts for example, alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts) and salts formed with suitable organic ligands such as quaternary ammonium salts.
- suitable organic ligands such as quaternary ammonium salts.
- pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound.
- zwitterions when a compound of the application contains both a basic moiety, such as, but not limited to an aliphatic primary, secondary, tertiary or cyclic amine, an aromatic or heteroaryl amine, pyridine or imidazole and an acidic moiety, such as, but not limited to tetrazole or carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the terms “salt(s)” as used herein. It is understood that certain compounds of the application may exist in zwitterionic form, having both anionic and cationic centers within the same compound and a net neutral charge. Such zwitterions are included within the application.
- Solvates of compounds of the application include, for example, those made with solvents that are pharmaceutically acceptable. Examples of such solvents include water (resulting solvate is called a hydrate) and ethanol and the like. Suitable solvents are physiologically tolerable at the dosage administered.
- Prodrugs of the compounds of the present application include, for example, conventional esters formed with available hydroxy, thiol, amino or carboxyl groups. Some common esters which have been utilized as prodrugs are phenyl esters, aliphatic (C 1 -C 24 ) esters, acyloxymethyl esters, carbamates and amino acid esters.
- compounds of the present application may have at least one chiral center and therefore can exist as enantiomers and/or diastereomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present application. It is to be further understood that while the stereochemistry of the compounds may be as shown in any given compound listed herein, such compounds may also contain certain amounts (for example, less than 20%, suitably less than 10%, more suitably less than 5%) of compounds of the present application having an alternate stereochemistry. It is intended that any optical isomers, as separated, pure or partially purified optical isomers or racemic mixtures thereof are included within the scope of the present application.
- the compounds of the present application can also include tautomeric forms, such as keto-enol tautomers and the like. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution. It is intended that any tautomeric forms which the compounds form, as well as mixtures thereof, are included within the scope of the present application.
- the compounds of the present application may further exist in varying amorphous and polymorphic forms and it is contemplated that any amorphous forms, polymorphs, or mixtures thereof, which form are included within the scope of the present application.
- the compounds of the present application may further be radiolabeled and accordingly all radiolabeled versions of the compounds of the application are included within the scope of the present application.
- the compounds of the application also include those in which one or more radioactive atoms are incorporated within their structure.
- III. Compositions [00180]
- the compounds of the present application are suitably formulated in a conventional manner into compositions using one or more carriers. Accordingly, the present application also includes a composition comprising one or more compounds of the application and a carrier.
- the compounds of the application are suitably formulated into pharmaceutical compositions for administration to subjects in a biologically compatible form suitable for administration in vivo. Accordingly, the present application further includes a pharmaceutical composition comprising one or more compounds of the application and a compositions are used in the treatment of any of the diseases, disorders or conditions described herein.
- the compounds of the application are administered to a subject in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art.
- a compound of the application is administered by oral, inhalation, parenteral, buccal, sublingual, insufflation, epidurally, nasal, rectal, vaginal, patch, pump, minipump, topical or transdermal administration and the pharmaceutical compositions formulated accordingly.
- administration is by means of a pump for periodic or continuous delivery.
- Conventional procedures and ingredients for the selection and preparation of suitable compositions are described, for example, in Remington's Pharmaceutical Sciences (2000 - 20th edition) and in The United States Pharmacopeia: The National Formulary (USP 24 NF19) published in 1999.
- Parenteral administration includes systemic delivery routes other than the gastrointestinal (GI) tract and includes, for example intravenous, intra-arterial, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary (for example, by use of an aerosol), intrathecal, rectal and topical (including the use of a patch or other transdermal delivery device) modes of administration.
- Parenteral administration may be by continuous infusion over a selected period of time.
- a compound of the application is orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it is enclosed in hard or soft shell gelatin capsules, or it is compressed into tablets, or it is incorporated directly with the food of the diet.
- the compound is incorporated with excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, caplets, pellets, granules, lozenges, chewing gum, powders, syrups, elixirs, wafers, aqueous solutions and suspensions and the like.
- carriers that are used include lactose, com starch, sodium citrate and salts of phosphoric acid.
- Pharmaceutically acceptable excipients include binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate), or solvents (e.g. medium chain triglycerides, ethanol, water).
- binding agents e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
- fillers e.g., lactose, microcrystalline cellulose or calcium phosphate
- lubricants e.g., magnesium
- the tablets are coated by methods well known in the art.
- pH sensitive enteric coatings such as EudragitsTM designed to control the release of active ingredients are optionally used.
- Oral dosage forms also include modified release, for example immediate release and timed-release, formulations.
- modified-release formulations include, for example, sustained-release (SR), extended-release (ER, XR, or XL), time- release or timed-release, controlled-release (CR), or continuous-release (CR or Contin), employed, for example, in the form of a coated tablet, an osmotic delivery device, a coated capsule, a microencapsulated microsphere, an agglomerated particle, e.g., as of molecular sieving type particles, or, a fine hollow permeable fiber bundle, or chopped hollow permeable fibers, agglomerated or held in a fibrous packet.
- SR sustained-release
- ER extended-release
- CR controlled-release
- Contin continuous-release
- Timed-release compositions are formulated, for example as liposomes or those wherein the active compound is protected with differentially degradable coatings, such as by microencapsulation, multiple coatings, etc.
- Liposome delivery systems include, for example, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
- liposomes are formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
- useful carriers, solvents or diluents include lactose, medium chain triglycerides, ethanol and dried com starch.
- liquid preparations for oral administration take the form of, for example, solutions, syrups or suspensions, or they are suitably presented as a dry product for constitution with water or other suitable vehicle before use.
- aqueous suspensions and/or emulsions are administered orally, the compound of the application is suitably suspended or dissolved in an oily phase that is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents are added.
- Such liquid preparations for oral administration are prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., medium chain triglycerides, almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid).
- suspending agents e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats
- emulsifying agents e.g., lecithin or acacia
- non-aqueous vehicles e.g., medium chain triglycerides, almond oil, oily esters or ethyl alcohol
- preservatives e.g., methyl or propyl p-hydroxybenzoates or sorbic acid.
- a compound of the application is administered parenterally.
- solutions of a compound of the application are prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose.
- dispersions are prepared in glycerol, liquid polyethylene glycols, DMSO and mixtures thereof with or without alcohol and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. A person skilled in the art would know how to prepare suitable formulations.
- sterile solutions of the compounds of the application are usually prepared and the pH's of the solutions are suitably adjusted and buffered.
- the total concentration of solutes should be controlled to render the preparation isotonic.
- ointments or droppable liquids are delivered, for example, by ocular delivery systems known to the art such as applicators or eye droppers.
- such compositions include mucomimetics such as hyaluronic acid, chondroitin sulfate, hydroxypropyl methylcellulose or polyvinyl alcohol, preservatives such as sorbic acid, EDTA or benzyl chromium chloride and the usual quantities of diluents or carriers.
- a compound of the application is formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion.
- Formulations for injection are, for example, presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
- the compositions take such forms as sterile suspensions, solutions or emulsions in oily or aqueous vehicles and contain formulating agents such as suspending, stabilizing and/or dispersing agents. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists.
- compositions for nasal administration are conveniently formulated as aerosols, drops, gels and powders.
- the compounds of the application are conveniently delivered in the form of a solution, dry powder formulation or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer.
- Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which, for example, take the form of a cartridge or refill for use with an atomising device.
- the sealed container is a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser comprises an aerosol dispenser, it will contain a propellant which is, for example, a compressed gas such as compressed air or an organic propellant such as fluorochlorohydrocarbon.
- Suitable propellants include but are not limited to dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, heptafluoroalkanes, carbon dioxide or another suitable gas.
- the dosage unit is suitably determined by providing a valve to deliver a metered amount.
- the pressurized container or nebulizer contains a solution or suspension of the active compound.
- Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator are, for example, formulated containing a powder mix of a compound of the application and a suitable powder base such as lactose or starch.
- compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein a compound of the application is formulated with a carrier such as sugar, acacia, tragacanth, or gelatin and glycerine.
- Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.
- Suppository forms of the compounds of the application are useful for vaginal, urethral and rectal administrations. Such suppositories will generally be constructed of a mixture of substances that is solid at room temperature but melts at body temperature.
- the substances commonly used to create such vehicles include but are not limited to theobroma oil (also known as cocoa butter), glycerinated gelatin, other glycerides, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol. See, for example: Remington's Pharmaceutical Sciences, 16th Ed., Mack Publishing, Easton, PA, 1980, pp. 1530-1533 for further discussion of suppository dosage forms. [00191] In some embodiments a compound of the application is coupled with soluble polymers as targetable drug carriers.
- Such polymers include, for example, polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxy-ethylaspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.
- a compound of the application is coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
- a drug for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
- the compounds of the application are particularly amenable to administration with the air of nano-carrier systems, such as liposomes, micelles, nanoparticles, nano-emulsions, lipidic nano-systems and the like (see for example, Bhat, M. et al., Chem. and Phys. of Lipids, 2021, 236, 105053). Accordingly the present application includes a composition comprising one or more compounds of the application and one or more components of a nano-carrier system.
- nano-carrier systems such as liposomes, micelles, nanoparticles, nano-emulsions, lipidic nano-systems and the like
- a compound of the application including pharmaceutically acceptable salts and/or solvates thereof is suitably used on their own but will generally be administered in the form of a pharmaceutical composition in which the one or more compounds of the application (the active ingredient) is in association with a pharmaceutically acceptable carrier.
- the pharmaceutical composition will comprise from about 0.05 wt% to about 99 wt% or about 0.10 wt% to about 70 wt%, of the active ingredient and from about 1 wt% to about 99.95 wt% or about 30 wt% to about 99.90 wt% of a pharmaceutically acceptable carrier, all percentages by weight being based on the total composition.
- the compounds of the application including pharmaceutically acceptable salts, solvates and/or prodrugs thereof are used are administered in a composition comprising an additional therapeutic agent. Therefore the present application also includes a pharmaceutical composition comprising one of more compounds of the application, or pharmaceutically acceptable salts, solvates and/or prodrugs thereof and an additional therapeutic agent, and optionally one or more pharmaceutically acceptable excipients.
- the additional therapeutic agent is another known agent useful for treatment of a disease, disorder or condition by activation of a serotonin receptor, for example those listed in the Methods and Uses section below.
- the additional therapeutic agent is a psychoactive drug.
- a compound also includes embodiments wherein one or more compounds are referenced.
- IV. Methods and Uses of the Application Compounds of the application are useful for treating diseases, disorders or conditions by modulating, for example activating, a serotonin receptor. Therefore, the compounds of the present application are useful as medicaments. Accordingly, the [00197] The present application also includes a method of treating a disease, disorder or condition by activation of a serotonin receptor comprising administering a therapeutically effective amount of one or more compounds of the application to a subject in need thereof.
- the present application also includes a use of one or more compounds of the application for treatment of a disease, disorder or condition by activation of a serotonin receptor as well as a use of one or more compounds of the application for the preparation of a medicament for treatment of a disease, disorder or condition by activation of a serotonin receptor.
- the application further includes one or more compounds of the application for use in treating a disease, disorder or condition by activation of a serotonin receptor.
- the serotonin receptor is 5-HT2A. Accordingly, the present application includes a method for activating 5-HT2A in a cell, either in a biological sample or in a patient, comprising administering an effective amount of one or more compounds of the application to the cell.
- the application also includes a use of one or more compounds of the application for activating 5-HT2A in a cell as well as a use of one or more compounds of the application for the preparation of a medicament for activating 5-HT2A in a cell.
- the application further includes one or more compounds of the application for use in activating 5-HT2A in a cell.
- the serotonin receptor is 5-HT1A.
- the present application includes a method for activating 5-HT1A receptors in a cell, either in a biological sample or in a patient, comprising administering an effective amount of one or more compounds of the application to the cell.
- the application also includes a use of one or more compounds of the application for activating 5-HT1A receptors in a cell as well as a use of one or more compounds of the application for the preparation of a medicament for activating 5-HT1A receptors in a cell.
- the application further includes one or more compounds of the application for use in activating 5-HT1A receptors in a cell.
- the present application also includes a method of treating a disease, disorder or condition by activation of 5-HT2A comprising administering a therapeutically effective amount of one or more compounds of the application to a subject in need thereof.
- the present application also includes a use of one or more compounds of the application for treatment of a disease, disorder or condition by activation of 5-HT 2A as well as a use of one or more compounds of the application for the preparation of a medicament for treatment of a disease, disorder or condition by activation of 5-HT2A.
- the application further includes one or more compounds of the application for use in treating a disease, disorder or condition by activation of 5-HT 2A .
- the present application also includes a method of treating a disease, disorder or condition by activation of 5-HT 1A comprising administering a therapeutically effective amount of one or more compounds of the application to a subject in need thereof.
- the present application also includes a use of one or more compounds of the application for treatment of a disease, disorder or condition by activation of 5-HT 1A as well as a use of one or more compounds of the application for the preparation of a medicament for treatment of a disease, disorder or condition by activation of 5-HT1A.
- the application further includes one or more compounds of the application for use in treating a disease, disorder or condition by activation of 5-HT1A.
- the disease, disorder or condition may also be treated or treatable via alternative mechanisms, for example by modulation, deactivation, antagonism or reverse agonism of a serotonin receptor, including 5-HT2A and/or 5-HT1A.
- the compounds of the application are useful for preventing, treating and/or reducing the severity of a mental illness disorder and/or condition in a subject. Therefore, in some embodiments, the disease, disorder or condition that is treated by activation of a serotonin receptor is a mental illness. Accordingly, the present application also includes a method of treating a mental illness comprising administering a therapeutically effective amount of one or more compounds of the application to a subject in need thereof. The present application also includes a use of one or more compounds of the application for treatment a mental illness, as well as a use of one or more compounds of the application for the preparation of a medicament for treatment of a mental illness. The application further includes one or more compounds of the application for use in treating a mental illness.
- the mental illness is selected from anxiety disorders such as generalized anxiety disorder, panic disorder, social anxiety disorder and specific phobias; depression such as, hopelessness, loss of pleasure, fatigue and suicidal thoughts; mood disorders, such as depression, bipolar disorder, cancer-related depression, anxiety and cyclothymic disorder; psychotic disorders, such as hallucinations, delusions, schizophrenia; impulse control and addiction disorders, such as pyromania (starting fires), kleptomania (stealing) and compulsive gambling; alcohol addiction; drug addiction, such as opioid addiction; personality disorders, such as antisocial personality disorder, obsessive- compulsive personality disorder and paranoid personality disorder; obsessive-compulsive disorder (OCD), such as thoughts or fears that cause a subject to perform certain rituals or routines; post-traumatic stress disorder (PTSD); stress response syndromes (formerly called adjustment disorders); dissociative disorders, formerly called multiple personality disorder, or “split personality,” and depersonalization disorder; factitious disorders; sexual and
- the disease, disorder or condition that is treated by activation of a serotonin receptor comprises cognitive impairment; ischemia including stroke; neurodegeneration; refractory substance use disorders; sleep disorders; pain, such as social pain, acute pain, cancer pain, chronic pain, breakthrough pain, bone pain, soft tissue pain, nerve pain, referred pain, phantom pain, neuropathic pain, cluster headaches and migraine; obesity and eating disorders; epilepsies and seizure disorders; neuronal cell death; excitotoxic cell death; or a combination thereof.
- the mental illness is selected from hallucinations and delusions and a combination thereof.
- the hallucinations are selected from visual hallucinations, auditory hallucinations, olfactory hallucinations, gustatory hallucinations, tactile hallucinations, proprioceptive hallucinations, equilibrioceptive hallucinations, nociceptive hallucinations, thermoceptive hallucinations and chronoceptive hallucinations, and a combination thereof.
- the disease, disorder or condition that is treated by activation of a serotonin receptor is psychosis or psychotic symptoms.
- the present application also includes a method of treating psychosis or psychotic symptoms comprising administering a therapeutically effective amount of one or more compounds of the application to a subject in need thereof.
- the present application also includes a use of one or more compounds of the application for treatment of psychosis or psychotic symptoms, as well as a use of one or more compounds of the application for the preparation of a medicament for treatment of psychosis or psychotic symptoms.
- the application further includes one or more compounds of the application for use in treating psychosis or psychotic symptoms.
- administering to said subject in need thereof a therapeutically effective amount of the compounds of the application does not result in a and delusions.
- administering to said subject in need thereof a therapeutically effective amount of the compounds of the application results in an improvement of psychosis or psychotic symptoms such as, but not limited to, hallucinations and delusions. In some embodiments, administering to said subject in need thereof a therapeutically effective amount of the compounds of the application results in an improvement of psychosis or psychotic symptoms.
- the compounds of the application are useful for treating a central nervous system (CNS) disorder in a subject in need of therapy, comprising administering a therapeutically effective amount of a compound of general formula I, or a pharmaceutically acceptable salt thereof to the subject.
- CNS central nervous system
- the disease, disorder or condition that is treated by activation of a serotonin receptor is a central nervous system (CNS) disease, disorder or condition and/or a neurological disease, disorder or condition.
- CNS central nervous system
- the present application also includes a method of treating a CNS disease, disorder or condition and/or a neurological disease, disorder or condition comprising administering a therapeutically effective amount of one or more compounds of the application to a subject in need thereof.
- the present application also includes a use of one or more compounds of the application for treatment a CNS disease, disorder or condition and/or a neurological disease, disorder or condition, as well as a use of one or more compounds of the application for the preparation of a medicament for treatment of a CNS disease, disorder or condition and/or a neurological disease, disorder or condition.
- the application further includes one or more compounds of the application for use in treating a CNS disease, disorder or condition and/or a neurological disease, disorder or condition.
- the CNS disease, disorder or condition and/or neurological disease, disorder or condition is selected from neurological diseases including neurodevelopmental diseases and neurodegenerative diseases such as Alzheimer’s disease; presenile dementia; senile dementia; vascular dementia; Lewy body dementia; cognitive impairment, Parkinson’s disease and Parkinsonian related disorders such as Parkinson dementia, corticobasal degeneration, and supranuclear palsy; epilepsy; CNS trauma; CNS infections; CNS inflammation; stroke; multiple sclerosis; Huntington’s disease; mitochondrial disorders; Fragile X syndrome; Angelman syndrome; hereditary ataxias; neuro-otological and eye movement disorders; neurodegenerative diseases of the retina amyotrophic lateral sclerosis; tardive dyskinesias; hyperkinetic disorders; attention deficit hyperactivity disorder and attention deficit disorders; restless leg syndrome; Tourette’s syndrome; schizophrenia; the reward system including eating disorders such as anorexia nervosa (“AN”) and bulimia nervosa (“BN”); and binge eating disorder
- the subject is a mammal. In another embodiment, the subject is human. In some embodiments, the subject is a non-human animal. In some embodiments, the subject is canine. In some embodiments, the subject is feline. Accordingly, the compounds, methods and uses of the present application are directed to both human and veterinary diseases, disorders and conditions. [00215] In some embodiments, the compounds of the application are useful for treating behavioral problems in subjects that are felines or canines. [00216] Therefore, in some embodiments, the disease, disorder or condition that is treated by activation of a serotonin receptor is behavioral problems in subjects that are felines or canines.
- the present application also includes a method of treating a behavioral problem comprising administering a therapeutically effective amount of one or more compounds of the application to a non-human subject in need thereof.
- the present application also includes a use of one or more compounds of the application for treatment a behavioral problem in a non-human subject, as well as a use of one or more compounds of the application for the preparation of a medicament for treatment of a behavioral problem in a non-human subject.
- the application further includes one or more compounds of the application for use in treating a behavioral problem in a non-human subject.
- the behavioral problems are selected from, but are not limited to, anxiety, fear, stress, sleep disturbances, cognitive dysfunction, aggression, excessive noise making, scratching, biting and a combination thereof.
- the non-human subject is canine. In some embodiments, the non-human subject is feline.
- the present application also includes a method of treating a disease, disorder or condition by activation of a serotonin receptor comprising administering a therapeutically effective amount of one or more compounds of the application in combination with another known agent useful for treatment of a disease, disorder or condition by activation of a serotonin receptor to a subject in need thereof.
- the present application also includes a use of one or more compounds of the application in combination with another known agent useful for treatment of a disease, disorder or condition by activation of a serotonin receptor, as well as a use of one or more compounds of the application in combination with another known agent useful for treatment of a disease, disorder or condition by activation of a serotonin receptor for the preparation of a medicament for treatment of a disease, disorder or condition by activation of a serotonin receptor.
- the application further includes one or more compounds of the application in combination with another known agent useful for treatment of a disease, disorder or condition by activation of a serotonin receptor for use in treating a disease, disorder or condition by activation of a serotonin receptor.
- the disease, disorder or condition that is treated by activation of a serotonin receptor is a mental illness.
- the mental illness is selected from hallucinations and delusions and a combination thereof.
- the disease, disorder or condition that is treated by activation of a serotonin receptor is a central nervous system (CNS) disorder.
- the disease, disorder or condition that is treated by activation of a serotonin receptor is psychosis or psychotic symptoms.
- the disease, disorder or condition that is treated by activation of a serotonin receptor is behavioral problems in a non-human subject.
- the disease, disorder or condition that is treated by activation of a serotonin receptor is a mental illness and the one or more compounds of the application are administered in combination with one or more additional treatments for a mental illness.
- the additional treatments for a mental illness is selected from antipsychotics, including typical antipsychotics and atypical antipsychotics; antidepressants including selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants and monoamine oxidase inhibitors (MAOIs) (e.g.
- the disease, disorder or condition that is treated by activation of a serotonin receptor is selected from attention deficit hyperactivity disorder and attention deficit disorder and a combination thereof.
- the disease, disorder or condition that is treated by activation of a serotonin receptor is attention deficit hyperactivity disorder and/or attention deficit disorder and a combination thereof and the one or more compounds of the application are administered in combination with one or more additional treatments for attention deficit hyperactivity disorder and/or attention deficit disorder and a combination thereof.
- the additional treatments for attention deficit hyperactivity disorder and/or attention deficit disorder and a combination thereof are selected from methylphenidate, atomoxetine and amphetamine and a combination thereof.
- the disease, disorder or condition that is treated by activation of a serotonin receptor is dementia or Alzheimer’s disease and the one or more compounds of the application are administered in combination with one or more additional treatments for dementia or Alzheimer’s disease.
- the additional treatments for dementia and Alzheimer’s disease are selected acetylcholinesterase inhibitors, NMDA antagonists and muscarinic agonists and antagonists, and nicotinic agonists.
- the acetylcholinesterase inhibitors are selected from donepezil, galantamine, rivastigmine, and phenserine, and combinations thereof.
- the NMDA antagonists are selected from MK-801, ketamine, phencyclidine, and memantine, and combinations thereof.
- the nicotinic agonists is nicotine, nicotinic acid, nicotinic alpha7 agonists or alpha2 beta4 agonists or combinations thereof.
- the muscarinic agonists is a muscarinic M1 agonist or a muscarinic M4 agonist, or combinations thereof.
- the muscarinic antagonist is a muscarinic M2 antagonist.
- the disease, disorder or condition that is treated by activation of a serotonin receptor is psychosis or psychotic symptoms and the one or more compounds of the application are administered in combination with one or more additional treatments for psychosis or psychotic symptoms.
- the additional treatments for psychosis or psychotic symptom are selected typical antipsychotics and atypical antipsychotics.
- the typical antipsychotics are selected from acepromazine, acetophenazine, benperidol, bromperidol, butaperazine, carfenazine, chlorproethazine, chlorpromazine, chlorprothixene, clopenthixol, cyamemazine, dixyrazine, droperidol, fluanisone, flupentixol, fluphenazine, fluspirilene, haloperidol, levomepromazine, lenperone, loxapine, mesoridazine, metitepine, molindone, moperone, oxypertine, oxyprotepine, penfluridol, perazine, periciazine, perphenazine, pimozide, i i t i ti i hl i i thi d l spiperone, sulforid
- the atypical antipsychotics are selected from amoxapine, amisulpride, aripiprazole, asenapine, blonanserin, brexpiprazole, cariprazine, carpipramine, clocapramine, clorotepine, clotiapine, clozapine, iloperidone, levosulpiride, lurasidone, melperone, mosapramine, nemonapride, olanzapine, paliperidone, perospirone, quetiapine, remoxipride, reserpine, risperidone, sertindole, sulpiride, sultopride, tiapride, veralipride, ziprasidone and zotepine, and combinations thereof.
- the disease, disorder or condition that is treated by activation of a serotonin receptor is a mental illness and the one or more compounds of the application are administered in combination with one or more additional treatments for a mental illness.
- the additional treatments for a mental illness is selected typical antipsychotics and atypical antipsychotics.
- effective amounts vary according to factors such as the disease state, age, sex and/or weight of the subject or species.
- the amount of a given compound or compounds that will correspond to an effective amount will vary depending upon factors, such as the given drug(s) or compound(s), the pharmaceutical formulation, the route of administration, the type of condition, disease or disorder, the identity of the subject being treated and the like, but can nevertheless be routinely determined by one skilled in the art.
- the compounds of the application are administered one, two, three or four times a year. In some embodiments, the compounds of the application are administered at least once a week. However, in another embodiment, the compounds are administered to the subject from about one time per two weeks, three weeks or one month. In another embodiment, the compounds are administered about one time per week to about once daily.
- the compounds are administered 1, 2, 3, 4, 5 or 6 times daily.
- the length of the treatment period depends on a variety of factors, such as the severity of the disease, disorder or condition, the age of the subject, the concentration and/or the activity of the compounds of the application and/or a combination thereof.
- the effective dosage of the compound used for the treatment may increase or decrease over the course of a particular treatment regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art In some instances chronic administration is required
- the compounds are administered to the subject in an amount and for duration sufficient to treat the subject.
- the compounds of the application are administered at doses that are hallucinogenic or psychotomimetic and taken in conjunction with psychotherapy or therapy and may occur once, twice, three, or four times a year. However, in some embodiments, the compounds are administered to the subject once daily, once every two days, once every 3 days, once a week, once every two weeks, once a month, once every two months, or once every three months at doses that are not hallucinogenic or psychotomimetic.
- a compound of the application is either used alone or in combination with other known agents useful for treating diseases, disorders or conditions by activation of a serotonin receptor, such as the compounds of the application.
- a compound of the application is administered contemporaneously with those agents.
- “contemporaneous administration” of two substances to a subject means providing each of the two substances so that they are both active in the individual at the same time. The exact details of the administration will depend on the pharmacokinetics of the two substances in the presence of each other and can include administering the two substances within a few hours of each other, or even administering one substance within 24 hours of administration of the other, if the pharmacokinetics are suitable. Design of suitable dosing regimens is routine for one skilled in the art.
- two substances will be administered substantially simultaneously, i.e., within minutes of each other, or in a single composition that contains both substances. It is a further embodiment of the present application that a combination of agents is administered to a subject in a non-contemporaneous fashion.
- a compound of the present application is administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form. Accordingly, the present application provides a single unit dosage form comprising one or more compounds of the application, an additional therapeutic agent and a pharmaceutically acceptable carrier.
- the dosage of a compound of the application varies depending on many factors such as the pharmacodynamic properties of the compound, the mode of administration, the age, health and weight of the recipient, the nature and extent of the symptoms, the frequency of the treatment and the type of concurrent treatment, if any and the clearance rate of the compound in the subject to be treated.
- One of skill in the art can determine the appropriate dosage based on the above factors.
- one or more compounds of the application are administered initially in a suitable dosage that is adjusted as required, depending on the clinical response.
- Dosages will generally be selected to maintain a serum level of the one or more compounds of the application from about 0.01 ⁇ g/cc to about 1000 ⁇ g/cc, or about 0.1 ⁇ g/cc to about 100 ⁇ g/cc.
- oral dosages of one or more compounds of the application will range between about 10 ⁇ g per day to about 1000 mg per day for an adult, suitably about 10 ⁇ g per day to about 500 mg per day, more suitably about 10 ⁇ g per day to about 200 mg per day.
- a representative amount is from about 0.0001 mg/kg to about 10 mg/kg, about 0.0001 mg/kg to about 1 mg/kg, about 0.01 mg/kg to about 0.1 mg/kg or about 0.0001 mg/kg to about 0.01 mg/kg will be administered.
- a representative amount is from about 0.001 ⁇ g/kg to about 10 mg/kg, about 0.1 ⁇ g/kg to about 10 mg/kg, about 0.01 ⁇ g/kg to about 1 mg/kg or about 0.1 ⁇ g/kg to about 1 mg/kg.
- a representative amount is from about 0.1 mg/kg to about 10 mg/kg or about 0.1 mg/kg to about 1 mg/kg.
- compositions are formulated for oral administration and the one or more compounds are suitably in the form of tablets containing 0.1, 0.25, 0.5, 0.75, 1.0, 5.0, 10.0, 20.0, 25.0, 30.0, 40.0, 50.0, 60.0, 70.0, 75.0, 80.0, 90.0, 100.0, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000 mg of active ingredient (one or more compounds of the application) per tablet.
- the one or more compounds of the application are administered in a single daily, weekly or monthly dose or the total daily dose is divided into two, three or four daily doses.
- the compounds of the application are used or administered in an effective amount which comprises administration of doses or dosage regimens that are devoid of clinically meaningful psychedelic/ psychotomimetic actions.
- the compounds of the application are used or administered in an effective amount which comprises administration of doses or dosage regimens that provide clinical effects similar to those exhibited by a human plasma psilocin Cmax of 4 ng/mL or less and/or human 5-HT2A human CNS receptor occupancy of 40% or less or those exhibited by a human plasma psilocin Cmax of 1 ng/mL or less and/or human 5-HT 2A human CNS receptor occupancy of 30% or less.
- the compounds of the application are used or administered in an effective amount which comprises administration of doses or dosage regimens that provide clinical effects similar to those exhibited by a human plasma psilocin Tmax in excess of 60 minutes, in excess of 120 minutes or in excess of 180 minutes.
- a compound also includes embodiments wherein one or more compounds are referenced.
- compounds of the application also includes embodiments wherein only one compound is referenced.
- V. Preparation of Compounds [00240] Compounds of the present application can be prepared by various synthetic processes. The choice of particular structural features and/or substituents may influence the selection of one process over another.
- R 29 and/or R 30 are a protecting group, it is removed in a separate step.
- the compounds of Formula I are prepared as shown in Scheme 2: Scheme 2 [00244] Therefore, in some embodiments, compounds of Formula A, wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in Formula I, are reacted under basic conditions using, for example, pyridine with compounds of Formula C, wherein R 33 and R 35 -R 40 are as defined in Formula I, R 34 is as defined in Formula I or is a suitable protecting group such as an alkyloxycarbonyl or benzyloxycarbonyl protecting group and LG’ is a suitable leaving group, such as chloro, to provide compounds of Formula D.
- Reduction of keto group in the compounds of Formula C for example using Al-based reducing agents such as lithium borohydride lithium aluminum hydride or lithium aluminum deuteride provides the compounds of Formula (I), wherein R 31 and R 33 are either H or D. If R 34 is a protecting group, it is removed in a separate step or, wherein the protecting group is removed in the presence of Al-based reducing agents is removed during the reduction of the compounds of Formula D. [00245] A person skilled in the art would appreciate that a similar reaction sequence can be used to prepare compounds of Formula I, wherein Q is (Q5).
- the compounds of Formula I are prepared as shown in Scheme 3: Scheme 3 [00247] Therefore, in some embodiments, the compounds of Formula A, wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in Formula I, are coupled with compounds of Formula E, wherein and R 15-18 and R 20-24 are as defined in Formula I, R 19 is as defined in Formula I or is a suitable protecting group such as an alkyloxycarbonyl or benzyloxycarbonyl protecting group and LG’’ is a suitable leaving group, such as iodo, bromo, tosyl group or mesyl group, under suitable conditions, for example, with sodium hydride (NaH) or sodium tertiary butoxide (t-BuONa) to provide compounds of Formula I.
- NaH sodium hydride
- t-BuONa sodium tertiary butoxide
- R 19 is a protecting group, it is removed in a sepa’’te step.
- a person skilled in the art would appreciate that a similar reaction sequence can be used to prepare compounds of Formula I, wherein Q is (Q1) or (Q6) and is a single bond.
- the compound of Formula I, wherein Q is (Q1), (Q2) or (Q6) and is a single bond are prepared using methods known in the art, for example, the methods described in JP 2015096495 A and WO2007102883 A2.
- R 19 is a protecting group, it is removed in a separate step.
- a person skilled in the art would appreciate that a similar reaction sequence can be used to prepare compounds of Formula I, wherein Q is (Q1) and (Q6).
- the compound of Formula I, wherein Q is (Q1) or (Q2) or (Q6) are prepared using methods known in the art, for example, the methods described in WO2010095663 A1 , WO2017007008 and WO2021127333 [00253]
- Q is (Q2) and is a double bond
- the compounds of Formula I are prepared as shown in Scheme 5: Scheme 5 [00254] Therefore, in some embodiments, compounds of Formula A, wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in Formula I are coupled with compounds of Formula G, wherein and R 15-18 and R 20-24 are as defined in Formula I, R 19 is as defined in Formula I or is a suitable protecting group such as alkyloxycarbon
- R 19 is a protecting group, it is removed in a separate step.
- R 19 is a protecting group, it is removed in a separate step.
- a person skilled in the art would appreciate that a similar reaction sequence can be used to prepare compounds of Formula I, wherein Q is (Q1) and (Q6) and is a double bond.
- the compound of Formula I, wherein Q is (Q1) or (Q2) or (Q6) and is a double bond are prepared using methods known in the art, for example, the methods described in WO2016112637A1 and JP 2016141632 A.
- the compounds of Formula I(a) are protected with a suitable protecting group such as a mesylate group to provide compounds of Formula I(b) wherein PG is a suitable protecting group which is further reacted with a suitable base such as sodium methoxide (NaOMe) to provide a compound of Formula I wherein is a double bond and R 7 is H. If R 11 is a protecting group, it is removed in a separate step.
- a suitable protecting group such as a mesylate group
- PG is a suitable protecting group which is further reacted with a suitable base such as sodium methoxide (NaOMe) to provide a compound of Formula I wherein is a double bond and R 7 is H.
- NaOMe sodium methoxide
- compounds of Formula I, wherein Q (Q6) and is a single bond, and the stereochemistry at the carbon to which R 53 is bonded is either R or S are prepared using methods known in the art, for example, the methods described in WO 2007102883 A2.
- compounds of Formula I, wherein Q is (Q1), (Q2) or (Q6) and is a single bond, and the stereochemistry at the carbon to which R 14 , R 24 or R 53 is bonded is either R or S are prepared using methods known in the art, for example, the methods described in JP 2014224104 and WO 2018092047 A1.
- the products of the processes of the application may be isolated according to known methods, for example, the compounds may be isolated by evaporation of the solvent, by filtration, centrifugation, chromatography or other suitable method.
- the reactions described above are performed in a suitable inert organic solvent and at temperatures and for times that will optimize the yield of the desired compounds.
- suitable inert organic solvents include, but are not limited to, 2- propanol, dimethylformamide (DMF), 1,4-dioxane, methylene chloride, chloroform, tetrahydrofuran (THF), toluene, and the like.
- DMF dimethylformamide
- THF tetrahydrofuran
- THF tetrahydrofuran
- the neutral compound is treated with an acid or base in a suitable solvent and the formed salt is isolated by filtration, extraction or any other suitable method.
- solvates of the compounds of the application will vary depending on the compound and the solvate. In general, solvates are formed by dissolving the compound in the appropriate solvent and isolating the solvate by cooling or using an antisolvent. The solvate is typically dried or azeotroped under ambient conditions. The selection of suitable conditions to form a particular solvate can be made by a person skilled in the art.
- Prodrugs of the compounds of the present application may be, for example, conventional esters formed with available hydroxy, thiol, amino or carboxyl groups.
- available hydroxy or amino groups may be acylated using an activated acid in the presence of a base, and optionally, in inert solvent (e.g. an acid chloride in pyridine).
- inert solvent e.g. an acid chloride in pyridine.
- Example 1 R-6-Methoxy-1-((1-methylpyrrolidin-2-yl)methyl)-1H-indazole ((R) I-111) – Synthesis of (R)-2-(2-(6-methoxy-1H-indazole-1-carbonyl)pyrrolidine-1-yl)-1-phenyl-2 ⁇ 2 - ethan-1-one (2): [00274] A solution of ((benzyloxy)carbonyl)-D-proline (6.73 g, 26.99 mmol) in dry THF (80 mL) was treated with thionyl chloride (3.93 mL, 53.99 mmol) at room temperature and the resulting solution was refluxed for additional 2 h.
- Example 6 2-(6-Methoxy-1H-indazol-1-yl)-N,N-bis(methyl-d3)ethan-1-amine (I-6) Synthesis of 2-(6-methoxy-1H-indazol-1-yl)ethyl methanesulfonate (11): [00290] Title compound was prepared as described above starting from 2-(6- methoxy-1H-indazol-1-yl)ethan-1-ol (1.1 g, 5.72 mmol). Crude product was used in the next step without any purification.
- Example 8 (R)-6-Methoxy-1-(pyrrolidin-2-ylmethyl)-1H-indazole hydrochloride ((R)-I- 121.HCl) Synthesis of tert-butyl (R)-2-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate (20): [00294] Title compound was prepared as described for compound 11 starting from tert-butyl (R)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (5.43 g, 26.99 mmol). Crude product was used in the next step without any purification.
- the cells were passaged about three times a week, maintained between ⁇ 30% to ⁇ 90% confluence.
- 2.2 Cell plating [00302] 1. The cell culture medium (DMEM medium containing 10% dialyzed FBS and 1 ⁇ penicillin-streptomycin, 100 ⁇ g/mL Hygromycin B and 300 ⁇ g/mL G418), [00303] 2. For induction, 1 ⁇ g/ml tetracycline (final concentration) was added to cell culture medium and incubated for 48 hours prior to seeding cells into plate at 37oC, 5% (v/v) CO2. The cell culture medium was removed from flask. Cells were washed with DPBS. [00304] 3.
- DMEM medium containing 10% dialyzed FBS and 1 ⁇ penicillin-streptomycin, 100 ⁇ g/mL Hygromycin B and 300 ⁇ g/mL G418),
- 1 ⁇ g/ml tetracycline final concentration was added to cell culture medium and in
- Cells were diluted to 6.67 ⁇ 10 5 /mL with cell culture medium. [00310] 9. 30 ⁇ L/well cell suspensions added into a 384-well cell plate (The cell density was 20,000 cells/well). [00311] 10. The cell plate was incubated overnight at 37 o C, 5% (v/v) CO2. 2.3 Cell handling [00312] On the day of experiments, culture medium was removed from the cell plate. [00313] 10 ⁇ L of assay buffer (20 mM HEPES, in 1 ⁇ HBSS, pH 7.4) was added to each well of the cell plate. [00314] 2 ⁇ dye solution was prepared following the manual of the FLIPR® Calcium 6 Assay Kit: [00315] i.
- the dye was diluted with assay buffer. [00316] ii. Probenecid was added to the final concentration of 5 mM. [00317] iii. Vortexed vigorously for 1–2 minutes. [00318] 4. 10 ⁇ L of 2 ⁇ dye solution was added to each well of the cell plate [00319] 5. The cell plate was placed on plate shaker, followed by shaking at 600 rpm for 2 minutes. [00320] 6. The plate was incubated at 37 o C for 2 hours followed by an additional 15-minute incubation at 25 o C. 2.4 Prepare 3 ⁇ compound [00321] 1. Serotonin HCl was prepared to the concentration of 10 mM with DMSO. [00322] 2.
- test compounds were prepared to the concentration of 10 mM with DMSO. [00323] 3. The compounds were added to a 384-well compound source plate. [00324] 4. 3-folds serial dilutions were performed with DMSO. [00325] 5. 90 nL/well of serial diluted compounds was transferred from source plate to a 384-well compound plate by using an Echo. [00326] 6. 30 ⁇ L/well of assay buffer (20mM HEPES in 1 ⁇ HBSS, pH 7.4) was added to the compound plate. [00327] 7. The plate was mixed on-plate shaker for 2 minutes. 2.5 FLIPR assay [00328] 1.
- Table 2 Effect of exemplary compounds of Formula I using FLIPR functional assay on human 5-HT2A receptor Compound ID# h5-HT2A, EC50 [nM] RFU@10 ⁇ M (1) Psilocybin ND (2) 257 Psilocin 72.5 308 (R)-I-111 ND 251 (S)-I-111 ND 367 (R)-I-52 ND 534 12 ND 463 16 ND 491 I-6 ND 523 I-119 ND 599 (R)-I-121.HCl ND 306 (R)-I-120.HCl ND 280 (1) Curve fitting with activation (%) @ 10mM with RFU (2) ND: not detected [00334] Exemplary compounds of Formula I were evaluated using radioligand binding assay on human 5-HT2A receptor
- EC50 (nM) concentrations are illustrated in Table 2. This assay confirms that exemplary compounds of the application are effective ligands of the target human 5-HT2A receptors.
- the assay buffer was prepared following the table below. Reagent Concentration Tris 50 mM CaCl 2 4 mM BSA 0.1% (w/v) Adjust pH to 7.4 followed by 0.2 ⁇ M sterile filtration [00337] 2. 8 doses of reference and test compounds starting from 10 mM stock solution as required was prepared by 5-fold serial dilutions with 100% (v/v) DMSO. [00338] 3. UniFilter-96 GF/B plate was pretreated: [00339] i. 50 ⁇ l/well of 0.5% (v/v) PEI was added to UniFilter-96 GF/C plates. The plates were sealed and incubated at 4oC for 3 hrs. [00340] ii.
- the assay plate was prepared: [00342] i. Cell membrane was diluted with assay buffer and 330 ⁇ l/well was added to 96 round deep well plates to reach a concentration of 20 ⁇ g/well. [00343] ii.8 concentrations of reference or test compounds were prepared and 110 ⁇ l/well was added to 96 round deep well plates. [00344] iii. [3H]-ketanserin was diluted with assay buffer to 5 nM (5X final concentration) and 110 ⁇ l/well was added to 96 round deep well plates. [00345] 5.
- the plate was centrifuged at 1000 rpm for 30 secs and then agitated at 600 rpm, R.T. for 5 min. [00346] 6. The plates were sealed and the plate incubated at 27oC for 90 min. [00347] 7. The incubation was stopped by vacuum filtration onto GF/B filter plates followed by 4 times washing with ice-cold wash buffer (50 mM Tris, pH7.4). [00348] 8. The plates were dried at 37oC for 45 min. [00349] 8. The filter plates were sealed and 40 ⁇ l/well of scintillation cocktail was added. [00350] 10. The plate was read by using a Microbeta 2 microplate counter. 3 Data Analysis [00351] 1.
- Table 3 Effect of exemplary compounds of Formula I using Radioligand binding assay on human 5-HT2A receptor Compound ID# h5-HT2A, IC 50 [nM] Psilocybin 4248 Psilocin 187.2 (R)-I-111 >30000 (S)-I-111 >30000 (R)-I-52 19429.6 12 5208.41 16 3403.52 I-6 5170.01 I-119 3582.94 (R)-I-121.HCl 2192.39 II. Results & Discussion [00354] Exemplary compounds of Formula I were evaluated using radioligand binding assay on human 5-HT2A receptor. IC 50 (nM) concentrations are illustrated in Table 3.
- the cells were passaged about three times a week, maintained between ⁇ 30% to ⁇ 90% confluence.
- 3.2 Cell plating [00357] 1. The cell culture medium (DMEM/F12 medium containing 10% dialyzed FBS, 1 ⁇ penicillin-streptomycin and 600 ⁇ g/mL Hygromycin B), TrypLETM Express and DPBS was warmed to R.T. in advance. [00358] 2. The cell culture medium was removed from flask. Washed cells with DPBS. [00359] 3. 1 mL TrypLETM Express was added to the flask, mixed well by gentle shaking and cells were incubated at 37 o C for a few minutes. [00360] 4.
- the cells were checked for morphological change under microscope, the digestion was stopped by adding 2 mL cell culture medium to the flask when most of cells turned to round. [00361] 5. The cell suspension was transferred into a 15 mL centrifuge tube, and then centrifuged at 1,200 rpm for 5 minutes. [00362] 6. The supernatant was removed. The cell pellet were resuspended with 2 mL cell culture medium. [00363] 7. The cell density were counted using cell counter. Only cells with >85% viability were used for the assay. [00364] 8. Cells were diluted to 4 ⁇ 10 5 /mL with cell culture medium. [00365] 9.
- probenecid was added to the final concentration of 5 mM.
- iii Vortexed vigorously for 1–2 minutes, adjust pH to 7.4.
- 4. 10 ⁇ L of 2 ⁇ dye solution was added to each well of the cell plate.
- the cell plate was placed on plate shaker, followed by shaking at 600 rpm for 2 minutes.
- the plate was incubated at 37 o C for 2 hours followed by an additional 15-minute incubation at 25 o C. 3.4 Prepare 3 ⁇ compounds.
- Serotonin was prepared to the concentration of 10 mM with DMSO, 3-folds serial dilutions were performed with DMSO. [00377] 2.
- Table 4 Effect of exemplary compounds of Formula I using FLIPR functional assay on human 5-HT1A receptor Compound ID# h5-HT1A, EC50 [nM] RFU@10 ⁇ M (1) Psilocybin ND (2) 143 Psilocin ND 140 (R) I-111 ND 76 (R)-I-52 ND 87 12 ND 1164 16 ND 268 I-6 3288 2486 I-119 ND 162 (R)-I-121.HCl ND 1165 (R)-I-120.HCl ND 170 (1) Curve fitting with activation (%) @ 10mM with RFU (2) Not detected [00388] Exemplary compounds of Formula I were evaluated using functional FLIPR assay on human 5-HT1A receptor.
- EC50 (nM) concentrations are illustrated in Table 4. This assay confirms that compounds of the application have moderate functional activity at the target human 5-HT1A receptors.
- the assay buffer was prepared following the table below. Reagent Concentration Tris 25 mM MgCl 2 10 mM CaCl2 1 mM BSA 0.5% (w/v) Adjust pH to 7.4 followed by 0.2 ⁇ M sterile filtration [00391] 2. 8 doses of reference and test compounds were prepared starting from 10 mM stock solution as required by 5-fold serial dilutions with 100% (v/v) DMSO. [00392] 3. UniFilter-96 GF/B plate was pretreated: [00393] i. 50 ⁇ l/well of 0.5% (v/v) PEI was added to UniFilter-96 GF/B plates. The plates were sealed and incubated at 4°C for 3 hrs.
- [3H]-8-Hydroxy-DPAT was diluted with assay buffer to 2 nM (4X final concentration) and 50 ⁇ l/well was added to 96 round well plates. [00399] 5. The plate was centrifuged at 1000 rpm for 30 secs and then agitated at 600 rpm, R.T. for 5 min. [00400] 6. The plates were sealed and the plate was incubated at 27oC for 90 min. [00401] 7. The incubation was stopped by vacuum filtration onto GF/B filter plates followed by 4 times washing with ice-cold wash buffer (50 mM Tris, pH7.4). [00402] 8. The plates were dried at 37oC for 45 min. [00403] 9.
- Table 5 Effect of exemplary compounds of Formula I using Radioligand binding assay on human 5-HT1A receptor Compound ID# h5-HT1A, IC50 [nM] Psilocybin 4785 Psilocin 195.7 (R) I-111 419.78 (R) I-52 924.39 12 46.81 16 616.50 I-6 23.79 I-119 486.50 (R)-I-121.HCl 33.57 (R)-I-120.HCl 668.21 Results & Discussion [00408] Exemplary compounds of Formula I were evaluated using radioligand binding assay on human 5-HT1A receptor. IC 50 (nM) concentrations are illustrated in Table 5.
- Example 14 Human, Rat and Mouse Liver Microsomes Stability Objective [00409] The objective of this study was to estimate in vitro metabolic stability of exemplary compounds of the application in pooled human, male rat and male mouse liver microsomes. The concentrations of compounds in reaction systems were evaluated by LC- MS/MS for estimating the stability in pooled human, male rat and male mouse liver microsomes. The in vitro intrinsic clearances of test compounds were determined as well. Protocol [00410] A master solution in the “Incubation Plate” containing phosphate buffer, ultra-pure H 2 O, MgCl 2 solution and liver microsomes was made according to Table 6.
- Peak areas were determined from extracted ion chromatograms.
- the slope value, k was determined by linear regression of the natural logarithm of the remaining percentage of the parent drug vs. incubation time curve.
- the in vitro half-life (in vitro t1/2) was determined from the slope value: [00418] Conversion of the in vitro t1/2 (min) into the in vitro intrinsic clearance (in vitro CLint, in ⁇ L/min/mg proteins) was done using the following equation (mean of duplicate determinations): [00419] For the exemplary compounds of the application or control compound that showed an initial fast disappearance followed by a slow disappearance, only the time points that were within the initial rate were included in the calculation.
- Human, rat and mouse liver microsomes contain a wide variety of drug metabolizing enzymes and are commonly used to support in vitro ADME (absorption, distribution, metabolism and excretion) studies. These microsomes are used to examine the potential first-pass metabolism by-products of orally administered drugs. Exemplary compounds of the application were evaluated for their stability in human, rat and mouse liver microsomes. [00421] A majority of the exemplary compounds of the application in two species, human and rat liver microsomes were recovered within a 60-minute time period indicating that the compounds were not rapidly cleared (see Table 7 for Exemplary compounds of Formula I).
- Table 7 Metabolic stability of exemplary compounds of Formula I and control compound diclofenac in human and rat with NADPH CLint Scaled-up Predicted Compound T 1/2 Species ( ⁇ L/min/mg CLint hepatic CL ID (min) protein) (mL/min/Kg) (mL/min/kg) Human 10.35 133.92 167.95 18.43 Diclofenac Rat 15.73 88.12 157.91 40.90 Human 110.55 12.54 15.72 8.94 I-6 Rat 7.10 195.17 349.75 47.68 (R)-I- Human 446.85 3.10 3.89 3.27 121.HCl Rat 42.62 32.52 58.27 28.35 Note: 1.
- Table 8 Metabolic stability of exemplary compounds of Formula I and control compound diclofenac in human, rat and mouse liver microsomes Example Remaining Percentage (%) Species Assay Format ID 0 min 30 min 60 min With Cofactors 100.00 5.38 1.80 Human Without Cofactors 100.00 99.36 95.90 Diclofenac With Cofactors 100.00 13.12 7.11 Rat Without Cofactors 100.00 100.63 97.86 With Cofactors 100.00 82.16 68.65 Human Without Cofactors 100.00 96.80 89.50 I-6 With Cofactors 100.00 5.35 0.51 Rat Without Cofactors 100.00 96.12 94.40 With Cofactors 100.00 92.80 91.11 Human (R)-I- Without Cofactors 100.00 98.12 96.49 121.HCl With Cofactors 100.00 52.52 37.70 Rat Without Cofactors 100.00 97.92 102.34 Discussion: [00422] The results demonstrate the exemplary compounds showed a spectrum of stability at 30 min and
- Example 15 Human, Rat, Mouse and Dog: Plasma stability [00423] 1. Preparation of Stock Solutions [00424] The stock solution of test compound is prepared in DMSO and diluted at the final concentration of 200 ⁇ M.1 mM lovastatin and propantheline working solution is pre- pared in DMSO and acetonitrile, respectively. Lovastatin is used as positive control for rat and dog plasma stability assay. Propantheline is used as positive control in human, mouse and monkey plasma stability assay [00425] 2.
- Procedures for Plasma Stability a.2.5 ⁇ L of 200 ⁇ M or 1 mM test compound or control compound solution is spiked to 497.5 ⁇ L plasma to reach a final concentration of 1 ⁇ M or 5 ⁇ M. The final concentration of organic solvents is 0.5 %. The assay is performed in duplicated. [00427] b. The reaction samples are incubated at 37°C at approximately 60 rpm in a water bath. [00428] c. Aliquots of 50 ⁇ L are taken from the reaction samples at 0, 30, 60, 120, 180 and 240 minutes.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present application relates to indazole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptors in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses and CNS disorders. Formula (I) wherein Q is selected from (Q1), (Q2), (Q3), (Q4) (Q5) and (Q6)
Description
TITLE: INDAZOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO RELATED APPLICATIONS [0001] The present application claims the benefit of priority of co-pending United States provisional patent application no.63/401,856 filed on August 29, 2022, the contents of which are incorporated herein by reference in their entirety. FIELD [0002] The application relates to indazole compounds for the treatment of different conditions that are treated by activation of serotonin receptors, for example, mental illnesses and neurological disease, in the fields of psychiatry, neurobiology and pharmacotherapy. BACKGROUND OF THE APPLICATION [0003] Mental health disorders, or mental illness, refer to a wide range of disorders that include, but are not limited to, depressive disorders, anxiety and panic disorders, schizophrenia, eating disorders, substance misuse disorders, post-traumatic stress disorder, attention deficit/hyperactivity disorder and obsessive-compulsive disorder. Many mental health disorders, as well as neurological disorders, are impacted by alterations, dysfunction, degeneration, and/or damage to the brain’s serotonergic system, which may explain, in part, common endophenotypes and comorbidities among neuropsychiatric and neurological diseases. [0004] The field of psychedelic neuroscience has witnessed a recent renaissance following decades of restricted research due to their legal status. Psychedelics (serotonergic hallucinogens) are powerful psychoactive substances that alter perception and mood and affect numerous cognitive processes. Today there is a consensus that psychedelics are agonists or partial agonists at brain serotonin 5-hydroxytryptamine 2A (5- HT2A) receptors. [0005] Psychedelics have both rapid onset and persisting effects long after their acute effects, which includes changes in mood and brain function. Long lasting effects may result from their unique receptor affinities, which affect neurotransmission via neuromodulatory systems that serve to modulate brain activity, i.e., neuroplasticity, and promote cell survival, are neuroprotective, and modulate brain neuroimmune systems. The mechanisms which lead to these long-term neuromodulatory changes are linked to epigenetic modifications, gene expression changes and modulation of pre- and post- synaptic receptor densities These previously under researched psychedelic drugs may
potentially provide the next-generation of neurotherapeutics, where treatment resistant psychiatric and neurological diseases, e.g., depression, post-traumatic stress disorder, dementia and addiction, may become treatable with attenuated pharmacological risk profiles. [0006] Although there is a general perception that psychedelic drugs are dangerous, from a physiologic safety standpoint, they are one of the safest known classes of CNS drugs. Preliminary data show that psychedelic administration in humans results in a unique profile of effects and potential adverse reactions that need to be appropriately addressed to maximize safety. The primary safety concerns are largely psychologic, rather than physiologic, in nature. Somatic effects vary but are relatively insignificant, even at doses that elicit powerful psychologic effects. Psilocybin, when administered in a controlled setting, has frequently been reported to cause transient, delayed headache, with incidence, duration, and severity increased in a dose-related manner [Johnson et al., Drug Alcohol Depend (2012) 123(1-3):132–140]. It has been found that repeated administration of psychedelics leads to a very rapid development of tolerance known as tachyphylaxis, a phenomenon believed to be mediated, in part, by 5-HT2A receptors. In fact, several studies have shown that rapid tolerance to psychedelics correlates with downregulation of 5-HT2A receptors. For example, daily LSD administration selectively decreased 5-HT2 receptor density in the rat brain [Buckholtz et al., Eur. J. Pharmacol. 1990, 109:421–425. 1985; Buckholtz et al., Life Sci.1985, 42:2439–2445]. [0007] Classic psychedelics and dissociative psychedelics are known to have rapid onset antidepressant and anti-addictive effects, unlike any currently available treatment. Randomized clinical control studies have confirmed antidepressant and anxiolytic effects of classic psychedelics in humans. [0008] Psilocybin (4-phosphoryloxy-N,N-dimethyltrypatmine) has the chemical formula C12H17N2O4P. It is a tryptamine and is one of the major psychoactive constituents in mushrooms of the psilocybe species. It was first isolated from psilocybe mushrooms by Hofmann in 1957, and later synthesized by him in 1958 [Passie et al. Addict Biol., 2002, 7(4):357-364], and was used in psychiatric and psychological research and in psychotherapy during the early to mid-1960s up until its controlled drug scheduling in 1970 in the US, and up until the 1980s in Germany [Passie 2005; Passie et al. Addict Biol., 2002, 7(4):357-364]. Research into the effects of psilocybin resumed in the mid-1990s, and it is currently the preferred compound for use in studies of the effects of serotonergic hallucinogens [Carter et al. J. Cogn. Neurosci., 2005 17(10):1497–1508; Gouzoulis-
Mayfrank et al. Neuropsychopharmacology 1999, 20(6):565-581; Hasler et al, Psychopharmacology (Berl) 2004, 172(2):145–156], likely because it has a shorter duration of action and suffers from less notoriety than LSD. Like other members of this class, psilocybin induces sometimes profound changes in perception, cognition and emotion, including emotional lability. [0009] In humans as well as other mammals, psilocybin is transformed into the active metabolite psilocin, or 4-hydroxy-N,N-dimethyltryptamine. It is likely that psilocin partially or wholly produces most of the subjective and physiological effects of psilocybin in humans and non-human animals. Recently, human psilocybin research confirmed the 5- HT2A activity of psilocybin and psilocin, and provides some support for indirect effects on dopamine through 5-HT2A activity and possible activity at other serotonin receptors. In fact, the most consistent finding for involvement of other receptors in the actions of psychedelics is the 5-HT1A receptor. That is particularly true for tryptamines and LSD, which generally have significant affinity and functional potency at this receptor. It is known that 5-HT1A receptors are colocalized with 5-HT2A receptors on cortical pyramidal cells [Martín-Ruiz et al. J Neurosci. 2001, 21(24):9856–986], where the two receptor types have opposing functional effects [Araneda et al. Neuroscience 1991, 40(2):399–412]. [0010] Although the exact role of the 5-HT2A receptor, and other 5-HT2 receptor family members, is not well understood with respect to the amygdala, it is evident that the 5-HT2A receptor plays an important role in emotional responses and is an important target to be considered in the actions of 5-HT2A agonist psychedelics. In fact, a majority of known 5-HT2A agonists produce hallucinogenic effects in humans, and rodents generalize from one 5-HT2A agonist to others, as between psilocybin and LSD [Aghajanian et al., Eur J Pharmacol., 1999, 367(2-3):197–206; Nichols at al., J Neurochem., 2004, 90(3):576–584]. Psilocybin has a stronger affinity for the human 5-HT2A receptor than for the rat receptor and it has a lower K(i) for both 5-HT2A and 5-HT2C receptors than LSD. Moreover, results from a series of drug-discrimination studies in rats found that 5HT2A antagonists, and not 5-HT1A antagonists, prevented rats from recognizing psilocybin [Winter et al., Pharmacol Biochem Behav., 2007, 87(4):472–480]. Daily doses of LSD and psilocybin reduce 5-HT2 receptor density in rat brain. [0011] Today, psilocybin is one of the most widely used psychedelics in human studies due to its relative safety, moderately long active duration, and good absorption in subjects. There remains strong research and therapeutic potential for psilocybin as recent studies have shown varying degrees of success in neurotic disorders, alcoholism,
depression in terminally ill cancer patients, obsessive compulsive disorder, addiction, anxiety, post-traumatic stress disorder and even cluster headaches. It could also be useful as a psychosis model for the development of new treatments for psychotic disorders. [Dubovyk and Monahan-Vaughn, ACS Chem. Neurosci. (2018), 9(9):2241−2251]. [0012] Recent developments in the field have occurred in clinical research, where several double-blind placebo-controlled phase 2 studies of psilocybin-assisted psychotherapy in patients with treatment resistant, major depressive disorder and cancer- related psychosocial distress have demonstrated unprecedented positive relief of anxiety and depression. Two recent small pilot studies of psilocybin assisted psychotherapy also have shown positive benefit in treating both alcohol and nicotine addiction. Recently, blood oxygen level–dependent functional magnetic resonance imaging and magnetoencephalography have been employed for in vivo brain imaging in humans after administration of a psychedelic, and results indicate that intravenously administered psilocybin and LSD produce decreases in oscillatory power in areas of the brain’s default mode network [Nichols DE. Pharmacol Rev., 2016, 68(2):264–355]. [0013] Preliminary studies using positron emission tomography (PET) showed that psilocybin ingestion (15 or 20 mg orally) increased absolute metabolic rate of glucose in frontal, and to a lesser extent in other, cortical regions as well as in striatal and limbic subcortical structures in healthy participants, suggesting that some of the key behavioral effects of psilocybin involve the frontal cortex [Gouzoulis-Mayfrank et al., Neuropsychopharmacology, 1999, 20(6):565-581; Vollenweider et al., Brain Res. Bull. 2001, 56(5):495–507]. Although 5-HT2A agonism is widely recognized as the primary action of classic psychedelic agents, psilocybin has lesser affinity for a wide range of other pre- and post-synaptic serotonin and dopamine receptors, as well as the serotonin reuptake transporter [Tyls et al., Eur. Neuropsychopharmacol., 2014, 24(3):342–356]. Psilocybin activates 5-HT1A receptors, which may contribute to antidepressant/anti-anxiety effects. [0014] Depression and anxiety are two of the most common psychiatric disorders worldwide. Depression is a multifaceted condition characterized by episodes of mood disturbances alongside other symptoms such as anhedonia, psychomotor complaints, feelings of guilt, attentional deficits and suicidal tendencies, all of which can range in severity. Similarly, anxiety disorders are a collective of etiologically complex disorders characterized by intense psychosocial distress and other symptoms depending on the subtype. Anxiety associated with life-threatening disease is the only anxiety subtype that has been studied in terms of psychedelic-assisted therapy. Pharmacological and
psychosocial interventions are commonly used to manage this type of anxiety, but their efficacy is mixed and limited such that they often fail to provide satisfactory emotional relief. Recent interest into the use of psychedelic-assisted therapy may represent a promising alternative for patients with depression and anxiety that are ineffectively managed by conventional methods. [0015] Generally, the psychedelic treatment model consists of administering the orally-active drug to induce a mystical experience lasting 4-9 h depending on the psychedelic [Halberstadt, Behav Brain Res., 2015, 277:99-120; Nichols, Pharmacol Rev., 2016, 68(2): 264-355]. This enables participants to work through and integrate difficult feelings and situations, leading to enduring anti-depressant and anxiolytic effects. Classical psychedelics like psilocybin and LSD are being studied as potential candidates. In one study with classical psychedelics for the treatment of depression and anxiety associated with life-threatening disease, it was found that, in a supportive setting, psilocybin, and LSD consistently produced significant and sustained anti-depressant and anxiolytic effects. [0016] Psychedelic treatment is generally well-tolerated with no persisting adverse effects. Regarding their mechanisms of action, they mediate their main therapeutic effects biochemically via serotonin receptor agonism, and psychologically by generating meaningful psycho-spiritual experiences that contribute to mental flexibility. Given the limited success rates of current treatments for anxiety and mood disorders, and considering the high morbidity associated with these conditions, there is potential for psychedelics to provide symptom relief in patients inadequately managed by conventional methods. [0017] Further emerging clinical research and evidence suggest psychedelic- assisted therapy, also shows potential as an alternative treatment for refractory substance use disorders and mental health conditions, and thus may be an important tool in a crisis where existing approaches have yielded limited success [dos Santos et al., Ther Adv Psychopharmacol., 2016, 6(3):193-213]. Similarly encouraging, are findings from a recent pilot study of psilocybin-assisted therapy for tobacco use disorder, demonstrating abstinence rates of 80% at six months follow-up and 67% at 12 months follow-up [Johnson et al., https://www.ncbi.nlm.nih.gov/pubmed/27441452 J Drug Alcohol Abuse, 2017, 43(1):55-60; Johnson et al., Psychopharmacol. 2014, 28(11):983-992], such rates are considerably higher than any documented in the tobacco cessation literature. Notably, mystical-type experiences generated from the psilocybin sessions were significantly correlated with positive treatment outcomes. These results coincide with bourgeoning evidence from recent clinical trials lending support to the effectiveness of psilocybin-
assisted therapy for treatment-resistant depression and end-of-life anxiety [Carhart-Harris et al. Neuropsychopharmacology, 2017, 42(11):2105-2113]. Research on the potential benefits of psychedelic-assisted therapy for opioid use disorder (OUD) is beginning to emerge, and accumulating evidence supports a need to advance this line of investigation. Available evidence from earlier randomized clinical trials suggests a promising role for treating OUD: higher rates of abstinence were observed among participants receiving high dose LSD and ketamine-assisted therapies for heroin addiction compared to controls at long-term follow-ups. Recently, a large United States population study among 44,000 individuals found that psychedelic use was associated with 40% reduced risk of opioid abuse and 27% reduced risk of opioid dependence in the following year, as defined by DSM-IV criteria [Pisano et al., J Psychopharmacol., 2017, 31(5):606-613]. Similarly, a protective moderating effect of psychedelic use was found on the relationship between prescription opioid use and suicide risk among marginalized women [Argento et al., J Psychopharmacol., 2018, 32(12):1385-1391]. Despite the promise of these preliminary findings with classical psychedelic agents, further research is warranted to determine what it may contribute to the opioid crisis response given their potential toxicity. Meanwhile, growing evidence on the safety and efficacy of psilocybin for the treatment of mental and substance use disorders should help to motivate further clinical investigation into its use as a novel intervention for OUD. [0018] Regular doses of psychedelics also ameliorate sleep disturbances, which are highly prevalent in depressive patients with more than 80% of them having complaints of poor sleep quality. The sleep symptoms are often unresolved by first-line treatment and are associated with a greater risk of relapse and recurrence. Interestingly, sleep problems often appear before other depression symptoms, and subjective sleep quality worsens before the onset of an episode in recurrent depression. Two other studies assessing electroencephalographic (EEG) brain activity during sleep showed that psychedelics, such as LSD, positively affect sleep patterns. Moreover, it has been shown that partial or a full night of sleep deprivation can alleviate symptoms of depression suggested by resetting circadian rhythms via modification of clock gene expression. It further was suggested that a single dose of a psychedelic causes a reset of the biological clock underlying sleep/wake cycles and thereby enhances cognitive-emotional processes in depressed people but also improving feelings of well-being and enhances mood in healthy individuals [Kuypers, Medical Hypotheses, 2019, 125:21–24]. [0019] In a systematic meta-analysis of clinical trials from 1960-2018 researching
and related psychiatric illness, it was found that psychedelic therapy (mostly with LSD) may improve cancer-related depression, anxiety, and fear of death. Four randomized controlled clinical trials were published between 2011 and 2016, mostly with psilocybin treatment, that demonstrated psychedelic-assisted treatment can produce rapid, robust, and sustained improvements in cancer-related psychological and existential distress. [Ross S, Int Rev Psychiatry, 2018, 30(4):317-330]. Thus, the use of psychedelics in the fields of oncology and palliative care is intriguing for several reasons. First, many patients facing cancer or other life-threatening illnesses experience significant existential distress related to loss of meaning or purpose in life, which can be associated with hopelessness, demoralization, powerlessness, perceived burdensomeness, and a desire for hastened death. Those features are also often at the core of clinically significant anxiety and depression, and they can substantially diminish quality of life in this patient population. The alleviation of those forms of suffering should be among the central aims of palliative care. Accordingly, several manualized psychotherapies for cancer-related existential distress have been developed in recent years, with an emphasis on dignity and meaning-making. However, there are currently no pharmacologic interventions for existential distress per se, and available pharmacologic treatments for depressive symptoms in patients with cancer have not demonstrated superiority over placebo. There remains a need for additional effective treatments for those conditions [Rosenbaum et al., Curr. Oncol., 2019, 26(4): 225–226]. [0020] Recently, there has been growing interest in a new dosing paradigm for psychedelics such as psilocybin and LSD referred to colloquially as microdosing. Under this paradigm, sub-perceptive doses of the serotonergic hallucinogens, approximately 10% or less of the full dose, are taken on a more consistent basis of once each day, every other day, or every three days, and so on. Not only is this dosing paradigm more consistent with current standards in pharmacological care, but may be particularly beneficial for certain conditions, such as Alzheimer’s disease and other neurodegenerative diseases, attention deficit disorder, attention deficit hyperactivity disorder, and for certain patient populations such as elderly, juvenile and patients that are fearful of or opposed to psychedelic assisted therapy. Moreover, this approach may be particularly well suited for managing cognitive deficits and preventing neurodegeneration. For example, subpopulations of low attentive and low motivated rats demonstrate improved performance on 5 choice serial reaction time and progressive ratio tasks, respectively, following doses of psilocybin below the threshold for eliciting the classical wet dog shake behavioral response associated with hallucinogenic doses (Blumstock et al., WO 2020/157569 A1, Higgins et al., Front. Pharmacol., 2001, DOI: 103389) Similarly treatment of patients with hallucinogenic doses of 5HT2A agonists is
associated with increased BDNF and activation of the mTOR pathway, which are thought to promote neuroplasticity and are hypothesized to serve as molecular targets for the treatment of dementias and other neurodegenerative disorders (Ly et al., Cell Rep., 2018, 23(11):3170-3182). Additionally, several groups have demonstrated that low, non- hallucinogenic and non-psychomimetic, doses of 5HT2A agonists also show similar neuroprotective and increased neuroplasticity effects (neuroplastogens) and reduced neuroinflammation, which could be beneficial in both neurodegenerative and neurodevelopmental diseases and chronic disorders (Manfredi et al., WO 2020/181194, Flanagan et al., Int. Rev. Psychiatry, 2018, 13:1-13; Nichols et al., 2016, Psychedelics as medicines; an emerging new paradigm). This repeated, lower, dose paradigm may extend the utility of these compounds to additional indications and may prove useful for wellness applications. [0021] Psychosis is often referred to as an abnormal state of mind that is characterized by hallucinatory experiences, delusional thinking, and disordered thoughts. Moreover, this state is accompanied by impairments in social cognition, inappropriate emotional expressions, and bizarre behavior. Most often, psychosis develops as part of a psychiatric disorder, of which, it represents an integral part of schizophrenia. It corresponds to the mostflorid phase of the illness. The veryfirst manifestation of psychosis in a patient is referred to as first-episode psychosis. It reflects a critical transitional stage toward the chronic establishment of the disease, that is presumably mediated by progressive structural and functional abnormalities seen in diagnosed patients. [ACS Chem. Neurosci., 2018, 9, 2241−2251]. Anecdotal evidence suggests that low, non-hallucinogenic, doses (microdosing) of psychedelics that are administered regularly can reduce symptoms of schizophrenia and psychosis. SUMMARY OF THE APPLICATION [0022] Compounds of the present application modulate the activity of serotonin receptor subtypes, in particular 5-HT2A, by direct binding to these receptors. [0023] Accordingly, the present application includes compounds of Formula I: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof,
wherein: R1 is selected from H, halo, NH2, C1-6alkyl, C1-6alkoxyl, NH(C1-6alkyl) and N(C1-6alkyl)2; Q is selected from Q1, Q2, Q3, Q4, Q5 and Q6: (Q1), (Q2), (Q3), (Q4) (Q5) and (Q6) is a single bond or a double bond provided that when in Q1 is a double bond then R8 and R14 are not present, when in Q2 is a double bond then R16 and R24 are not present, and when in Q6 is a double bond then R53 and R62 are not present; R2 and R5 are independently selected from H, halo, OH, C1-6alkyl and C1-6alkoxy; one or both of R3 and R4 is independently selected from H, halo, C1-6alkyl and C1-6alkoxy, or R3 and R4 are linked together to form O-(CH2)1-2O, or one of R3 and R4 is selected from X-L-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy; X is selected from a direct bond, O, C(O), NRa, NRaC(O), C(O)NRa, OC(O), C(O)O, OC(O)O, NRaC(O)O, OC(O)NRa and NRaC(O)NRa; L is selected from a direct bond, C1-6alkylene, C2-6alkenylene, C1-6alkyleneO, C2- 6alkenyleneO, C1-6alkyleneC(O), C2-6alkenyleneC(O), C1-6alkyleneNRbC(O), C2- 6alkenyleneNRbC(O), C1-6alkyleneC(O)NRb, C2-6alkenyleneC(O)NRb, C1-6alkyleneOC(O), C2-6alkenyleneOC(O), C1-6alkyleneC(O)O, C2-6alkenyleneC(O)O, C1-6alkyleneOC(O)NRb, C2-6alkenyleneOC(O)NRb, C1-6alkyleneNRbC(O)O C2-6alkenyleneNRbC(O)O, C1- 6alkyleneOC(O)O, C2-6alkenyleneOC(O)O, C1-6alkyleneNRbC(O)NRb and C2- 6alkenyleneNRbC(O)NRb;
Ra is selected from H and C1-6alkyl; Rb is selected from H, C1-6alkyl and A; A is selected from H, C1-30alkyl, C2-30alkenyl, phenyl, C3-6cycloalkyl, 3- to 6-membered heterocycloalkyl comprising 1 to 4 heteromoeities independently selected from O, S, S(O), SO2, N and NR63 and 5- to 6-membered heteroaryl comprising 1 to 4 heteromoeities independently selected from O, S, S(O), SO2, N and NR63, wherein the phenyl, C3- 10cycloalkyl, 3- to 6-membered heterocycloalkyl and 5- to 6-membered heteroaryl are optionally substituted with one or more substituents independently selected from halo, OH, C1-4alkyl and OC1-4alkyl; R7, R8, R9, R10, R12, R13, R14, R15, R16, R17, R18, R20, R21, R22, R23, R24, R25, R26, R27, R28, R31, R32, R33, R35, R36, R37, R38, R39, R40, R41, R42, R43, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R57, R58, R59, R60, R61 and R62 are independently selected from H, halo and C1- 6alkyl; R11, R19, R34, R44 and R56 are independently selected from H, C1-6alkyl and C(O)-A’; R29 and R30 are independently selected from H and C1-6alkyl; or one of R29 and R30 is C(O)-A’ and the other is selected from H and C1-6alkyl; wherein A' is selected from Y, O-Y and O-C1-4alkylene-O-C(O)-Y; and Y is selected from C7-30alkyl and C7-30alkenyl; or R29 and R30, together with the N atom to which they are bound, form a 3- to 6-membered heterocyclic ring which optionally comprises one or two additional heteromoieties independently selected from O, S, S(O), SO2, N, and NR64 and which is optionally substituted with one or more substituents independently selected from halo, OH, C1-4alkyl and OC1-4alkyl; R63 and R64 are independently selected from H and C1-6alkyl; and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof, provided when Q is Q3; at least one of R2, R3, R4, R5, R25, R26, R27, R28, R29 and R30 is D or comprises D, or at least one of R2, R3, R4, R5 is alkyl substituted with one or more fluorine and/or chlorine atoms; or at least three of R2, R3, R4, R5 are not H; or when Q is Q3; R3 and R4 are linked together to form O-(CH2)1-2O; or
when Q is Q3; one of R3 and R4 is selected from X-L-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy; and A is not H, C1-6alkyl or C2-6alkenyl; when Q is Q1 or Q4 then R7-R14 or R31- R40 respectively are not all H, when one of R3 and R4 is halo and the other of R3 and R4 is H. [0024] In some embodiments, the compound of Formula I is defined as follows: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R1 is H; Q is selected from Q1, Q2, Q3, Q4, Q5 and Q6: (Q1), (Q2) (Q3), (Q4) (Q5) and (Q6); is a single bond or a double bond provided that when in Q1 is a double bond then R8 and R14 are not present, when in Q2 is a double bond then R16 and R24 are not present, and when in Q6 is a double bond then R53 and R62 are not present; R2 and R5 are independently selected from H, D and F; one or both of R3 and R4 is selected from H, C1-4alkoxy, C1-4fluoralkoxy and C1- 4deuteroalkoxy, or R3 and R4 are linked together to form O-(CH2)1-2O;
R7, R8, R9, R10, R12, R13, R14, R15, R16, R17, R18, R20, R21, R22, R23, R24, R25, R26, R27, R28, R31, R32, R33, R35, R36, R37, R38, R39, R40, R41, R42, R43, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R57, R58, R59, R60, R61 and R62 are independently selected from H and D; and R11, R19, R29, R30, R34, R44 and R56 are independently selected from H, C1-4alkyl, C1- 4fluoroalkyl and C1-4deuteroalkyl. [0025] The present application also includes a compound selected from compound 12 and compound 16, (12) (16) or a pharmaceutically acceptable salt, solvate and/or prodrug thereof. [0026] In a further embodiment, the compounds of the application are used as medicaments. Accordingly, the application also includes a compound of the application for use as a medicament. [0027] The present application also includes a method of treating psychosis or psychotic symptoms comprising administering a therapeutically effective amount of one or more compounds of the application to a subject in need thereof. [0028] The present application also includes a method of treating a mental illness comprising administering a therapeutically effective amount of one or more compounds of the application to a subject in need thereof. [0029] The present application also includes a method of treating a central nervous system (CNS) disease, disorder or condition and/or neurological disease, disorder or condition comprising administering a therapeutically effective amount of one or more compounds of the application to a subject in need thereof. [0030] The application additionally provides a process for the preparation of compounds of the application. General and specific processes are discussed in more detail below and set forth in the examples below. [0031] Other features and advantages of the present application will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating embodiments of the application are given by way of illustration only and the scope of the claims should not be
limited by these embodiments but should be given the broadest interpretation consistent with the description as a whole. DETAILED DESCRIPTION I. Definitions [0032] Unless otherwise indicated, the definitions and embodiments described in this and other sections are intended to be applicable to all embodiments and aspects of the present application herein described for which they are suitable as would be understood by a person skilled in the art. [0033] The term "compound(s) of the application" or "compound(s) of the present application" and the like as used herein refers to a compound of Formula I, compound 12 and compound 16 and includes pharmaceutically acceptable salts, solvates and/or prodrugs thereof as well as all stereoisomers and regioisomers. [0034] The term "composition(s) of the application" or "composition(s) of the present application" and the like as used herein refers to a composition, such a pharmaceutical composition, comprising one or more compounds of the application. [0035] The term "and/or" as used herein means that the listed items are present, or used, individually or in combination. In effect, this term means that "at least one of or "one or more" of the listed items is used or present. The term "and/or" with respect to pharmaceutically acceptable salts, solvates and/or prodrugs thereof means that the compounds of the application exist as individual salts, solvates and prodrugs, as well as a combination of, for example, a salt of a solvate of a compound of the application. [0036] As used in the present application, the singular forms "a", "an" and "the" include plural references unless the content clearly dictates otherwise. For example, an embodiment including "a compound" should be understood to present certain embodiments with one compound, or two or more additional compounds. [0037] As used in this application and claim(s), the words "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have" and "has"), "including" (and any form of including, such as "include" and "includes") or "containing" (and any form of containing, such as "contain" and "contains"), are inclusive or open-ended and do not exclude additional, unrecited elements or process steps. [0038] The term “consisting” and its derivatives as used herein are intended to be
groups, integers and/or steps and also exclude the presence of other unstated features, elements, components, groups, integers and/or steps. [0039] The term “consisting essentially of”, as used herein, is intended to specify the presence of the stated features, elements, components, groups, integers and/or steps as well as those that do not materially affect the basic and novel characteristic(s) of these features, elements, components, groups, integers and/or steps. [0040] In embodiments comprising an “additional” or “second” component, such as an additional or second compound, the second component as used herein is chemically different from the other components or first component. A “third” component is different from the other, first and second components and further enumerated or “additional” components are similarly different. [0041] The term “suitable” as used herein means that the selection of the particular compound or conditions would depend on the specific synthetic manipulation to be performed, the identity of the molecule(s) to be transformed and/or the specific use for the compound, but the selection would be well within the skill of a person trained in the art. All process/method steps described herein are to be conducted under conditions sufficient to provide the product shown. A person skilled in the art would understand that all reaction conditions, including, for example, reaction solvent, reaction time, reaction temperature, reaction pressure, reactant ratio and whether or not the reaction should be performed under an anhydrous or inert atmosphere, can be varied to optimize the yield of the desired product and it is within their skill to do so. [0042] The terms "about", “substantially” and “approximately” as used herein mean a reasonable amount of deviation of the modified term such that the end result is not significantly changed. These terms of degree should be construed as including a deviation of at least ±5% of the modified term if this deviation would not negate the meaning of the word it modifies or unless the context suggests otherwise to a person skilled in the art. [0043] The present description refers to a number of chemical terms and abbreviations used by those skilled in the art. Nevertheless, definitions of selected terms are provided for clarity and consistency. [0044] The term "solvate" as used herein means a compound, or a salt and/or prodrug of a compound, wherein molecules of a suitable solvent are incorporated in the crystal lattice.
[0045] The term “prodrug” as used herein means a compound, or salt and/or prodrug of a compound, that, after administration, is converted into an active drug. [0046] The term “alkyl” as used herein, whether it is used alone or as part of another group, means straight or branched chain, saturated alkyl groups. The number of carbon atoms that are possible in the referenced alkyl group are indicated by the prefix “Cn1-n2”. Thus, for example, the term “C1-6alkyl” (or “C1-C6alkyl”) means an alkyl group having 1, 2, 3, 4, 5, or 6 carbon atoms. [0047] The term “alkenyl” as used herein, whether it is used alone or as part of another group, means straight or branched chain, saturated alkenyl groups containing at least one double bond. The number of carbon atoms that are possible in the referenced alkenyl group are indicated by the prefix “Cn1-n2”. Thus, for example, the term “C2-6alkyl” (or “C2-C6alkyl”) means an alkenyl group having 2, 3, 4, 5, or 6 carbon atoms. [0048] The term “alkenylene” as used herein, whether it is used alone or as part of another group, means a straight or branched chain, unsaturated alkylene group, that is, an unsaturated carbon chain that contains substituents on two of its ends and at least one double bond. The number of carbon atoms that are possible in the referenced alkenylene group are indicated by the prefix “Cn1-n2”. For example, the term C2-6alkenylene means an alkenylene group having 2, 3, 4, 5 or 6 carbon atoms. [0049] As used herein, the term “alkoxy” as used herein, alone or in combination, includes an alkyl group connected to an oxygen-connecting atom. [0050] The term “cycloalkyl,” as used herein, whether it is used alone or as part of another group, means a saturated carbocyclic group containing from 3 to 6 carbon atoms and one or more rings. The number of carbon atoms that are possible in the referenced cycloalkyl group are indicated by the numerical prefix “Cn1-n2”. For example, the term C3- 6cycloalkyl means a cycloalkyl group having 3, 4, 5 or 6 carbon atoms. [0051] The term “heterocycloalkyl” as used herein, whether it is used alone or as part of another group, refers to cyclic groups containing at least one non-aromatic ring containing from 3 to 6 atoms in which one or more of the atoms are a heteromoiety selected from O, S, S(O), SO2, NH, NC1-6alkyl and N and the remaining atoms are C. Heterocycloalkyl groups are either saturated or unsaturated (i.e. contain one or more double bonds). When a heterocycloalkyl group contains the prefix Cn1-n2 or “n1 to n2” this prefix indicates the number of carbon atoms in the corresponding carbocyclic group, in which one or more, suitably 1 to 4, of the ring atoms is replaced with a heteromoeity as
[0052] The term “aryl” as used herein, whether it is used alone or as part of another group, refers to carbocyclic groups containing at least one aromatic ring and contains from 6 to 10 carbon atoms.
[0053] The term “heteroaryl” as used herein, whether it is used alone or as part of another group, refers to cyclic groups containing at least one heteroaromatic ring containing 5-6 atoms in which one or more of the atoms are a heteroatom selected from O, S and N and the remaining atoms are C. When a heteroaryl group contains the prefix Cn1-n2 this prefix indicates the number of carbon atoms in the corresponding carbocyclic group, in which one or more, suitably 1 to 4, of the ring atoms is replaced with a heteroatom as defined above.
[0054] The term “halogen” (or “halo”) whether it is used alone or as part of another group, refers to a halogen atom and includes fluoro, chloro, bromo and iodo.
[0055] The term “haloalkyl” as used herein refers to an alkyl group as defined above in which one or more of the available hydrogen atoms have been replaced with a halogen. Thus, for example, “C1-6haloalkyl” refers to a C1 to C6 linear or branched alkyl group as defined above with one or more halogen substituents.
[0056] The term “deuteroalkyl” as used herein refers to an alkyl group as defined above in which one or more of the available hydrogen atoms have been replaced with a deuterium. Thus, for example, “C1-6deuteroalkyl” refers to a C1 to C6 linear or branched alkyl group as defined above with one or more deuterium substituents.
[0057] The term “available”, as in “available hydrogen atoms” or “available atoms” refers to atoms that would be known to a person skilled in the art to be capable of replacement by a substituent.
[0058] As used herein, the term “one or more” item includes a single item selected from the list as well as mixtures of two or more items selected from the list.
[0059] The term “alternate isotope thereof’ as used herein refers to an isotope of an element that is other than the isotope that is most abundant in nature.
[0060] In the compounds of general Formula I and pharmaceutically acceptable salts, solvates and/or prodrugs thereof, the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present application is meant to include all suitable isotopic variations of the compounds of general Formula I and
pharmaceutically acceptable salts, solvates and/or prodrugs thereof. For example, different isotopic forms of hydrogen (H) include protium (1H), deuterium (2H) and tritium (3H). Protium is the predominant hydrogen isotope found in nature. [0061] The term “compound” refers to the compound and, in certain embodiments, to the extent they are stable, any hydrate or solvate thereof. A hydrate is the compound complexed with water and a solvate is the compound complexed with a solvent, which may be an organic solvent or an inorganic solvent. A “stable” compound is a compound that can be prepared and isolated and whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein (e.g., therapeutic administration to a subject). The compounds of the present application are limited to stable compounds embraced by general Formula (I), or pharmaceutically acceptable salts, solvates and/or prodrugs thereof. [0062] The term “pharmaceutically acceptable” means compatible with the treatment of subjects. [0063] The term “pharmaceutically acceptable carrier” means a non-toxic solvent, dispersant, excipient, adjuvant or other material which is mixed with the active ingredient in order to permit the formation of a pharmaceutical composition, i.e., a dosage form capable of administration to a subject. [0064] The term “pharmaceutically acceptable salt” means either an acid addition salt or a base addition salt which is suitable for, or compatible with, the treatment of subjects. [0065] An acid addition salt suitable for, or compatible with, the treatment of subjects is any non-toxic organic or inorganic acid addition salt of any basic compound. [0066] A base addition salt suitable for, or compatible with, the treatment of subjects is any non-toxic organic or inorganic base addition salt of any acidic compound. [0067] The term "protecting group" or "PG" and the like as used herein refers to a chemical moiety which protects or masks a reactive portion of a molecule to prevent side reactions in those reactive portions of the molecule, while manipulating or reacting a different portion of the molecule. After the manipulation or reaction is complete, the protecting group is removed under conditions that do not degrade or decompose the remaining portions of the molecule. The selection of a suitable protecting group can be made by a person skilled in the art. Many conventional protecting groups are known in the art for example as described in "Protective Groups in Organic Chemistry" McOmie JFW
Ed., Plenum Press, 1973, in Greene, T.W. and Wuts, P.G.M., "Protective Groups in Organic Synthesis", John Wiley & Sons, 3rd Edition, 1999 and in Kocienski, P. Protecting Groups, 3rd Edition, 2003, Georg Thieme Verlag (The Americas). [0068] The term "subject" as used herein includes all members of the animal kingdom including mammals, and suitably refers to humans. Thus the methods of the present application are applicable to both human therapy and veterinary applications. [0069] The term "treating" or "treatment" as used herein and as is well understood in the art, means an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results include, but are not limited to alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease and remission (whether partial or total), whether detectable or undetectable. "Treating" and "treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. "Treating" and "treatment" as used herein also include prophylactic treatment. For example, a subject with early neurological disease can be treated to prevent progression, or alternatively a subject in remission can be treated with a compound or composition of the application to prevent recurrence. Treatment methods comprise administering to a subject a therapeutically effective amount of one or more of the compounds of the application and optionally consist of a single administration, or alliteratively comprise a series of administrations.. [0070] As used herein, the term "effective amount" or "therapeutically effective amount" means an amount of one or more compounds of the application that is effective, at dosages and for periods of time necessary to achieve the desired result. For example, in the context of treating a disease, disorder or condition mediated or treated by agonism or activation of serotonergic receptors and downstream second messengers, an effective amount is an amount that, for example, increases said activation compared to the activation without administration of the one or more compounds. [0071] “Palliating” a disease, disorder or condition means that the extent and/or undesirable clinical manifestations of a disease, disorder or condition are lessened and/or time course of the progression is slowed or lengthened, as compared to not treating the disorder.
[0072] The term "administered" as used herein means administration of a therapeutically effective amount of one or more compounds or compositions of the application to a cell, tissue, organ or subject. [0073] The term "prevention" or "prophylaxis", or synonym thereto, as used herein refers to a reduction in the risk or probability of a patient becoming afflicted with a disease, disorder or condition or manifesting a symptom associated with a disease, disorder or condition. [0074] The "disease, disorder or condition" as used herein refers to a disease, disorder or condition treated or treatable by activation of a serotonin receptor, for example 5-HT2A and particularly using a serotonin receptor agonist such as one or more compounds of the application herein described. [0075] The disease, disorder or condition may also be treated or treatable via alternative mechanisms, for example by modulation, deactivation, antagonism or reverse agonism of a serotonin receptor, including 5-HT2A and/or 5-HT1A. [0076] The term “treating a disease, disorder or condition by activation of a serotonin receptor” as used herein means that the disease, disorder or condition to be treated is affected by, modulated by and/or has some biological basis, either direct or indirect, that includes serotonergic activity, in particular increases in serotonergic activity. These diseases respond favourably when serotonergic activity associated with the disease, disorder or condition is modulated, for example agonized, by one or more of the compounds or compositions of the application. [0077] The term “activation” as used herein includes agonism, partial agonist and positive allosteric modulation of a serotonin receptor. [0078] The terms “5-HT1A” and “5-HT2A” are used herein mean the 5-HT1A and 5- HT2A receptor subtypes of the 5-HT serotonin receptor, respectively. [0079] The term “therapeutic agent” as used herein refers to any drug or active agent that has a pharmacological effect when administered to a subject. II. Compounds [0080] The present application includes compounds of Formula I:
or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein:
R1 is selected from H, halo, NH2, C1-6alkyl, C1-6alkoxyl, NH( C1-6alkyl) and N( C1-6alkyl)2;
- is a single bond or a double bond provided that when - in Q1 is a double bond then R8 and R14 are not present, when in Q2 is a double bond then R16 and R24 are not present, and when in Q6 is a double bond then R53 and R62 are not present;
R2 and R5 are independently selected from H, OH, halo, C1-6alkyl and C1-6alkoxy; one or both of R3 and R4 is independently selected from H, halo, C1-6alkyl and C1-6alkoxy, or
R3 and R4 are linked together to form O-(CH2)1-2O, or one of R3 and R4 is selected from X-L-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy;
X is selected from a direct bond, O, C(O), NRa, NRaC(O), C(O)NRa, OC(O), C(O)O, OC(O)O, NRaC(O)O, OC(O)NRa and NRaC(O)NRa;
L is selected from a direct bond, C1-6alkylene, C2-6alkenylene, C1-6alkyleneO, C2-
6alkenyleneO, C1-6alkyleneC(O), C2-6alkenyleneC(O), C1-6alkyleneNRbC(O), C2- 6alkenyleneNRbC(O), C1-6alkyleneC(O)NRb, C2-6alkenyleneC(O)NRb, C1-6alkyleneOC(O), C2-6alkenyleneOC(O), C1-6alkyleneC(O)O, C2-6alkenyleneC(O)O, C1-6alkyleneOC(O)NRb, C2-6alkenyleneOC(O)NRb, C1-6alkyleneNRbC(O)O C2-6alkenyleneNRbC(O)O, C1- 6alkyleneOC(O)O, C2-6alkenyleneOC(O)O, C1-6alkyleneNRbC(O)NRb and C2- 6alkenyleneNRbC(O)NRb; Ra is selected from H and C1-6alkyl; Rb is selected from H, C1-6alkyl, and A; A is selected from H, C1-30alkyl, C2-30alkenyl, phenyl, C3-6cycloalkyl, 3- to 6-membered heterocycloalkyl comprising 1 to 4 heteromoeities independently selected from O, S, S(O), SO2, N and NR63 and 5- to 6-membered heteroaryl comprising 1 to 4 heteromoeities independently selected from O, S, S(O), SO2, N and NR63, wherein the phenyl, C3- 10cycloalkyl, 3- to 6-membered heterocycloalkyl and 5- to 6-membered heteroaryl are optionally substituted with one or more substituents independently selected from halo, OH, C1-4alkyl and OC1-4alkyl; R7, R8, R9, R10, R12, R13, R14, R15, R16, R17, R18, R20, R21, R22, R23, R24, R25, R26, R27, R28, R31, R32, R33, R35, R36, R37, R38, R39, R40, R41, R42, R43, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R57, R58, R59, R60, R61 and R62 are independently selected from H, halo and C1- 6alkyl; R11, R19, R34, R44 and R56 are independently selected from H, C1-6alkyl and C(O)-A’; R29 and R30 are independently selected from H and C1-6alkyl, or one of R29 and R30 is C(O)-A’ and the other is selected from H and C1-6alkyl; wherein A' is selected from Y, O-Y and O-C1-4alkylene-O-C(O)-Y; Y is selected from C7-30alkyl and C7-30alkenyl; or R29 and R30, together with the N atom to which they are bound, form a 3- to 6-membered heterocyclic ring which optionally comprises one or two additional heteromoieties independently selected from O, S, S(O), SO2, N, and NR64 and which is optionally substituted with one or more substituents independently selected from halo, OH, C1-4alkyl and OC1-4alkyl; R63 and R64 are independently selected from H and C1-6alkyl; and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate
provided when Q is Q3; at least one of R2, R3, R4, R5, R25, R26, R27, R28, R29 and R30 is D or comprises D, or at least one of R2, R3, R4, R5 is alkyl substituted with one or more fluorine and/or chlorine atoms; or at least three of R2, R3, R4, R5 are not H; or when Q is Q3; R3 and R4 are linked together to form O-(CH2)1-2O; or when Q is Q3; one of R3 and R4 is selected from X-L-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy; and A is not H, C1-6alkyl or C2-6alkenyl; when Q is Q1 or Q4 then R7-R14 or R31- R40 respectively are not all H, when one of R3 and R4 is halo and the other of R3 and R4 is H. [0081] As used herein, by “substituted” in the context of “substituted with a fluorine atom or chlorine atom” or “substituted with alternate isotope thereof” or “ substituted with deuterium” means any hydrogen can be replaced with a fluorine atom or chlorine atom, or any atom can be replaced with alternate isotope thereof, such as deuterium. Accordingly, in some embodiments, all available hydrogen atoms are optionally and independently replaced with a fluorine atom or chlorine atom and all available atoms are optionally replaced with alternate isotope thereof. In some embodiments, all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium. [0082] In some embodiments, when Q is Q3; at least one of R2, R3, R4, R5, R25, R26, R27, R28, R29 and R30 is D or comprises D. [0083] In some embodiments, at least one of R2, R3, R4, R5 is alkyl substituted with one or more fluorine and/or chlorine atoms. [0084] In some embodiments, at least three of R2, R3, R4, R5 are not H. [0085] In some embodiments, R3 and R4 are linked together to form O-(CH2)1-2O. [0086] In some embodiments, one of R3 and R4 is selected from X-L-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy; and A is not H, C1- 6alkyl or C2-6alkenyl; [0087] In some embodiments, when Q is Q1 or Q4 then R7-R14 or R31- R40 respectively are not all H, when one of R3 and R4 is halo and the other of R3 and R4 is H. [0088] In some embodiments, when all available atoms are optionally replaced with alternate isotope thereof, all available hydrogen atoms in a group are optionally replaced with deuterium.
[0089] In some embodiments, Q is Q1, , and is a single bond and the compound of Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R1, R2, R3, R4, R5, R7, R8, R9, R10, R11, R12, R13 and R14 are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof, provided R7-R14 are not all H, when one of R3 and R4 is halo and the other of R3 and R4 is H. [0090] In some embodiments, Q is Q1, , and is a double bond and the compound of Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof,
wherein: R1, R2, R3, R4, R5, R7, R9, R10, R11, R12 and R13 are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof. [0091] In some embodiments, Q is Q2, , and is a single bond and the compound of Formula I has the following structure: I Or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R1, R2, R3, R4, R5, R15, R16, R17, R18, R19, R20, R21, R22, R23 and R24 are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof. [0092] In some embodiments, Q is Q2, , and is a double bond and the compound of Formula I has the following structure:
I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R1, R2, R3, R4, R5, R15, R17, R18, R19, R20, R21, R22 and R23 are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof. [0093] In some embodiments, Q is Q3, , and the compound of Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R1, R2, R3, R4, R5, R25, R26, R27, R28, R29 and R30 are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof, provided at least one of R2, R3, R4, R5, R25, R26, R27, R28, R29 and R30 is D or comprises D, or at least one of R2, R3, R4, R5 is alkyl substituted with one or more fluorine and/or chlorine
R3 and R4 are linked together to form O-(CH2)1-2O; or one of R3 and R4 is X-L-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy; and A is not H, C1-6alkyl or C2-6alkenyl. [0094] In some embodiments, Q is Q4, , and the compound of Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R1, R2, R3, R4, R5, R31, R32, R33, R34, R35, R36, R37, R38, R39 and R40 are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof, provided R2, R5, R31- R40 are not all H, when one of R3 and R4 is halo and the other of R3 and R4 is H. [0095] In some embodiments, Q is Q5 , and the compound of Formula I has the following structure:
I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R1, R2, R3, R4, R5, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51 and R52 are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof. [0096] In some embodiments, Q is Q6, , and is a single bond and the compound of Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R1, R2, R3, R4, R5, R53, R54, R55, R56, R57, R58, R59, R60, R61 and R62 are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate
[0097] In some embodiments, Q is Q6, , and is a double bond and the compound of Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R1, R2, R3, R4, R5, R54, R55, R56, R57, R58, R59, R60 and R61 are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof. [0098] In some embodiments, R1, R2, R4 and R5 are all H and the compound Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R3 and Q are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof,
provided when Q is Q3; at least one of R2, R3, R4, R5, R25, R26, R27, R28, R29 and R30 is D or comprises D, or R3 is alkyl substituted with one or more fluorine and/or chlorine atoms; or when Q is Q3; R3 is X-L-A and A is not H, C1-6alkyl or C2-6alkenyl, or when Q is Q1 or Q4 then R7-R14 or R31- R40 respectively are not all H, when R3 is halo. [0099] In some embodiments, R1, R2, R3 and R5 are all H and the compound Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R4 and Q are as defined for Formula I, and wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof, provided when Q is Q3; at least one of R2, R3, R4, R5, R25, R26, R27, R28, R29 and R30 is D or comprises D, or R4 is alkyl substituted with one or more fluorine and/or chlorine atoms; or when Q is Q3; R4 is X-L-A and A is not H, C1-6alkyl or C2-6alkenyl; when Q is Q1 or Q4 then R7-R14 or R31- R40 respectively are not all H, when R4 is halo. [00100] In some embodiments, R1, R2 and R5 are all H and the compound Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein:
R3, R4 and Q are as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof, provided when Q is Q3; at least one of R2, R3, R4, R5, R25, R26, R27, R28, R29 and R30 is D or comprises D, or at least one of R3 and R4 is alkyl substituted with one or more fluorine and/or chlorine atoms; or when Q is Q3; R3 and R4 are linked together to form O-(CH2)1-2O; or when Q is Q3; one of R3 and R4 is selected from X-L-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy; and A is not H, C1-6alkyl or C2-6alkenyl; when Q is Q1 or Q4 then R7-R14 or R31- R40 respectively are not all H, when one of R3 and R4 is halo and the other of R3 and R4 is H. [00101] In some embodiments, R1 is H and R2, R3, R4 and R5 are all D and the compound of Formula I has the following structure: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: Q is as defined for Formula I, and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof. [00102] In some embodiments, R7, R8, R9, R10, R12, R13, R14, R15, R16, R17, R18, R20, R21, R22, R23, R24, R25, R26, R27, R28, R31, R32, R33, R35, R36, R37, R38, R39, R40, R41, R42, R43, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R57, R58, R59, R60, R61 and R62 are independently selected from H, D, F, Cl, C1-6alkyl, C1-6fluoroalkyl and C1-6deuteroalkyl. In some embodiments, R7, R8, R9, R10, R12, R13, R14, R15, R16, R17, R18, R20, R21, R22, R23, R24, R25, R26, R27, R28, R31, R32, R33, R35, R36, R37, R38, R39, R40, R41, R42, R43, R45, R46, R47, R48,
from H, F, D, CH3, CD2H, CDH2, CD3, CF3, CHF2, CH2CH3, CH2CH2D, CH2CD2H and CD2CD3. In some embodiments, R7, R8, R9, R10, R12, R13, R14, R15, R16, R17, R18, R20, R21, R22, R23, R24, R25, R26, R27, R28, R31, R32, R33, R35, R36, R37, R38, R39, R40, R41, R42, R43, R45, R46, R47, R48, R49, R50, R51 , R52, R53, R54, R55, R57, R58, R59, R60, R61 and R62 are independently selected from H and D. [00103] In some embodiments, R8, R9, R10, R11, R13, R14, R15, R16, R17, R18, R19, R21, R22, R23, R24, R30, R31, R32, R33, R34, R35, R36, R37, R38, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R52, R53, R54, R55, R56 and R57 are independently selected from H and D. [00104] In some embodiments, R25, R26, R27 and R28 are independently selected from H and D. In some embodiments, R25, R26, R27 and R28 are H. In some embodiments, R25, R26, R27 and R28 are D. In some embodiments, R25 and R26 are H and R27 and R28 are D. In some embodiments, R25 and R26 are D and R27 and R28 are H. [00105] In some embodiments, when Q is (Q4) or (Q5), the stereochemistry at the carbon to which R33 or R43 is bonded is either R or S. Therefore in some embodiments, Q4 is or and Q5 is or . [00106] In some embodiments, the stereochemistry at the carbon to which R33 or R43 is bonded is R. In some embodiments, the stereochemistry at the carbon to which R33 or R43 is bonded is S.
[00107] In some embodiments, when Q is (Q1), (Q2) or (Q6) and is a single bond, the stereochemistry at the carbon to which R14, R24 or R53 is bonded is either R or S. Therefore in some embodiments, Q1 is or , Q2 is or , and Q6 is or . [00108] In some embodiments, the stereochemistry at the carbon to which R14, R24 or R53 is bonded is R. In some embodiments, the stereochemistry at the carbon to which R14, R24 or R53 is bonded is S. [00109] In some embodiments Q is selected from one of the following groups:
, wherein R11, R19, R29, R30, R34, R44 and R56 are independently selected from H, D, C1-6alkyl, C1-6fluoroalkyl, C1-6deuteroalkyl and C(O)-A’. In some embodiments, R11, R19, R29, R30, R34, R44 and R56 are independently selected from H, C1-4alkyl, C1-4fluoroalkyl, C1-4deuteroalkyl and C(O)-A’. In some embodiments, R11, R19, R29, R30, R34, R44 and R56 are independently selected from H, C1-4alkyl, C1-4fluoroalkyl and C1-4deuteroalkyl. In some embodiments, R11, R19, R29, R30, R34, R44 and R56 are independently selected from H, CH3, CD3, CD2H, CF2H and CF3. In some embodiments, R11, R19, R29, R30, R34, R44 and R56 are independently selected from H, CH3 and CD3. In some embodiments, R11, R19, R29, R30, R34, R44 and R56 are independently selected from CH3 and CD3. [00110] In some embodiments Q is selected from one of the following groups: , wherein R34 is selected from H, D, C1-6alkyl, C1-6fluoroalkyl, C1-6deuteroalkyl and C(O)-A’.
and C(O)-A’. In some embodiments, R34 is selected from H, C1-4alkyl, C1-4fluoroalkyl and C1-4deuteroalkyl. In some embodiments, R34 is selected from H, CH3, CD3, CD2H, CF2H and CF3. In some embodiments, R34 is selected from H, CH3 and CD3. In some embodiments, R34 is selected from CH3 and CD3. [00111] In some embodiments, R29 and R30, together with the N atom to which they are bound, form a 3- to 6-membered heterocyclic ring which optionally comprises one or two additional heteromoieties independently selected from O, N and NR64 and which is optionally substituted with one or more substituents independently selected from halo, OH, C1-4alkyl and OC1-4alkyl. [00112] In some embodiments, R11, R19, R29, R30, R34, R44 and R56 are independently selected from C(O)-A’. [00113] In some embodiments, one of R29 and R30 is C(O)-A’ and the other is selected from H and C1-6alkyl. In some embodiments, one of R29 and R30 is C(O)-A’ and the other is selected from H and C1-4alkyl. [00114] In some embodiments, A' is selected from Y, O-Y and O-C1-2alkylene-O- C(O)-Y, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom. In some embodiments, A' is selected from Y, O-Y and O-C1alkylene-O-C(O)-Y, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom. [00115] In some embodiments, Y is C10-25alkyl, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom. In some embodiments, Y is C13-21alkyl, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom. [00116] In some embodiments, Y is C10-25alkenyl, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom. In some embodiments, Y' is C13-21alkenyl, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom. In some embodiments, Y is C10-25alkenyl and comprises 1, 2, 3, 4, 5 or 6 double bonds. [00117] In some embodiments, the alkyl or alkene group of Y is an alkyl or alkenyl group present in a fatty acid, wherein all available H atoms are optionally substituted with deuterium. In some embodiments, Y is an alkenyl group present in a fatty acid, wherein all available H atoms are optionally substituted with deuterium. In some embodiments, the fatty acid is an omega-6 fatty acid (ie an unsaturated or polyunsaturated fatty acid wherein
the double bond that is closest to the methyl end of the molecule is located at carbon numbered 6 starting from the end methyl group) or an omega-3 fatty acid (i.e. an unsaturated or polyunsaturated fatty acid wherein the double bond that is closest to the methyl end of the molecule is located at carbon numbered 3 starting from the end methyl group), wherein all available H atoms are optionally substituted with deuterium. In some embodiments, Y is an alkyl group present in a fatty acid wherein all available H atoms are optionally substituted with deuterium. In some embodiments, the alkyl or alkene group of Y is an alkyl or alkene group present in a fatty acid selected from the list of fatty acids in Table 1 : Table 1 Common Name Lipid Number Chemical Name linoleic acid (LA) 18:2 (n-6) all-cis-9,12- octadecadienoic acid, rumenic acid 18:2 (n-6) 9Z,11E-octadecadienoic (conjugated linoleic acid) acid, conjugated linoleic acid 18:2 (n-6) 10E,12Z-octadecadienoic acid, conjugated linoleic acid 18:2 (n-6) 9Z,12E-octadecadienoic acid, gamma-linolenic acid (GLA) 18:3 (n-6) all-cis-6,9,12- octadecatrienoic acid, calendic acid 18:3 (n-6) 8E,10E,12Z- octadecatrienoic acid, eicosadienoic acid 20:2 (n−6) all-cis-11,14-eicosadienoic acid, dihomo-gamma-linolenic 20:3 (n−6) all-cis-8,11,14- acid (DGLA) eicosatrienoic acid, arachidonic acid (AA, ARA) 20:4 (n−6) all-cis-5,8,11,14- eicosatetraenoic acid
docosadienoic acid 22:2 (n−6) all-cis-13,16-docosadienoic acid, adrenic acid 22:4 (n−6) all-cis-7,10,13,16- docosatetraenoic acid, osbond acid 22:5 (n−6) all-cis-4,7,10,13,16- docosapentaenoic acid, tetracosatetraenoic acid 24:4 (n−6) all-cis-9,12,15,18- tetracosatetraenoic acid, tetracosapentaenoic acid 24:5 (n−6) all-cis-6,9,12,15,18- tetracosapentaenoic acid, α-linolenic acid (ALA) 18:3 (n−3) all-cis-9,12,15- octadecatrienoic acid, stearidonic acid (SDA) 18:4 (n−3) all-cis-6,9,12,15- octadecatetraenoic acid, hexadecatrienoic acid 16:3 (n−3) all-cis-7,10,13- (HTA) hexadecatrienoic acid, eicosatrienoic acid (ETE) 20:3 (n−3) all-cis-11,14,17- eicosatrienoic acid, eicosatetraenoic acid (ETA) 20:4 (n−3) all-cis-8,11,14,17- eicosatetraenoic acid, eicosapentaenoic acid 20:5 (n−3) all-cis-5,8,11,14,17- (EPA) eicosapentaenoic acid, heneicosapentaenoic acid 21:5 (n−3) all-cis-6,9,12,15,18- (HPA) heneicosapentaenoic acid, docosapentaenoic acid 22:5 (n−3) all-cis-7,10,13,16,19- (DPA) docosapentaenoic acid, docosahexaenoic acid 22:6 (n−3) all-cis-4,7,10,13,16,19- (DHA) docosahexaenoic acid, tetracosapentaenoic acid 24:5 (n−3) all-cis-9,12,15,18,21- tetracosapentaenoic acid,
tetracosahexaenoic acid 24:6 (n−3) all-cis-6,9,12,15,18,21- (Nisinic acid) tetracosahexaenoic acid, myristoleic acid 14:1 (n-5) 9Z-tetradecenoic acid, palmitoleic acid 16:1 (n-7) (9Z)-hexadecenoic acid, sapienic acid 16:1 (n-10) (6Z)-hexadecenoic acid, oleic acid 18-1 (n-9) (9Z)-octadecenoic acid, elaidic acid 18:1 (n-9) (E)-octadecenoic acid, vaccenic acid 18:1 (n-7) (11E)-octadecenoic acid, eruric acid 22-1 (n-9) (13Z)-Docosenoic acid, caprylic acid 8:0 octanoic acid, capric acid 10:0 decanoic acid, lauric acid 12:0 dodecanoic acid, myristic acid 14:0 tetradecanoic acid, palmitic acid 16:0 hexadecenoic acid, stearic acid 18:0 octadecanoic acid, arachidic acid 20:0 lcosanoic acid, behenic acid 22:0 docosanoic acid, lignoceric acid 24:0 tetracosanoic acid, and cerotic acid 26:0 hexacosanoic acid, wherein all available H atoms are optionally substituted with deuterium. [00118] In some embodiments, the alkene group of Y is an alkyl or alkenyl group present in linoleic acid, eicosadienoic acid and docosahexanoic acid. [00119] In some embodiments, Y is the alkyl or alkenyl group of a fatty acid wherein 1-10, 2-8, 2-6 or 2-4 H atoms are substituted with deuterium. [00120] In some embodiments, Y is (CH2)7CH=CH(CH2)7CH3. In some embodiments, Y is (CH2)7CH=CHCH2CH=CH(CH2)4CH3. In some embodiments, Y is (CH2)8CH=CHCH2CH=CH(CH2)4CH3. In some embodiments, Y is (CH2)7CH=CHCH2CH=CHCH2CH=CH(CH2)1CH3. In some embodiments, Y is
(CH2)3CH=CHCH2CH=CH(CH2)1CH=CHCH2CH=CH(CH2)3CH3. In some embodiments, Y is (CH2)2CH=CHCH2CH=CHCH2CH=CHCH2CH=CHCH2CH=CHCH2CH=CH(CH2)1CH3. Therefore, in some embodiments, Y is (CH2)7CH=CH(CH2)7CH3, (CH2)7CH=CHCH2CH=CH(CH2)4CH3, (CH2)8CH=CHCH2CH=CH(CH2)4CH3, (CH2)7CH=CHCH2CH=CHCH2CH=CH(CH2)1CH3, (CH2)3CH=CHCH2CH=CH(CH2)1CH=CHCH2CH=CH(CH2)3CH3, or (CH2)2CH=CHCH2CH=CHCH2CH=CHCH2CH=CHCH2CH=CHCH2CH=CH(CH2)1CH3. [00121] In some embodiments, A' is Y. [00122] In some embodiments, A' is -O-Y. [00123] In some embodiments, A' is -O-C3alkylene-O-C(O)-Y. [00124] In some embodiments, R1 is selected from H, halo, NH2, C1-4alkyl, C1- 4alkoxy, NH(C1-4alkyl) and N(C1-4alkyl)2. In some embodiments, R1 is selected from H, D, Cl, F, NH2, C1-4alkyl, C1-4alkoxy, C1-4fluoroalkyl, C1-4deuteroalkyl, NH(C1-4alkyl), NH(C1- 4deuteroalkyl), NH(C1-4flouroalkyl), N(C1-4alkyl)2, N(C1-4fluoroalkyl)2, N(C1-4deuteroalkyl)2, N(C1-4fluoroalkyl)(C1-4alkyl), N(C1-4fluoroalkyl)(C1-4deuteroalkyl) and N(C1-4deuteroalkyl)(C1- 4alkyl). In some embodiments, R1 is selected from H, D, Cl, F, NH2, C1-2alkyl, C1-2alkoxy, C1- 2fluoroalkyl, C1-2deuteroalkyl, NH(C1-2alkyl), NH(C1-2deuteroalkyl), NH(C1-2flouroalkyl), N(C1-2alkyl)2, N(C1-2fluoroalkyl)2, N(C1-2deuteroalkyl)2, N(C1-2fluoroalkyl)(C1-2alkyl), N(C1- 2fluoroalkyl)(C1-2deuteroalkyl) and N(C1-2deuteroalkyl)(C1-2alkyl). In some embodiments, R1 is selected from H, D, Cl, F, OH, C1-2alkyl, C1-2alkoxy, C1-2fluoroalkyl and C1-2deuteroalkyl. In some embodiments R1 is selected from H, D, F, NH2, CH3, CF2H, CD2H, CH3O, CF3, CD3, NH(CH3), NH(CD3), NH(CF3), N(CH3)2, N(CF3)2 and N(CD3)2. In some embodiments R1 is selected from H, D, F, NH2, CH3, CF2H, CD2H, CH3O, CF3 and CD3. In some embodiments R1 is selected from H, D, F, CH3, CF2H, CD2H, CH3O, CF3 and CD3. In some embodiments, R1 is selected from H and D. In some embodiments, R1 is D. In some embodiments R1 is H. [00125] In some embodiments, R2 and R5 are independently selected from H, D, Cl, F, OH, C1-4alkyl, C1-4alkoxy, C1-4fluoroalkoxy, C1-4deuteroalkoxy, C1-4fluoroalkyl and C1- 4deuteroalkyl. In some embodiments, R2 and R5 are independently selected from H, D, Cl, F, OH, C1-4alkyl, C1-4alkoxy, C1-4fluoroalkyl and C1-4deuteroalkyl. In some embodiments, R2 and R5 are independently selected from H, D, Cl, F, OH, C1-2alkyl, C1-2alkoxy, C1- 2fluoroalkoxy, C1-2deuteroalkoxy, C1-2fluoroalkyl and C1-2deuteroalkyl. In some embodiments, R2 and R5 are independently selected from H, D, Cl, F, OH, C1-2alkyl, C1- lk C fl lk l d C d t lk l I b di t R d R
independently selected from H, D, F, OH, CH3, CH3O, CF2HO, CD2HO, CF3O, CD3O, CF2H, CD2H, CF3 and CD3. In some embodiments, R2 and R5 are independently selected from H, D, F, OH, CH3, CF2H, CD2H, CH3O, CF3 and CD3. In some embodiments, R2 and R5 are independently selected from H, D, F, OH, CH3, CH3O, CF2HO, CF3O and CD3O. In some embodiments, R2 and R5 are independently selected from H and D. In some embodiments, at least one of R2 and R5 is D. In some embodiments, each of R2 and R5 are D. In some embodiments, each of R2 and R5 are H. [00126] In some embodiments, one or both of R3 and R4 is independently selected from H, D, F, Cl, C1-6alkyl, C1-6fluoroalkyl, C1-6deuteroalkyl, C1-6alkoxy, C1-6fluoroalkoxy and C1-6deuteroalkoxy. In some embodiments both of R3 and R4 are independently selected from H, D, F, Cl, C1-4alkyl, C1-4fluoroalkyl, C1-4deuteroalkyl, C1-4alkoxy, C1-4fluoroalkoxy and C1-4deuteroalkoxy. In some embodiments, one or both of R3 and R4 is independently selected from H, D, F, Cl, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CF3, CF2H, CH2CF2H, CH2CF3, CH2CFH2, CH(CF3)2, CD3, CH(CH3)2O, CH3CH2CH2O, CH3CH2O, CH3O, CF3O, CHF2O, CF2HCH2O, CF3CH2O, (CF3)2CHO, and CD3O. In some embodiments, one or both of R3 and R4 is independently selected from H, D, F, Cl, CH3, CH(CH3)2, CF3, CF2H, CD3, CH(CH3)2O, CH3O, CF3O, CHF2O, and CD3O. [00127] In some embodiments both of R3 and R4 are independently selected from H, D, F, Cl, C1-6alkyl, C1-6fluoroalkyl, C1-6deuteroalkyl, C1-6alkoxy, C1-6fluoroalkoxy and C1- 6deuteroalkoxy In some embodiments both of R3 and R4 are independently selected from D, F, Cl, C1-6alkyl, C1-6fluoroalkyl, C1-6deuteroalkyl, C1-6alkoxy, C1-6fluoroalkoxy and C1- 6deuteroalkoxy. In some embodiments both of R3 and R4 are independently selected from H, D, F, Cl, C1-4alkyl, C1-4fluoroalkyl, C1-4deuteroalkyl, C1-4alkoxy, C1-4fluoroalkoxy and C1- 4deuteroalkoxy.In some embodiments both of R3 and R4 are independently selected from H, D, F, Cl, CH3, CH(CH3)2, CF3, CF2H, CD3, CH(CH3)2O, CH3O, CF3O, CHF2O, and CD3O. In some embodiments both of R3 and R4 are independently selected from D, F, Cl, CH3, CH(CH3)2, CF3, CF2H, CD3, CH(CH3)2O, CH3O, CF3O, CHF2O, and CD3O. In some embodiments both of R3 and R4 are independently selected from CH3O, CF3O, CHF2O, and CD3O. In some embodiments both of R3 and R4 are CD3O or both of R3 and R4 are CH3O. [00128] In some embodiments, R3 is H or D and R4 is selected from H, D, F, Cl, C1- 6alkyl, C1-6fluoroalkyl, C1-6deuteroalkyl, C1-6alkoxy, C1-6fluoroalkoxy and C1-6deuteroalkoxy. In some embodiments, R3 is H or D and R4 is selected from H, D, F, Cl, C1-4alkyl, C1- 4fluoroalkyl, C1-4deuteroalkyl, C1-4alkoxy, C1-4fluoroalkoxy and C1-4deuteroalkoxy. In some embodiments, R3 is H or D and R4 is selected from H, D, F, Cl, CH(CH3)2, CH3, CF3, CF2H,
CD3, CH(CH3)2O CH3O, CF3O, CHF2O, and CD3O. In some embodiments, R3 is H or D and R4 is selected from D, F, Cl, CH3, CH(CH3)2, CF3, CF2H, CD3, CH(CH3)2O, CH3O, CF3O, CHF2O, and CD3O. In some embodiments, R3 is H or D and R4 is selected from CH(CH3)2O CH3O, CF3O, CHF2O, and CD3O. In some embodiments, R3 is H and R4 is selected from CH3O and CD3O. [00129] In some embodiments, R4 is H or D and R3 is selected from H, D, F, Cl, C1- 6alkyl, C1-6fluoroalkyl, C1-6deuteroalkyl, C1-6alkoxy, C1-6fluoroalkoxy and C1-6deuteroalkoxy. In some embodiments, R4 is H or D and R3 is selected from H, D, F, Cl, C1-4alkyl, C1- 4fluoroalkyl, C1-4deuteroalkyl, C1-4alkoxy, C1-4fluoroalkoxy and C1-4deuteroalkoxy. In some embodiments, R4 is H or D and R3 is selected from D, F, Cl, CH3, CH(CH3)2, CF3, CF2H, CD3, CH(CH3)2O, CH3O, CF3O, CHF2O, and CD3O. In some embodiments, R4 is H or D and R3 is selected from CH(CH3)2O CH3O, CF3O, CHF2O, and CD3O. In some embodiments, R4 is H and R3 is selected from CH3O and CD3O. [00130] In some embodiments, R2, R3, R4 and R5 are selected from D, F, Cl, CH3, CH(CH3)2, CF3, CF2H, CD3, CH(CH3)2O CH3O, CF3O, CHF2O, and CD3O. In some embodiments, R2, R3, R4 and R5 are all H or In some embodiments, R2, R3, R4 and R5 are all D. In some embodiments R2, R3, R4 and R5 are selected from CH(CH3)2O CH3O, CF3O, CHF2O, and CD3O. In some embodiments, two of R2, R3, R4 and R5 are selected from H or D and the remaining of R2, R3, R4 and R5 are selected from CH(CH3)2O CH3O, CF3O, CHF2O, and CD3O. In some embodiments, two of R2, R3, R4 and R5 are selected from H or D and the remaining of R2, R3, R4 and R5 are selected from CH3O and CD3O. In some embodiments, one of R2, R3, R4 and R5 is selected from H or D and the remaining of R2, R3, R4 and R5 are selected from CH(CH3)2O CH3O, CF3O, CHF2O, and CD3O. In some embodiments, one of R3, R4 R5 and R6 is selected from H or D and the remaining of R2, R3, R4 and R5 are selected from CH3O and CD3O. [00131] In some embodiments, R3 and R4 are linked together to form O-CH2O. [00132] In some embodiments, one of R3 and R4 is selected from X-L-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy. [00133] In some embodiments, X is a direct bond and one of R3 and R4 is selected from L-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy. In some embodiments, X is selected from O, C(O), NRa, NRaC(O), C(O)NRa, OC(O), C(O)O, OC(O)O, NRaC(O)O, OC(O)NRa and NRaC(O)NRa. In some embodiments, X is selected from O, C(O), OC(O), C(O)O and OC(O)O. In some embodiments, X is selected from O, OC(O) d C(O)O I b di t X i O I b di t X i l t d
from OC(O) and C(O)O. In some embodiments, X is selected from O, NRa, NRaC(O), C(O)NRa, NRaC(O)O, OC(O)NRa and NRaC(O)NRa. In some embodiments, X is selected from NRaC(O), C(O)NRa, NRaC(O)O, OC(O)NRa and NRaC(O)NRa. In some embodiments, X is selected from NRaC(O), and C(O)NRa. In some embodiments, X is selected from NRaC(O)O, OC(O)NRa and NRaC(O)NRa. In some embodiments, X is selected from O, OC(O), C(O)O, NRaC(O), and C(O)NRa. [00134] In some embodiments, L is selected from a direct bond, C1-4alkylene, C2- 4alkenylene, C1-4alkyleneO, C2-4alkenyleneO, C1-4alkyleneC(O), C2-4alkenyleneC(O) C1- 4alkyleneNRbC(O), C2-4alkenyleneNRbC(O), C1-4alkyleneC(O)NRb, C2- 4alkenyleneC(O)NRb, C1-4alkyleneOC(O), C2-4alkenyleneOC(O), C1-4alkyleneC(O)O, C2- 4alkenyleneC(O)O, C1-4alkyleneOC(O)NRb, C2-4alkenyleneOC(O)NRb, C1- 4alkyleneNRbC(O)O C2-4alkenyleneNRbC(O)O, C1-4alkyleneOC(O)O, C2- 4alkenyleneOC(O)O, C1-4alkyleneNRbC(O)NRb and C2-4alkenyleneNRbC(O)NRb. In some embodiments, L is selected from a direct bond, C1-2alkylene, C2-4alkenylene, C1-2alkyleneO, C2-4alkenyleneO, C1-2alkyleneC(O), C2-4alkenyleneC(O) C1-2alkyleneNRbC(O), C2- 4alkenyleneNRbC(O), C1-2alkyleneC(O)NRb, C2-4alkenyleneC(O)NRb, C1-2alkyleneOC(O), C2-4alkenyleneOC(O), C1-2alkyleneC(O)O, C2-4alkenyleneC(O)O, C1-2alkyleneOC(O)NRb, C2-4alkenyleneOC(O)NRb, C1-2alkyleneNRbC(O)O C2-4alkenyleneNRbC(O)O, C1- 2alkyleneOC(O)O, C2-4alkenyleneOC(O)O, C1-2alkyleneNRbC(O)NRb and C2- 4alkenyleneNRbC(O)NRb. In some embodiments, L is selected from a direct bond, C1- 2alkylene, C1-2alkyleneO, C1-2alkyleneC(O), C1-2alkyleneNRbC(O), C1-2alkyleneC(O)NRb, C1-2alkyleneOC(O), C1-2alkyleneC(O)O, C1-2alkyleneOC(O)NRb, C1-2alkyleneNRbC(O)O, C1-2alkyleneOC(O)O, and C1-2alkyleneNRbC(O)NRb. In some embodiments, L is selected from a direct bond, CH2, CF2, CD2, CH2-O, CF2-O, CD2-O, CH2-C(O), CF2-C(O), CD2-C(O), CH2-NRbC(O), CD2-NRbC(O), CF2-NRbC(O), CH2-C(O)NRb, CF2-C(O)NRb, CD2-C(O)NRb, CH2-OC(O), CD2-OC(O), CF2-OC(O), CH2-C(O)O, CF2-C(O)O, CD2-C(O)O, CH2- OC(O)NRb, CD2-OC(O)NRb, CF2-OC(O)NRb, CH2-NRbC(O)O, CF2-NRbC(O)O, CD2- NRbC(O)O, CH2-OC(O)O, CF2-OC(O)O, CD2-OC(O)O, CH2-NRbC(O)NRb, CF2- NRbC(O)NRb and CD2-NRbC(O)NRb. [00135] In some embodiments, X is a direct bond and L is a direct bond and one of R3 and R4 is selected from A and the other of R3 and R4 is selected from H, halo, C1-4alkyl and C1-4alkoxy. [00136] In some embodiments, X is selected from O, OC(O), C(O)O, NRaC(O), and C(O)NRa and one of R3 and R4 is selected from O-C1-2alkylene-A, O-C1-2alkyleneO-A, O-
C1-2alkyleneC(O)-A, O-C1-2alkyleneNRbC(O)-A, O-C1-2alkyleneC(O)NRb-A, O-C1- 2alkyleneOC(O)-A, O-C1-2alkyleneC(O)O-A, O-C1-2alkyleneOC(O)NRb-A, O-C1- 2alkyleneNRbC(O)O-A, O-C1-2alkyleneOC(O)O-A, O-C1-2alkyleneNRbC(O)NRb-A, OC(O)- C1-2alkylene-A, OC(O)-C1-2alkyleneO-A, OC(O)-C1-2alkyleneC(O)-A, OC(O)-C1- 2alkyleneNRbC(O)-A, OC(O)-C1-2alkyleneC(O)NRb-A, OC(O)-C1-2alkyleneOC(O) -A, OC(O)-C1-2alkyleneC(O)O-A, OC(O)-C1-2alkyleneOC(O)NRb-A, OC(O)-C1- 2alkyleneNRbC(O)O-A, OC(O)-C1-2alkyleneOC(O)O-A, OC(O)-C1-2alkyleneNRbC(O)NRb-A, C(O)O-C1-2alkylene-A, C(O)O-C1-2alkyleneO-A, C(O)O-C1-2alkyleneC(O)-A, C(O)O-C1- 2alkyleneNRbC(O)-A, C(O)O-C1-2alkyleneC(O)NRb-A, C(O)O-C1-2alkyleneOC(O)-A, C(O)O-C1-2alkyleneC(O)O-A, C(O)O-C1-2alkyleneOC(O)NRb-A, C(O)O-C1- 2alkyleneNRbC(O)O-A, C(O)O-C1-2alkyleneOC(O)O-A, C(O)O-C1-2alkyleneNRbC(O)NRb-A, NRaC(O)-C1-2alkylene-A, NRaC(O)-C1-2alkyleneO-A, NRaC(O)-C1-2alkyleneC(O)-A, NRaC(O)-C1-2alkyleneNRbC(O)-A, NRaC(O)-C1-2alkyleneC(O)NRb-A, NRaC(O)-C1- 2alkyleneOC(O)-A, NRaC(O)-C1-2alkyleneC(O)O-A, NRaC(O)-C1-2alkyleneOC(O)NRb-A, NRaC(O)-C1-2alkyleneNRbC(O)O-A, NRaC(O)-C1-2alkyleneOC(O)O-A, NRaC(O)-C1- 2alkyleneNRbC(O)NRb-A, C(O)NRa-C1-2alkylene-A, C(O)NRa-C1-2alkyleneO-A, C(O)NRa- C1-2alkyleneC(O)-A, C(O)NRa-C1-2alkyleneNRbC(O)-A, C(O)NRa-C1-2alkyleneC(O)NRb-A, C(O)NRa-C1-2alkyleneOC(O)-A, C(O)NRa-C1-2alkyleneC(O)O-A, C(O)NRa-C1- 2alkyleneOC(O)NRb-A, C(O)NRa-C1-2alkyleneNRbC(O)O-A, C(O)NRa-C1- 2alkyleneOC(O)O-A, and C(O)NRa-C1-2alkyleneNRbC(O)NRb-A and the other of R3 and R4 is selected from H, halo, C1-4alkyl and C1-4alkoxy wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. In some embodiments, X is selected from O, OC(O), C(O)O, NRaC(O), and C(O)NRa and one of R3 and R4 is selected from O-C1-2alkylene-A, O-C1-2alkyleneO-A, O-C1-2alkyleneC(O)-A, O-C1- 2alkyleneNRbC(O)-A, O-C1-2alkyleneC(O)NRb-A, O-C1-2alkyleneOC(O)-A, O-C1- 2alkyleneC(O)O-A, O-C1-2alkyleneOC(O)NRb-A, O-C1-2alkyleneNRbC(O)O-A, O-C1- 2alkyleneOC(O)O-A, O-C1-2alkyleneNRbC(O)NRb-A, OC(O)-C1-2alkylene-A, OC(O)-C1- 2alkyleneO-A, OC(O)-C1-2alkyleneC(O)-A, OC(O)-C1-2alkyleneNRbC(O)-A, OC(O)-C1- 2alkyleneC(O)NRb-A, OC(O)-C1-2alkyleneOC(O) -A, OC(O)-C1-2alkyleneC(O)O-A, OC(O)- C1-2alkyleneOC(O)NRb-A, OC(O)-C1-2alkyleneNRbC(O)O-A, OC(O)-C1-2alkyleneOC(O)O- A, OC(O)-C1-2alkyleneNRbC(O)NRb-A, C(O)O-C1-2alkylene, C(O)O-C1-2alkyleneO-A, C(O)O-C1-2alkyleneC(O)-A, C(O)O-C1-2alkyleneNRbC(O)-A, C(O)O-C1-2alkyleneC(O)NRb- A, C(O)O-C1-2alkyleneOC(O)-A, C(O)O-C1-2alkyleneC(O)O-A, C(O)O-C1- 2alkyleneOC(O)NRb-A, C(O)O-C1-2alkyleneNRbC(O)O-A, C(O)O-C1-2alkyleneOC(O)O-A, C(O)O-C1-2alkyleneNRbC(O)NRb-A, NRaC(O)-C1-2alkylene-A, NRaC(O)-C1-2alkyleneO-A,
NRaC(O)-C1-2alkyleneC(O)-A, NRaC(O)-C1-2alkyleneNRbC(O) -A, NRaC(O)-C1- 2alkyleneC(O)NRb-A, NRaC(O)-C1-2alkyleneOC(O)-A, NRaC(O)-C1-2alkyleneC(O)O-A, NRaC(O)-C1-2alkyleneOC(O)NRb-A, NRaC(O)-C1-2alkyleneNRbC(O)O-A, NRaC(O)-C1- 2alkyleneOC(O)O-A, NRaC(O)-C1-2alkyleneNRbC(O)NRb-A, C(O)NRa-C1-2alkylene-A, C(O)NRa-C1-2alkyleneO-A, C(O)NRa-C1-2alkyleneC(O)-A, C(O)NRa-C1-2alkyleneNRbC(O)- A, C(O)NRa-C1-2alkyleneC(O)NRb-A, C(O)NRa-C1-2alkyleneOC(O)-A, C(O)NRa-C1- 2alkyleneC(O)O-A, C(O)NRa-C1-2alkyleneOC(O)NRb-A, C(O)NRa-C1-2alkyleneNRbC(O)O- A, C(O)NRa-C1-2alkyleneOC(O)O-A, and C(O)NRa-C1-2alkyleneNRbC(O)NRb-A and the other of R3 and R4 is selected from H, halo, C1-4alkyl and C1-4alkoxy wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. [00137] In some embodiments, the other of R3 and R4 is selected from H, F, Cl, C1- 4alkyl, C1-4haloalkyl, C1-4deuteroalkyl and C1-4alkoxy wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. In some embodiments, the other of R3 and R4 is selected from D, F, Cl, CH3, CH(CH3)2, CF3, CF2H, CD3, CH(CH3)2O, CH3O, CF3O, CHF2O, and CD3O wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. and the other of R3 and R4 is H or D. [00138] In some embodiments, R3 is X-L-A and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy. In some embodiments, of R4 is X-L-A and R3 is selected from H, halo, C1- 6alkyl and C1-6alkoxy. [00139] In some embodiments, Ra is selected from H and C1-4alkyl. [00140] In some embodiments, Rb is selected from H, C1-4alkyl, and A'. [00141] In some embodiments, A is H, and one of R3 and R4 is selected OH, C(O)H, NHRa, NHRaC(O), C(O)NHRa, OC(O)H, C(O)OH, OC(O)OH, NRaC(O)OH, OC(O)NHRa, NHRaC(O)NRa, X-C1-4alkylene, X-C2-4alkenylene, X-C1-4alkyleneOH, X-C2-4alkenyleneOH, X-C1-4alkyleneC(O)H, X-C2-4alkenyleneC(O)H, X-C1-4alkyleneNRbC(O)H, X-C2- 4alkenyleneNRbC(O)H, X-C1-4alkyleneC(O)NHRb, X-C2-4alkenyleneC(O)NHRb, X-C1- 4alkyleneOC(O)H, X-C2-4alkenyleneOC(O)H, X-C1-4alkyleneC(O)OH, C2- 4alkenyleneC(O)H, X-C1-4alkyleneOC(O)NHRb, X-C2-4alkenyleneOC(O)NHRb, X-C1- 4alkyleneNRbC(O)OH, X-C2-4alkenyleneNRbC(O)OH, X-C1-4alkyleneOC(O)OH, X-C2- 4alkenyleneOC(O)OH, X-C1-4alkyleneNRbC(O)NHRb and X-C2-4alkenyleneNRbC(O)NHRb and the other of R3 and R4 is selected from H, halo, C1-4alkyl and C1-4alkoxy, wherein all il bl h d t ti ll d i d d tl b tit t d ith fl i t
or deuterium atom. In some embodiments, A is H, and one of R3 and R4 is selected OH, C(O)H, NHRa, NHRaC(O), C(O)NHRa, OC(O)H, C(O)OH, OC(O)OH, NRaC(O)OH, OC(O)NHRa, NHRaC(O)NRa, X-C1-2alkylene, X-C2-4alkenylene, X-C1-2alkyleneOH, X-C2- 4alkenyleneOH, X-C1-2alkyleneC(O)H, X-C2-4alkenyleneC(O)H, X-C1-2alkyleneNRbC(O)H, X-C2-4alkenyleneNRbC(O)H, X-C1-2alkyleneC(O)NHRb, X-C2-4alkenyleneC(O)NHRb, X-C1- 2alkyleneOC(O)H, X-C2-4alkenyleneOC(O)H, X-C1-2alkyleneC(O)OH, C2- 4alkenyleneC(O)H, X-C1-2alkyleneOC(O)NHRb, X-C2-4alkenyleneOC(O)NHRb, X-C1- 2alkyleneNRbC(O)OH, X-C2-4alkenyleneNRbC(O)OH, X-C1-2alkyleneOC(O)OH, X-C2- 4alkenyleneOC(O)OH, X-C1-2alkyleneNRbC(O)NHRb and X-C2-4alkenyleneNRbC(O)NHRb and the other of R3 and R4 is selected from H, halo, C1-4alkyl and C1-4alkoxy, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. [00142] In some embodiments, A is H and X is a direct bond. Therefore, in some embodiments, and one of R3 and R4 is selected from C1-4alkyl, C2-4alkenyl, C1-4alkyleneOH, C2-6alkenyleneOH, C1-4alkyleneC(O)H, C2-4alkenyleneC(O)H, C1-4alkyleneNRbC(O)H, C2- 4alkenyleneNRbC(O)H, C1-4alkyleneC(O)NHRb, C2-4alkenyleneC(O)NHRb, C1- 4alkyleneOC(O)H, C2-4alkenyleneOC(O)H, C1-4alkyleneC(O)OH, C2-4alkenyleneC(O)H, C1- 4alkyleneOC(O)NHRb, C2-6alkenyleneOC(O)NHRb, C1-4alkyleneNRbC(O)OH, C2- 4alkenyleneNRbC(O)OH, C1-4alkyleneOC(O)OH, C2-4alkenyleneOC(O)OH, C1- 4alkyleneNRbC(O)NHRb and C2-4alkenyleneNRbC(O)NHRb and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy. [00143] In some embodiments, A is H and X is selected from O, C(O), NRa, NRaC(O), C(O)NRa, OC(O), C(O)O, OC(O)O, NRaC(O)O, OC(O)NRa and NRaC(O)NRa. In some embodiments, A is H and X is selected from O, C(O), OC(O), C(O)O and OC(O)O. In some embodiments, A is H and X is selected from O, OC(O) and C(O)O. In some embodiments, A is H and X is O. In some embodiments, A is H and X is selected from OC(O) and C(O)O. In some embodiments, A is H and X is selected from NRa, NRaC(O), C(O)NRa, NRaC(O)O, OC(O)NRa and NRaC(O)NRa. In some embodiments, A is H and X is selected from NRaC(O), C(O)NRa, NRaC(O)O, OC(O)NRa and NRaC(O)NRa. In some embodiments, A is H and X is selected from NRaC(O), and C(O)NRa. In some embodiments, A is H and X is selected from NRaC(O)O, OC(O)NRa and NRaC(O)NRa. [00144] In some embodiments, A is H, and L is a direct bond, and one of R3 and R4 is selected from X-H. Therefore, in some embodiments, and one of R3 and R4 is selected from OH, C(O)H, NHRa, NHRaC(O), C(O)NHRa, OC(O)H, C(O)OH, OC(O)OH,
NRaC(O)OH, OC(O)NHRa and NHRaC(O)NRa, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. [00145] In some embodiments, when A is H, Rb is selected from H and C1-4alkyl, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. [00146] In some embodiments, one of R3 and R4 is selected from A, O-A, C(O)-A, C(O)-A, C(O)O-A, C1-4alkylene-A, C1-4alkylene-C(O)-A, C1-4alkylene-C(O)O-A, O-C1- 4alkylene-A, O-C1-4alkylene-C(O)-A, and O-C1-4alkylene-C(O)O-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. [00147] In some embodiments, one of R3 and R4 is selected from A, O-A, C(O)-A, C(O)-A, and C(O)O-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1- 6alkoxy, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. In some embodiments, one of R3 and R4 is A. In some embodiments, one of R3 and R4 is O-A. In some embodiments, one of R3 and R4 is C(O)-A. In some embodiments, one of R3 and R4 is C(O)O-A. [00148] In some embodiments, one of R3 and R4 is selected from C1-4alkylene-A, C1- 4alkylene-C(O)-A, C1-4alkylene-C(O)O-A, O-C1-4alkylene-A, O-C1-4alkylene-C(O)-A, and O- C1-4alkylene-C(O)O-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1- 6alkoxy, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. In some embodiments, one of R3 and R4 is C1- 4alkylene-A. In some embodiments, one of R3 and R4 is C1-4alkylene-C(O)-A. In some embodiments, one of R3 and R4 is C1-4alkylene-C(O)O-A. In some embodiments, one of R3 and R4 is O-C1-4alkylene-A. In some embodiments, one of R3 and R4 is O-C1-4alkylene- C(O)-A. In some embodiments, one of R3 and R4 is O-C1-4alkylene-C(O)O-A. [00149] In some embodiments, one of R3 and R4 is selected from A, O-A, C(O)-A, C(O)O-A, C1-4alkylene-A, C1-4alkylene-C(O)-A, C1-4alkylene-C(O)O-A, O-C1-4alkylene-A, O-C1-4alkylene-C(O)-A, and O-C1-4alkylene-C(O)O-A and the other of R3 and R4 is selected from H, F, Cl, C1-4alkyl and C1-4alkoxy, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. In some embodiments, one of R3 and R4 is selected from A, O-A, C(O)-A, C(O)O-A, C1-4alkylene- A, C1-4alkylene-C(O)-A, C1-4alkylene-C(O)O-A, O-C1-4alkylene-A, O-C1-4alkylene-C(O)-A, and O-C1-4alkylene-C(O)O-A and the other of R3 and R4 is selected from H, F, Cl, C1-4alkyl, C h l lk l C d t lk l d C lk h i ll il bl h d t
optionally and independently substituted with a fluorine atom or deuterium atom. In some embodiments, one of R3 and R4 is selected from A, O-A, C(O)-A, C(O)O-A, C1-2alkylene- A, C1-2alkylene-C(O)-A, C1-2alkylene-C(O)O-A, O-C1-2alkylene-A, O-C1-2alkylene-C(O)-A, and O-C1-2alkylene-C(O)O-A and the other of R3 and R4 is selected from D, F, Cl, CH3, CH(CH3)2, CF3, CF2H, CD3, CH(CH3)2O, CH3O, CF3O, CHF2O, and CD3O wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. In some embodiments, one of R3 and R4 is selected from A, O-A, C(O)- A, C(O)O-A, C1-2alkylene-A, C1-2alkylene-C(O)-A, C1-2alkylene-C(O)O-A, O-C1-2alkylene-A, O-C1-2alkylene-C(O)-A, and O-C1-2alkylene-C(O)O-A and the other of R3 and R4 is H or D, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. In some embodiments, one of R3 and R4 is selected from A, O-A, C(O)-A, C(O)O-A, CH2-A, CD2-A, CF2-A, CH2-C(O)-A, CF2-C(O)-A, CD2-C(O)-A, CH2-C(O)O-A, CD2-C(O)O-A, CF2-C(O)O-A, O-CH2A, O-CF2A,O-CD2A, O-CH2-C(O)-A, O- CD2-C(O)-A, O-CF2-C(O)-A, O- CH2-C(O)O-A, O- CF2-C(O)O-A, and O- CD2-C(O)O-A and the other of R3 and R4 is H or D. [00150] In some embodiments, R3 is selected from A, O-A, C(O)-A, C(O)O-A, C1- 2alkylene-A, C1-2alkylene-C(O)-A, C1-2alkylene-C(O)O-A, O-C1-2alkylene-A, O-C1-2alkylene- C(O)-A, and O-C1-2alkylene-C(O)O-A and O-C1-2alkylene-A and R4 is H or D, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. In some embodiments, R3 is selected from A, O-A, C(O)-A, C(O)O-A, CH2-A, CD2-A, CF2-A, CH2-C(O)-A, CF2-C(O)-A, CD2-C(O)-A, CH2-C(O)O-A, CD2-C(O)O- A, CF2-C(O)O-A, O-CH2A, O-CF2A, O-CD2A O-CH2-C(O)-A, O-CD2-C(O)-A, O-CF2-C(O)- A, O- CH2-C(O)O-A, O- CF2-C(O)O-A, and O- CD2-C(O)O-A, and R4 is H or D. In some embodiments, R4 is selected from A, O-A, C(O)-A, C(O)O-A, C1-2alkylene-A, C1-2alkylene- C(O)-A, C1-2alkylene-C(O)O-A, O-C1-2alkylene-A, O-C1-2alkylene-C(O)-A, and O-C1- 2alkylene-C(O)O-A and O-C1-2alkylene-A and R3 is H or D, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. In some embodiments, R4 is selected from A, O-A, C(O)-A, C(O)O-A, CH2-A, CD2-A, CF2- A, CH2-C(O)-A, CF2-C(O)-A, CD2-C(O)-A, CH2-C(O)O-A, CD2-C(O)O-A, CF2-C(O)O-A, O- CH2A, O-CF2A, O-CD2A O-CH2-C(O)-A, O-CD2-C(O)-A, O-CF2-C(O)-A, O- CH2-C(O)O-A, O- CF2-C(O)O-A, and O- CD2-C(O)O-A, and R3 is H or D. [00151] In some embodiments, A is selected from C1-30alkyl, C2-30alkenyl, phenyl, C3- 6cycloalkyl, 3- to 6-membered heterocycloalkyl comprising 1 to 3 heteromoeities independently selected from O, S, S(O), SO2, N and NR64 and 5- to 6-membered heteroaryl
wherein the phenyl, C3-10cycloalkyl, 3- to 6-membered heterocycloalkyl and 5- to 6- membered heteroaryl are optionally substituted with one or two substituents independently selected from F, Cl, OH, C1-4alkyl, C1-4deuteroalkyl, C1-4fluoroalkyl, OC1-4alkyl, OC1- 4deuteroalkyl and OC1-4fluoroalkyl, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. In some embodiments, A is selected from C1-30alkyl, C2-30alkenyl, phenyl, C3-6cycloalkyl, 3- to 6-membered heterocycloalkyl comprising 1 to 3 heteromoeities independently selected from O, S, S(O), SO2, N and NR63 and 5- to 6-membered heteroaryl comprising 1 to 3 heteromoeities independently selected from O, S, S(O), SO2, N and NR53, wherein the phenyl, C3- 10cycloalkyl, 3- to 6-membered heterocycloalkyl and 5- to 6-membered heteroaryl are optionally substituted with one or two substituents independently selected from F, Cl, OH, C1-4alkyl, C1-4deuteroalkyl, C1-4fluoroalkyl, OC1-4alkyl, OC1-4deuteroalkyl and OC1- 4fluoroalkyl. [00152] In some embodiments, A is selected from phenyl, C3-6cycloalkyl, 3- to 6- membered heterocycloalkyl comprising 1 to 3 heteromoeities independently selected from O, S, S(O), SO2, N and NR53 and 5- to 6-membered heteroaryl comprising 1 to 3 heteromoeities independently selected from O, S, S(O), SO2, N and NR63, wherein the phenyl, C3-10cycloalkyl, 3- to 6-membered heterocycloalkyl and 5- to 6-membered heteroaryl are optionally substituted with one or two substituents independently selected from F, Cl, OH, C1-4alkyl, C1-4deuteroalkyl, C1-4fluoroalkyl, OC1-4alkyl, OC1-4deuteroalkyl and OC1-4fluoroalkyl. In some embodiments, A is selected from phenyl, C3-6cycloalkyl, 5- to 6- membered heterocycloalkyl comprising 1 to 2 heteromoeities independently selected from O, S, S(O), SO2, N and NR63 and 5- to 6-membered heteroaryl comprising 1 to 3 heteromoeities independently selected from O, S, S(O), SO2, N and NR63, wherein the phenyl, C3-10cycloalkyl, 3- to 6-membered heterocycloalkyl and 5- to 6-membered heteroaryl are optionally substituted with one or two substituents independently selected from F, Cl, OH, C1-4alkyl, C1-4deuteroalkyl, C1-4fluoroalkyl, OC1-4alkyl, OC1-4deuteroalkyl and OC1-4fluoroalkyl. [00153] In some embodiments, the C3-6cycloalkyl in A is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. In some embodiments, the C3-6cycloalkyl in A is cyclopropyl which is optionally substituted with one or two substituents independently selected from F, Cl, C1-4alkyl, C1-4deuteroalkyl, C1-4fluoroalkyl, OC1-4alkyl, OC1-4deuteroalkyl and OC1-4fluoroalkyl.
[00154] In some embodiments, the 3- to 6-membered heterocycloalkyl comprising 1 to 3 heteromoeities independently selected from O, S, S(O), SO2, N and NR64 in A is selected from aziridinyl, oxiranyl, thiiranyl, oxaxiridinyl, dioxiranyl, azetidinyl, oxetanyl, theitanyl, diazetidinyl, dioxetanyl, dithietanyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, isoxthiolidinyl, thiazolidinyl, isothiazolidinyl, dioxolanyl, dithiolanyl, piperidinyl, triazolyl, furazanyl, oxadiazolyl, thiadiazolyl, dioxazolyl, dithiazolyl, tetrazolyl, oxatetrazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothiopyranyl oxide, tetrahydrothiopyranyl dioxide, dihydropyranyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl and dithianyl, each of which are optionally substituted with one or two substituents independently selected from F, C, C1- 4alkyl, C1-4deuteroalkyl, C1-4fluoroalkyl, OC1-4alkyl, OC1-4deuteroalkyl and OC1-4fluoroalkyl. In some embodiments, the 3- to 6-membered heterocycloalkyl comprising 1 to 3 heteromoeities independently selected from O, S, S(O), SO2, N and NR64 in A are selected from tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, dioxolanyl, , piperidinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothiopyranyl oxide, tetrahydrothiopyranyl dioxide, dihydropyranyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl, each of which are optionally substituted with one or two substituents independently selected from F, C, C1- 4alkyl, C1-4deuteroalkyl, C1-4fluoroalkyl, OC1-4alkyl, OC1-4deuteroalkyl and OC1-4fluoroalkyl. [00155] In some embodiments, the 5- to 6-membered heteroaryl in A is selected from furyl, imidazolyl, isothiazolyl, thiazolyl, pyridyl, pyrazinyl, pyrazolyl, pyrrolyl, thienofuryl, triazolyl and thienyl, each of which are optionally substituted with one or two substituents independently selected from F, C, C1-4alkyl, C1-4deuteroalkyl, C1-4fluoroalkyl, OC1-4alkyl, OC1-4deuteroalkyl and OC1-4fluoroalkyl. In some embodiments, the 5- to 6- membered heteroaryl in A is selected from furyl, isothiazolyl, thiazolyl, pyridyl and pyrrolyl, each of which are optionally substituted with one or two substituents independently selected from F, C, C1-4alkyl, C1-4deuteroalkyl, C1-4fluoroalkyl, OC1-4alkyl, OC1-4deuteroalkyl and OC1-4fluoroalkyl. [00156] In some embodiments, the phenyl, C3-10cycloalkyl, 3- to 6-membered heterocycloalkyl and 5- to 6-membered heteroaryl in A are optionally substituted with one or two substituents independently selected from F, Cl, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CF3, CF2H, CH2CF2H, CH2CF3, CH2CFH2, CH(CF3)2, CD3, CH(CH3)2O, CH3CH2CH2O, CH3CH2O, CH3O, CF3O, CHF2O, CF2HCH2O, CF3CH2O, (CF3)2CHO, and CD3O.
[00157] In some embodiments, A is selected from C1-30alkyl and C2-30alkenyl wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom. [00158] In some embodiments, A is C10-25alkyl, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom. In some embodiments, A is C13-21alkyl, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom. [00159] In some embodiments, A is C10-25alkenyl, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom. In some embodiments, A is C13-21alkenyl, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom. In some embodiments, A is C10-25alkenyl and comprises 1, 2, 3, 4, 5 or 6 double bonds. [00160] In some embodiments, the alkyl or alkene group of A is an alkyl or alkenyl group present in a fatty acid, wherein all available H atoms are optionally substituted with deuterium. In some embodiments, A is an alkenyl group present in a fatty acid, wherein all available H atoms are optionally substituted with deuterium. In some embodiments, the fatty acid is an omega-6 fatty acid (i.e. an unsaturated or polyunsaturated fatty acid wherein the double bond that is closest to the methyl end of the molecule is located at carbon numbered 6 starting from the end methyl group) or an omega-3 fatty acid (i.e. an unsaturated or polyunsaturated fatty acid wherein the double bond that is closest to the methyl end of the molecule is located at carbon numbered 3 starting from the end methyl group), wherein all available H atoms are optionally substituted with deuterium. In some embodiments, A is an alkyl group present in a fatty acid wherein all available H atoms are optionally substituted with deuterium. In some embodiments, the alkyl or alkene group of A is an alkyl or alkene group present in a fatty acid selected from the list of fatty acids in Table 1 wherein all available H atoms are optionally substituted with deuterium. [00161] In some embodiments, the alkene group of A is an alkyl or alkenyl group present in linoleic acid, eicosadienoic acid or decosahexanoic acid. [00162] In some embodiments, when A is the alkyl or alkenyl group of a fatty acid wherein 1-10, 2-8, 2-6 or 2-4 H atoms are substituted with deuterium. [00163] In some embodiments, A is (CH2)7CH=CH(CH2)7CH3. In some embodiments, A is (CH2)7CH=CHCH2CH=CH(CH2)4CH3. In some embodiments, A is (CH2)8CH=CHCH2CH=CH(CH2)4CH3. In some embodiments, A is
(CH2)3CH=CHCH2CH=CH(CH2)1CH=CHCH2CH=CH(CH2)3CH3. In some embodiments, A is (CH2)2CH=CHCH2CH=CHCH2CH=CHCH2CH=CHCH2CH=CHCH2CH=CH(CH2)1CH3. [00164] In some embodiments, R63 and R64 are independently selected from H, D, C1-4alkyl, C1-4fluoroalkyl and C1-4deuteroalkyl. In some embodiments, R63 and R64 are independently selected from H, D, CH3, CF3 and CD3. In some embodiments, R63 and R64 are independently selected from H and D. [00165] In some embodiments, the compound of Formula I is defined as follows: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R1 is H; Q is selected from Q1, Q2, Q3, Q4, Q5 and Q6: (Q1), (Q2), (Q3), (Q4) (Q5), and (Q6) is a single bond or a double bond provided that when in Q1 is a double bond then R8 and R14 are not present, when in Q2 is a double bond then R16 and R24 are not present, and when in Q6 is a double bond then R53 and R62 are not present; R2 and R5 are independently selected from H, D and F; one or both of R3 and R4 is selected from H, C1-4alkoxy, C1-4fluoralkoxy and C1- 4deuteroalkoxy or
R3 and R4 are linked together to form O-(CH2)1-2O; R7, R8, R9, R10, R12, R13, R14, R15, R16, R17, R18, R20, R21, R22, R23, R24, R25, R26, R27, R28, R31, R32, R33, R35, R36, R37, R38, R39, R40, R41, R42, R43, R45, R46, R47, R48, R49, R50, R51 and R52 are independently selected from H and D; and R11, R19, R29 and R30, R34 and R44 are independently selected from H, C1-4alkyl, C1- 4fluoroalkyl and C1-4deuteroalkyl, provided when Q is Q3; at least one of R2, R3, R4, R5, R25, R26, R27, R28, R29 and R30 is D or comprises D, or at least one of R2, R3, R4, R5 is alkyl substituted with one or more fluorine and/or chlorine atoms; or at least three of R2, R3, R4, R5 are not H; or when Q is Q3; R3 and R4 are linked together to form O-(CH2)1-2O. [00166] In some embodiments, the compound of Formula I is defined as follows: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, R1 is selected from H, halo, NH2, C1-6alkyl, C1-6alkoxyl, NH(C1-6alkyl) and N(C1-6alkyl)2; Q is selected from Q1, Q2, Q3, Q4, Q5 and Q6: (Q1), (Q2), (Q3), (Q4), (Q5) and (Q6) is a single bond or a double bond provided that when in Q1 is a double bond then R8 and R14 are not present, when in Q2 is a double bond then R16 and R24 are not present and when in Q6 is a double bond then R53 and R62 are not present;
R2 and R5 are independently selected from H, halo, OH, C1-6alkyl and C1-6alkoxy; one or both of R3 and R4 is independently selected from H, halo, C1-6alkyl and C1-6alkoxy, or R3 and R4 are linked together to form O-(CH2)1-2O, or one of R3 and R4 is selected from X-L-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy; X is selected from a direct bond, O, C(O), NRa, NRaC(O), C(O)NRa, OC(O), C(O)O, OC(O)O, NRaC(O)O, OC(O)NRa and NRaC(O)NRa; L is selected from a direct bond, C1-6alkylene, C2-6alkenylene, C1-6alkyleneO, C2- 6alkenyleneO, C1-6alkyleneC(O), C2-6alkenyleneC(O), C1-6alkyleneNRbC(O), C2- 6alkenyleneNRbC(O), C1-6alkyleneC(O)NRb, C2-6alkenyleneC(O)NRb, C1-6alkyleneOC(O), C2-6alkenyleneOC(O), C1-6alkyleneC(O)O, C2-6alkenyleneC(O)O, C1-6alkyleneOC(O)NRb, C2-6alkenyleneOC(O)NRb, C1-6alkyleneNRbC(O)O C2-6alkenyleneNRbC(O)O, C1- 6alkyleneOC(O)O, C2-6alkenyleneOC(O)O, C1-6alkyleneNRbC(O)NRb and C2- 6alkenyleneNRbC(O)NRb; Ra is selected from H and C1-6alkyl; Rb is selected from H, C1-6alkyl, and A; A is selected from H, C1-30alkyl, C2-30alkenyl, phenyl, C3-6cycloalkyl, 3- to 6-membered heterocycloalkyl comprising 1 to 4 heteromoeities independently selected from O, S, S(O), SO2, N and NR53 and 5- to 6-membered heteroaryl comprising 1 to 4 heteromoeities independently selected from O, S, S(O), SO2, N and NR63, wherein the phenyl, C3- 10cycloalkyl, 3- to 6-membered heterocycloalkyl and 5- to 6-membered heteroaryl are optionally substituted with one or more substituents independently selected from halo, OH, C1-4alkyl and OC1-4alkyl; R7, R8, R9, R10, R12, R13, R14, R15, R16, R17, R18, R20, R21, R22, R23, R24, R25, R26, R27, R28, R31, R32, R33, R35, R36, R37, R38, R39, R40, R41, R42, R43, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R57, R58, R59, R60, R61 and R62 are independently selected from H, halo and C1- 6alkyl; R11, R19, R34, R44 and R56 are independently selected from H, C1-6alkyl and C(O)-A’; R29 and R30 are independently selected from H and C1-6alkyl; or one of R29 and R30 is C(O)-A’ and the other is selected from H and C1-6alkyl;
wherein A' is selected from Y, O-Y and O-C1-4alkylene-O-C(O)-Y; and Y is selected from C7-30alkyl and C7-30alkenyl; or R29 and R30, together with the N atom to which they are bound, form a 3- to 6-membered heterocyclic ring which optionally comprises one or two additional heteromoieties independently selected from O, S, S(O), SO2, N, and NR64 and which is optionally substituted with one or more substituents independently selected from halo, OH, C1-4alkyl and OC1-4alkyl; R63 and R64 are independently selected from H and C1-6alkyl; and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof, provided one of R11, R19, R29, R30 R34, R44 and R56 is C(O)-A’; or one of R3 and R4 is selected from X-L-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy provided A is not H, C1-6alkyl or C1-6alkeynyl when X and L are both direct bonds. [00167] In some embodiments, one of R11, R19, R29, R30 R34, R44 and R56 is C(O)-A’. In some embodiments, one of R3 and R4 is selected from A, O-A, C(O)-A, C(O)O-A, C1- 4alkylene-A, C1-4alkylene-C(O)-A, C1-4alkylene-C(O)O-A, O-C1-4alkylene-A, O-C1-4alkylene- C(O)-A and O-C1-4alkylene-C(O)O-A. [00168] In some embodiments, the compounds of Formula I are selected from the compounds listed below, or a pharmaceutically acceptable salt, solvate and/or prodrug thereof: Compound I.D. Chemical Structures I-1 I-2
I-46 (R)-I-47 (R)-I-48 (R)-I-49 (R)-I-50 (R)-I-51 (R)-I-52 (S)-I-53
(R)-I-53 (R)-I-54 (R)-I-55 (R)-I-56 (R)-I-57 (S)-I-57 (R)-I-58 (R)-I-59 (R)-I-60
(R)-I-61 (R)-I-62 (R)-I-63 (R)-I-64 (R)-I-65 (R)-I-66 (R)-I-67 (R)-I-68
(R)-I-69 (R)-I-70 (R)-I-71 (R)-I-72 (R)-I-73 (R)-I-74 (R)-I-75 (R)-I-76
(R)-I-77 (R)-I-78 (R)-I-79 (R)-I-80 (R)-I-81 (R)-I-82 (R)-I-83 (R)-I-84 (R)-I-85
(R)-I-86 (R)-I-87 (R)-I-88 (R)-I-89 (R)-I-90 (R)-I-91 (R)-I-92 (R)-I-93 (R)-I-94
(R)-I-95 (R)-I-96 (R)-I-97 (R)-I-98 (R)-I-99 (R)-I-100 (R)-I-101 (R)-I-102
(R)-I-103 (R)-I-104 I-105 I-106 I-107 I-108 I-109
I-110 (R)-I-111 (S)-I-111 (R)-I-112 I-113 I-114
(S)-I-115 (S)-I-116 (S)-I-117 (R)-I-118 I-119 (R)-I-120.HCl .HCl, and
(R)-I-121.HCl .HCl or a pharmaceutically acceptable salt, solvate and/or prodrug thereof. [00169] The present application also includes a compound selected from compound 12 and compound 16, 12 and 16 or a pharmaceutically acceptable salt, solvate and/or prodrug thereof. [00170] In some embodiments, the pharmaceutically acceptable salt is an acid addition salt or a base addition salt. The selection of a suitable salt may be made by a person skilled in the art. Suitable salts include acid addition salts that may, for example, be formed by mixing a solution of a compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid. Additionally, acids that are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.) and Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley VCH; S. Berge et al, Journal of Pharmaceutical Sciences 197766(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website). [00171] An acid addition salt suitable for, or compatible with, the treatment of subjects is any non-toxic organic or inorganic acid addition salt of any basic compound. Basic compounds that form an acid addition salt include, for example, compounds comprising an amine group Illustrative inorganic acids which form suitable salts include
hydrochloric, hydrobromic, sulfuric, nitric and phosphoric acids, as well as acidic metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids which form suitable salts include mono-, di- and tricarboxylic acids. Illustrative of such organic acids are, for example, acetic, trifluoroacetic, propionic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, mandelic, salicylic, 2- phenoxybenzoic, p-toluenesulfonic acid and other sulfonic acids such as methanesulfonic acid, ethanesulfonic acid and 2-hydroxyethanesulfonic acid. In some embodiments, exemplary acid addition salts also include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates (“mesylates”), naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates) and the like. In some embodiments, the mono- or di-acid salts are formed and such salts exist in either a hydrated, solvated or substantially anhydrous form. In general, acid addition salts are more soluble in water and various hydrophilic organic solvents and generally demonstrate higher melting points in comparison to their free base forms. The selection criteria for the appropriate salt will be known to one skilled in the art. Other non-pharmaceutically acceptable salts such as but not limited to oxalates may be used, for example in the isolation of compounds of the application for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt. [00172] A base addition salt suitable for, or compatible with, the treatment of subjects is any non-toxic organic or inorganic base addition salt of any acidic compound. Acidic compounds that form a basic addition salt include, for example, compounds comprising a carboxylic acid group. Illustrative inorganic bases which form suitable salts include lithium, sodium, potassium, calcium, magnesium or barium hydroxide as well as ammonia. Illustrative organic bases which form suitable salts include aliphatic, alicyclic or aromatic organic amines such as isopropylamine, methylamine, trimethylamine, picoline, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2- diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. Exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine dicyclohexylamine choline and caffeine The selection of the appropriate
salt may be useful, for example, so that an ester functionality, if any, elsewhere in a compound is not hydrolyzed. The selection criteria for the appropriate salt will be known to one skilled in the art. In some embodiments, exemplary basic salts also include ammonium salts, alkali metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamine, Abutyl amine, choline and salts with amino acids such as arginine, lysine and the like. Basic nitrogen containing groups may be quarternized with agents such as lower alkyl halides (e.g., methyl, ethyl and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl and dibutyl sulfates), long chain halides (e.g., decyl, lauryl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides) and others. Compounds carrying an acidic moiety can be mixed with suitable pharmaceutically acceptable salts to provide, for example, alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts) and salts formed with suitable organic ligands such as quaternary ammonium salts. Also, in the case of an acid (-COOH) or alcohol group being present, pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound. [00173] All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the application and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the application. In addition, when a compound of the application contains both a basic moiety, such as, but not limited to an aliphatic primary, secondary, tertiary or cyclic amine, an aromatic or heteroaryl amine, pyridine or imidazole and an acidic moiety, such as, but not limited to tetrazole or carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the terms “salt(s)” as used herein. It is understood that certain compounds of the application may exist in zwitterionic form, having both anionic and cationic centers within the same compound and a net neutral charge. Such zwitterions are included within the application. [00174] Solvates of compounds of the application include, for example, those made with solvents that are pharmaceutically acceptable. Examples of such solvents include water (resulting solvate is called a hydrate) and ethanol and the like. Suitable solvents are physiologically tolerable at the dosage administered. [00175] Prodrugs of the compounds of the present application include, for example, conventional esters formed with available hydroxy, thiol, amino or carboxyl groups. Some
common esters which have been utilized as prodrugs are phenyl esters, aliphatic (C1-C24) esters, acyloxymethyl esters, carbamates and amino acid esters. [00176] It is understood and appreciated that in some embodiments, compounds of the present application may have at least one chiral center and therefore can exist as enantiomers and/or diastereomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present application. It is to be further understood that while the stereochemistry of the compounds may be as shown in any given compound listed herein, such compounds may also contain certain amounts (for example, less than 20%, suitably less than 10%, more suitably less than 5%) of compounds of the present application having an alternate stereochemistry. It is intended that any optical isomers, as separated, pure or partially purified optical isomers or racemic mixtures thereof are included within the scope of the present application. [00177] In some embodiments, the compounds of the present application can also include tautomeric forms, such as keto-enol tautomers and the like. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution. It is intended that any tautomeric forms which the compounds form, as well as mixtures thereof, are included within the scope of the present application. [00178] The compounds of the present application may further exist in varying amorphous and polymorphic forms and it is contemplated that any amorphous forms, polymorphs, or mixtures thereof, which form are included within the scope of the present application. [00179] The compounds of the present application may further be radiolabeled and accordingly all radiolabeled versions of the compounds of the application are included within the scope of the present application. The compounds of the application also include those in which one or more radioactive atoms are incorporated within their structure. III. Compositions [00180] The compounds of the present application are suitably formulated in a conventional manner into compositions using one or more carriers. Accordingly, the present application also includes a composition comprising one or more compounds of the application and a carrier. The compounds of the application are suitably formulated into pharmaceutical compositions for administration to subjects in a biologically compatible form suitable for administration in vivo. Accordingly, the present application further includes a pharmaceutical composition comprising one or more compounds of the application and a
compositions are used in the treatment of any of the diseases, disorders or conditions described herein. [00181] The compounds of the application are administered to a subject in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art. For example, a compound of the application is administered by oral, inhalation, parenteral, buccal, sublingual, insufflation, epidurally, nasal, rectal, vaginal, patch, pump, minipump, topical or transdermal administration and the pharmaceutical compositions formulated accordingly. In some embodiments, administration is by means of a pump for periodic or continuous delivery. Conventional procedures and ingredients for the selection and preparation of suitable compositions are described, for example, in Remington's Pharmaceutical Sciences (2000 - 20th edition) and in The United States Pharmacopeia: The National Formulary (USP 24 NF19) published in 1999. [00182] Parenteral administration includes systemic delivery routes other than the gastrointestinal (GI) tract and includes, for example intravenous, intra-arterial, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary (for example, by use of an aerosol), intrathecal, rectal and topical (including the use of a patch or other transdermal delivery device) modes of administration. Parenteral administration may be by continuous infusion over a selected period of time. [00183] In some embodiments, a compound of the application is orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it is enclosed in hard or soft shell gelatin capsules, or it is compressed into tablets, or it is incorporated directly with the food of the diet. In some embodiments, the compound is incorporated with excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, caplets, pellets, granules, lozenges, chewing gum, powders, syrups, elixirs, wafers, aqueous solutions and suspensions and the like. In the case of tablets, carriers that are used include lactose, com starch, sodium citrate and salts of phosphoric acid. Pharmaceutically acceptable excipients include binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate), or solvents (e.g. medium chain triglycerides, ethanol, water). In embodiments, the tablets are coated by methods well known in the art. In the case of tablets, capsules, caplets, pellets or granules for oral administration, pH sensitive enteric coatings, such as Eudragits™ designed to control the release of active ingredients are
optionally used. Oral dosage forms also include modified release, for example immediate release and timed-release, formulations. Examples of modified-release formulations include, for example, sustained-release (SR), extended-release (ER, XR, or XL), time- release or timed-release, controlled-release (CR), or continuous-release (CR or Contin), employed, for example, in the form of a coated tablet, an osmotic delivery device, a coated capsule, a microencapsulated microsphere, an agglomerated particle, e.g., as of molecular sieving type particles, or, a fine hollow permeable fiber bundle, or chopped hollow permeable fibers, agglomerated or held in a fibrous packet. Timed-release compositions are formulated, for example as liposomes or those wherein the active compound is protected with differentially degradable coatings, such as by microencapsulation, multiple coatings, etc. Liposome delivery systems include, for example, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. In some embodiments, liposomes are formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines. For oral administration in a capsule form, useful carriers, solvents or diluents include lactose, medium chain triglycerides, ethanol and dried com starch. [00184] In some embodiments, liquid preparations for oral administration take the form of, for example, solutions, syrups or suspensions, or they are suitably presented as a dry product for constitution with water or other suitable vehicle before use. When aqueous suspensions and/or emulsions are administered orally, the compound of the application is suitably suspended or dissolved in an oily phase that is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents are added. Such liquid preparations for oral administration are prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., medium chain triglycerides, almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid). Useful diluents include lactose and high molecular weight polyethylene glycols. [00185] It is also possible to freeze-dry the compounds of the application and use the lyophilizates obtained, for example, for the preparation of products for injection. [00186] In some embodiments, a compound of the application is administered parenterally. For example, solutions of a compound of the application are prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. In some embodiments, dispersions are prepared in glycerol, liquid polyethylene glycols, DMSO and mixtures
thereof with or without alcohol and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. A person skilled in the art would know how to prepare suitable formulations. For parenteral administration, sterile solutions of the compounds of the application are usually prepared and the pH's of the solutions are suitably adjusted and buffered. For intravenous use, the total concentration of solutes should be controlled to render the preparation isotonic. For ocular administration, ointments or droppable liquids are delivered, for example, by ocular delivery systems known to the art such as applicators or eye droppers. In some embodiments, such compositions include mucomimetics such as hyaluronic acid, chondroitin sulfate, hydroxypropyl methylcellulose or polyvinyl alcohol, preservatives such as sorbic acid, EDTA or benzyl chromium chloride and the usual quantities of diluents or carriers. For pulmonary administration, diluents or carriers will be selected to be appropriate to allow the formation of an aerosol. [00187] In some embodiments, a compound of the application is formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection are, for example, presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. In some embodiments, the compositions take such forms as sterile suspensions, solutions or emulsions in oily or aqueous vehicles and contain formulating agents such as suspending, stabilizing and/or dispersing agents. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. Alternatively, the compounds of the application are suitably in a sterile powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. [00188] In some embodiments, compositions for nasal administration are conveniently formulated as aerosols, drops, gels and powders. For intranasal administration or administration by inhalation, the compounds of the application are conveniently delivered in the form of a solution, dry powder formulation or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer. Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which, for example, take the form of a cartridge or refill for use with an atomising device. Alternatively, the sealed container is a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser
comprises an aerosol dispenser, it will contain a propellant which is, for example, a compressed gas such as compressed air or an organic propellant such as fluorochlorohydrocarbon. Suitable propellants include but are not limited to dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, heptafluoroalkanes, carbon dioxide or another suitable gas. In the case of a pressurized aerosol, the dosage unit is suitably determined by providing a valve to deliver a metered amount. In some embodiments, the pressurized container or nebulizer contains a solution or suspension of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator are, for example, formulated containing a powder mix of a compound of the application and a suitable powder base such as lactose or starch. The aerosol dosage forms can also take the form of a pump-atomizer. [00189] Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein a compound of the application is formulated with a carrier such as sugar, acacia, tragacanth, or gelatin and glycerine. Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter. [00190] Suppository forms of the compounds of the application are useful for vaginal, urethral and rectal administrations. Such suppositories will generally be constructed of a mixture of substances that is solid at room temperature but melts at body temperature. The substances commonly used to create such vehicles include but are not limited to theobroma oil (also known as cocoa butter), glycerinated gelatin, other glycerides, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol. See, for example: Remington's Pharmaceutical Sciences, 16th Ed., Mack Publishing, Easton, PA, 1980, pp. 1530-1533 for further discussion of suppository dosage forms. [00191] In some embodiments a compound of the application is coupled with soluble polymers as targetable drug carriers. Such polymers include, for example, polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxy-ethylaspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, in some embodiments, a compound of the application is coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters,
polyacetals, polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels. [00192] The compounds of the application are particularly amenable to administration with the air of nano-carrier systems, such as liposomes, micelles, nanoparticles, nano-emulsions, lipidic nano-systems and the like (see for example, Bhat, M. et al., Chem. and Phys. of Lipids, 2021, 236, 105053). Accordingly the present application includes a composition comprising one or more compounds of the application and one or more components of a nano-carrier system. [00193] A compound of the application including pharmaceutically acceptable salts and/or solvates thereof is suitably used on their own but will generally be administered in the form of a pharmaceutical composition in which the one or more compounds of the application (the active ingredient) is in association with a pharmaceutically acceptable carrier. Depending on the mode of administration, the pharmaceutical composition will comprise from about 0.05 wt% to about 99 wt% or about 0.10 wt% to about 70 wt%, of the active ingredient and from about 1 wt% to about 99.95 wt% or about 30 wt% to about 99.90 wt% of a pharmaceutically acceptable carrier, all percentages by weight being based on the total composition. [00194] In some embodiments, the compounds of the application including pharmaceutically acceptable salts, solvates and/or prodrugs thereof are used are administered in a composition comprising an additional therapeutic agent. Therefore the present application also includes a pharmaceutical composition comprising one of more compounds of the application, or pharmaceutically acceptable salts, solvates and/or prodrugs thereof and an additional therapeutic agent, and optionally one or more pharmaceutically acceptable excipients. In some embodiments, the additional therapeutic agent is another known agent useful for treatment of a disease, disorder or condition by activation of a serotonin receptor, for example those listed in the Methods and Uses section below. In some embodiments, the additional therapeutic agent is a psychoactive drug. [00195] To be clear, in the above, the term “a compound” also includes embodiments wherein one or more compounds are referenced. IV. Methods and Uses of the Application [00196] Compounds of the application are useful for treating diseases, disorders or conditions by modulating, for example activating, a serotonin receptor. Therefore, the compounds of the present application are useful as medicaments. Accordingly, the
[00197] The present application also includes a method of treating a disease, disorder or condition by activation of a serotonin receptor comprising administering a therapeutically effective amount of one or more compounds of the application to a subject in need thereof. [00198] The present application also includes a use of one or more compounds of the application for treatment of a disease, disorder or condition by activation of a serotonin receptor as well as a use of one or more compounds of the application for the preparation of a medicament for treatment of a disease, disorder or condition by activation of a serotonin receptor. The application further includes one or more compounds of the application for use in treating a disease, disorder or condition by activation of a serotonin receptor. [00199] In some embodiments, the serotonin receptor is 5-HT2A. Accordingly, the present application includes a method for activating 5-HT2A in a cell, either in a biological sample or in a patient, comprising administering an effective amount of one or more compounds of the application to the cell. The application also includes a use of one or more compounds of the application for activating 5-HT2A in a cell as well as a use of one or more compounds of the application for the preparation of a medicament for activating 5-HT2A in a cell. The application further includes one or more compounds of the application for use in activating 5-HT2A in a cell. [00200] In some embodiments, the serotonin receptor is 5-HT1A. Accordingly, the present application includes a method for activating 5-HT1A receptors in a cell, either in a biological sample or in a patient, comprising administering an effective amount of one or more compounds of the application to the cell. The application also includes a use of one or more compounds of the application for activating 5-HT1A receptors in a cell as well as a use of one or more compounds of the application for the preparation of a medicament for activating 5-HT1A receptors in a cell. The application further includes one or more compounds of the application for use in activating 5-HT1A receptors in a cell. [00201] The present application also includes a method of treating a disease, disorder or condition by activation of 5-HT2A comprising administering a therapeutically effective amount of one or more compounds of the application to a subject in need thereof. The present application also includes a use of one or more compounds of the application for treatment of a disease, disorder or condition by activation of 5-HT2A as well as a use of one or more compounds of the application for the preparation of a medicament for treatment of a disease, disorder or condition by activation of 5-HT2A. The application further includes
one or more compounds of the application for use in treating a disease, disorder or condition by activation of 5-HT2A. [00202] The present application also includes a method of treating a disease, disorder or condition by activation of 5-HT1A comprising administering a therapeutically effective amount of one or more compounds of the application to a subject in need thereof. The present application also includes a use of one or more compounds of the application for treatment of a disease, disorder or condition by activation of 5-HT1A as well as a use of one or more compounds of the application for the preparation of a medicament for treatment of a disease, disorder or condition by activation of 5-HT1A. The application further includes one or more compounds of the application for use in treating a disease, disorder or condition by activation of 5-HT1A. [00203] The disease, disorder or condition may also be treated or treatable via alternative mechanisms, for example by modulation, deactivation, antagonism or reverse agonism of a serotonin receptor, including 5-HT2A and/or 5-HT1A. [00204] In some embodiments, the compounds of the application are useful for preventing, treating and/or reducing the severity of a mental illness disorder and/or condition in a subject. Therefore, in some embodiments, the disease, disorder or condition that is treated by activation of a serotonin receptor is a mental illness. Accordingly, the present application also includes a method of treating a mental illness comprising administering a therapeutically effective amount of one or more compounds of the application to a subject in need thereof. The present application also includes a use of one or more compounds of the application for treatment a mental illness, as well as a use of one or more compounds of the application for the preparation of a medicament for treatment of a mental illness. The application further includes one or more compounds of the application for use in treating a mental illness. [00205] In some embodiments, the mental illness is selected from anxiety disorders such as generalized anxiety disorder, panic disorder, social anxiety disorder and specific phobias; depression such as, hopelessness, loss of pleasure, fatigue and suicidal thoughts; mood disorders, such as depression, bipolar disorder, cancer-related depression, anxiety and cyclothymic disorder; psychotic disorders, such as hallucinations, delusions, schizophrenia; impulse control and addiction disorders, such as pyromania (starting fires), kleptomania (stealing) and compulsive gambling; alcohol addiction; drug addiction, such as opioid addiction; personality disorders, such as antisocial personality disorder, obsessive- compulsive personality disorder and paranoid personality disorder; obsessive-compulsive
disorder (OCD), such as thoughts or fears that cause a subject to perform certain rituals or routines; post-traumatic stress disorder (PTSD); stress response syndromes (formerly called adjustment disorders); dissociative disorders, formerly called multiple personality disorder, or “split personality,” and depersonalization disorder; factitious disorders; sexual and gender disorders, such as sexual dysfunction, gender identity disorder and the paraphilia’s; somatic symptom disorders, formerly known as a psychosomatic disorder or somatoform disorder; and combinations thereof. [00206] In some embodiments, the disease, disorder or condition that is treated by activation of a serotonin receptor comprises cognitive impairment; ischemia including stroke; neurodegeneration; refractory substance use disorders; sleep disorders; pain, such as social pain, acute pain, cancer pain, chronic pain, breakthrough pain, bone pain, soft tissue pain, nerve pain, referred pain, phantom pain, neuropathic pain, cluster headaches and migraine; obesity and eating disorders; epilepsies and seizure disorders; neuronal cell death; excitotoxic cell death; or a combination thereof. [00207] In some embodiments, the mental illness is selected from hallucinations and delusions and a combination thereof. [00208] In some embodiments, the hallucinations are selected from visual hallucinations, auditory hallucinations, olfactory hallucinations, gustatory hallucinations, tactile hallucinations, proprioceptive hallucinations, equilibrioceptive hallucinations, nociceptive hallucinations, thermoceptive hallucinations and chronoceptive hallucinations, and a combination thereof. [00209] In some embodiments, the disease, disorder or condition that is treated by activation of a serotonin receptor is psychosis or psychotic symptoms. Accordingly, the present application also includes a method of treating psychosis or psychotic symptoms comprising administering a therapeutically effective amount of one or more compounds of the application to a subject in need thereof. [00210] The present application also includes a use of one or more compounds of the application for treatment of psychosis or psychotic symptoms, as well as a use of one or more compounds of the application for the preparation of a medicament for treatment of psychosis or psychotic symptoms. The application further includes one or more compounds of the application for use in treating psychosis or psychotic symptoms. [00211] In some embodiments, administering to said subject in need thereof a therapeutically effective amount of the compounds of the application does not result in a
and delusions. In some embodiments, administering to said subject in need thereof a therapeutically effective amount of the compounds of the application results in an improvement of psychosis or psychotic symptoms such as, but not limited to, hallucinations and delusions. In some embodiments, administering to said subject in need thereof a therapeutically effective amount of the compounds of the application results in an improvement of psychosis or psychotic symptoms. [00212] In some embodiments, the compounds of the application are useful for treating a central nervous system (CNS) disorder in a subject in need of therapy, comprising administering a therapeutically effective amount of a compound of general formula I, or a pharmaceutically acceptable salt thereof to the subject. [00213] Therefore, in some embodiments, the disease, disorder or condition that is treated by activation of a serotonin receptor is a central nervous system (CNS) disease, disorder or condition and/or a neurological disease, disorder or condition. Accordingly, the present application also includes a method of treating a CNS disease, disorder or condition and/or a neurological disease, disorder or condition comprising administering a therapeutically effective amount of one or more compounds of the application to a subject in need thereof. The present application also includes a use of one or more compounds of the application for treatment a CNS disease, disorder or condition and/or a neurological disease, disorder or condition, as well as a use of one or more compounds of the application for the preparation of a medicament for treatment of a CNS disease, disorder or condition and/or a neurological disease, disorder or condition. The application further includes one or more compounds of the application for use in treating a CNS disease, disorder or condition and/or a neurological disease, disorder or condition. In some embodiments the CNS disease, disorder or condition and/or neurological disease, disorder or condition is selected from neurological diseases including neurodevelopmental diseases and neurodegenerative diseases such as Alzheimer’s disease; presenile dementia; senile dementia; vascular dementia; Lewy body dementia; cognitive impairment, Parkinson’s disease and Parkinsonian related disorders such as Parkinson dementia, corticobasal degeneration, and supranuclear palsy; epilepsy; CNS trauma; CNS infections; CNS inflammation; stroke; multiple sclerosis; Huntington’s disease; mitochondrial disorders; Fragile X syndrome; Angelman syndrome; hereditary ataxias; neuro-otological and eye movement disorders; neurodegenerative diseases of the retina amyotrophic lateral sclerosis; tardive dyskinesias; hyperkinetic disorders; attention deficit hyperactivity disorder and attention deficit disorders; restless leg syndrome; Tourette’s syndrome; schizophrenia;
the reward system including eating disorders such as anorexia nervosa (“AN”) and bulimia nervosa (“BN”); and binge eating disorder (“BED”), trichotillomania, dermotillomania, nail biting; migraine; fibromyalgia; and peripheral neuropathy of any etiology, and combinations thereof. [00214] In some embodiments, the subject is a mammal. In another embodiment, the subject is human. In some embodiments, the subject is a non-human animal. In some embodiments, the subject is canine. In some embodiments, the subject is feline. Accordingly, the compounds, methods and uses of the present application are directed to both human and veterinary diseases, disorders and conditions. [00215] In some embodiments, the compounds of the application are useful for treating behavioral problems in subjects that are felines or canines. [00216] Therefore, in some embodiments, the disease, disorder or condition that is treated by activation of a serotonin receptor is behavioral problems in subjects that are felines or canines. Accordingly, the present application also includes a method of treating a behavioral problem comprising administering a therapeutically effective amount of one or more compounds of the application to a non-human subject in need thereof. The present application also includes a use of one or more compounds of the application for treatment a behavioral problem in a non-human subject, as well as a use of one or more compounds of the application for the preparation of a medicament for treatment of a behavioral problem in a non-human subject. The application further includes one or more compounds of the application for use in treating a behavioral problem in a non-human subject. [00217] In some embodiments, the behavioral problems are selected from, but are not limited to, anxiety, fear, stress, sleep disturbances, cognitive dysfunction, aggression, excessive noise making, scratching, biting and a combination thereof. [00218] In some embodiments, the non-human subject is canine. In some embodiments, the non-human subject is feline. [00219] The present application also includes a method of treating a disease, disorder or condition by activation of a serotonin receptor comprising administering a therapeutically effective amount of one or more compounds of the application in combination with another known agent useful for treatment of a disease, disorder or condition by activation of a serotonin receptor to a subject in need thereof. The present application also includes a use of one or more compounds of the application in combination with another known agent useful for treatment of a disease, disorder or condition by
activation of a serotonin receptor, as well as a use of one or more compounds of the application in combination with another known agent useful for treatment of a disease, disorder or condition by activation of a serotonin receptor for the preparation of a medicament for treatment of a disease, disorder or condition by activation of a serotonin receptor. The application further includes one or more compounds of the application in combination with another known agent useful for treatment of a disease, disorder or condition by activation of a serotonin receptor for use in treating a disease, disorder or condition by activation of a serotonin receptor. [00220] In some embodiments, the disease, disorder or condition that is treated by activation of a serotonin receptor is a mental illness. In some embodiments, the mental illness is selected from hallucinations and delusions and a combination thereof. In some embodiments, the disease, disorder or condition that is treated by activation of a serotonin receptor is a central nervous system (CNS) disorder. In some embodiments, the disease, disorder or condition that is treated by activation of a serotonin receptor is psychosis or psychotic symptoms. In some embodiments, the disease, disorder or condition that is treated by activation of a serotonin receptor is behavioral problems in a non-human subject. [00221] In some embodiments, the disease, disorder or condition that is treated by activation of a serotonin receptor is a mental illness and the one or more compounds of the application are administered in combination with one or more additional treatments for a mental illness. In some embodiments, the additional treatments for a mental illness is selected from antipsychotics, including typical antipsychotics and atypical antipsychotics; antidepressants including selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants and monoamine oxidase inhibitors (MAOIs) (e.g. bupropion); anti-anxiety medication including benzodiazepines such as alprazolam; mood stabilizers such as lithium and anticonvulsants such carbamazepine, divalproex (valproic acid), lamotrigine, gabapentin and topiramate. [00222] In some embodiments, the disease, disorder or condition that is treated by activation of a serotonin receptor is selected from attention deficit hyperactivity disorder and attention deficit disorder and a combination thereof. In some embodiments, the disease, disorder or condition that is treated by activation of a serotonin receptor is attention deficit hyperactivity disorder and/or attention deficit disorder and a combination thereof and the one or more compounds of the application are administered in combination with one or more additional treatments for attention deficit hyperactivity disorder and/or attention deficit disorder and a combination thereof. In some embodiments, the additional treatments for
attention deficit hyperactivity disorder and/or attention deficit disorder and a combination thereof are selected from methylphenidate, atomoxetine and amphetamine and a combination thereof. [00223] In some embodiments, the disease, disorder or condition that is treated by activation of a serotonin receptor is dementia or Alzheimer’s disease and the one or more compounds of the application are administered in combination with one or more additional treatments for dementia or Alzheimer’s disease. In some embodiments, the additional treatments for dementia and Alzheimer’s disease are selected acetylcholinesterase inhibitors, NMDA antagonists and muscarinic agonists and antagonists, and nicotinic agonists. [00224] In some embodiments, the acetylcholinesterase inhibitors are selected from donepezil, galantamine, rivastigmine, and phenserine, and combinations thereof. [00225] In some embodiments, the NMDA antagonists are selected from MK-801, ketamine, phencyclidine, and memantine, and combinations thereof. [00226] In some embodiments, the nicotinic agonists is nicotine, nicotinic acid, nicotinic alpha7 agonists or alpha2 beta4 agonists or combinations thereof. [00227] In some embodiments, the muscarinic agonists is a muscarinic M1 agonist or a muscarinic M4 agonist, or combinations thereof. [00228] In some embodiments, the muscarinic antagonist is a muscarinic M2 antagonist. [00229] In some embodiments, the disease, disorder or condition that is treated by activation of a serotonin receptor is psychosis or psychotic symptoms and the one or more compounds of the application are administered in combination with one or more additional treatments for psychosis or psychotic symptoms. In some embodiments, the additional treatments for psychosis or psychotic symptom are selected typical antipsychotics and atypical antipsychotics. [00230] In some embodiments, the typical antipsychotics are selected from acepromazine, acetophenazine, benperidol, bromperidol, butaperazine, carfenazine, chlorproethazine, chlorpromazine, chlorprothixene, clopenthixol, cyamemazine, dixyrazine, droperidol, fluanisone, flupentixol, fluphenazine, fluspirilene, haloperidol, levomepromazine, lenperone, loxapine, mesoridazine, metitepine, molindone, moperone, oxypertine, oxyprotepine, penfluridol, perazine, periciazine, perphenazine, pimozide, i i t i i ti i hl i i thi d l
spiperone, sulforidazine, thiopropazate, thioproperazine, thioridazine, thiothixene, timiperone, trifluoperazine, trifluperidol, triflupromazine and zuclopenthixol and combinations thereof. [00231] In some embodiments, the atypical antipsychotics are selected from amoxapine, amisulpride, aripiprazole, asenapine, blonanserin, brexpiprazole, cariprazine, carpipramine, clocapramine, clorotepine, clotiapine, clozapine, iloperidone, levosulpiride, lurasidone, melperone, mosapramine, nemonapride, olanzapine, paliperidone, perospirone, quetiapine, remoxipride, reserpine, risperidone, sertindole, sulpiride, sultopride, tiapride, veralipride, ziprasidone and zotepine, and combinations thereof. [00232] In some embodiments, the disease, disorder or condition that is treated by activation of a serotonin receptor is a mental illness and the one or more compounds of the application are administered in combination with one or more additional treatments for a mental illness. In some embodiments, the additional treatments for a mental illness is selected typical antipsychotics and atypical antipsychotics. [00233] In some embodiments, effective amounts vary according to factors such as the disease state, age, sex and/or weight of the subject or species. In some embodiments, the amount of a given compound or compounds that will correspond to an effective amount will vary depending upon factors, such as the given drug(s) or compound(s), the pharmaceutical formulation, the route of administration, the type of condition, disease or disorder, the identity of the subject being treated and the like, but can nevertheless be routinely determined by one skilled in the art. [00234] In some embodiment, the compounds of the application are administered one, two, three or four times a year. In some embodiments, the compounds of the application are administered at least once a week. However, in another embodiment, the compounds are administered to the subject from about one time per two weeks, three weeks or one month. In another embodiment, the compounds are administered about one time per week to about once daily. In another embodiment, the compounds are administered 1, 2, 3, 4, 5 or 6 times daily. The length of the treatment period depends on a variety of factors, such as the severity of the disease, disorder or condition, the age of the subject, the concentration and/or the activity of the compounds of the application and/or a combination thereof. It will also be appreciated that the effective dosage of the compound used for the treatment may increase or decrease over the course of a particular treatment regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art In some instances chronic administration is required For
example, the compounds are administered to the subject in an amount and for duration sufficient to treat the subject. [00235] In some embodiments, the compounds of the application are administered at doses that are hallucinogenic or psychotomimetic and taken in conjunction with psychotherapy or therapy and may occur once, twice, three, or four times a year. However, in some embodiments, the compounds are administered to the subject once daily, once every two days, once every 3 days, once a week, once every two weeks, once a month, once every two months, or once every three months at doses that are not hallucinogenic or psychotomimetic. [00236] A compound of the application is either used alone or in combination with other known agents useful for treating diseases, disorders or conditions by activation of a serotonin receptor, such as the compounds of the application. When used in combination with other known agents useful in treating diseases, disorders by activation of a serotonin receptor, it is an embodiment that a compound of the application is administered contemporaneously with those agents. As used herein, “contemporaneous administration” of two substances to a subject means providing each of the two substances so that they are both active in the individual at the same time. The exact details of the administration will depend on the pharmacokinetics of the two substances in the presence of each other and can include administering the two substances within a few hours of each other, or even administering one substance within 24 hours of administration of the other, if the pharmacokinetics are suitable. Design of suitable dosing regimens is routine for one skilled in the art. In particular embodiments, two substances will be administered substantially simultaneously, i.e., within minutes of each other, or in a single composition that contains both substances. It is a further embodiment of the present application that a combination of agents is administered to a subject in a non-contemporaneous fashion. In some embodiments, a compound of the present application is administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form. Accordingly, the present application provides a single unit dosage form comprising one or more compounds of the application, an additional therapeutic agent and a pharmaceutically acceptable carrier. [00237] The dosage of a compound of the application varies depending on many factors such as the pharmacodynamic properties of the compound, the mode of administration, the age, health and weight of the recipient, the nature and extent of the symptoms, the frequency of the treatment and the type of concurrent treatment, if any and
the clearance rate of the compound in the subject to be treated. One of skill in the art can determine the appropriate dosage based on the above factors. In some embodiments, one or more compounds of the application are administered initially in a suitable dosage that is adjusted as required, depending on the clinical response. Dosages will generally be selected to maintain a serum level of the one or more compounds of the application from about 0.01 μg/cc to about 1000 μg/cc, or about 0.1 μg/cc to about 100 μg/cc. As a representative example, oral dosages of one or more compounds of the application will range between about 10 μg per day to about 1000 mg per day for an adult, suitably about 10 μg per day to about 500 mg per day, more suitably about 10 μg per day to about 200 mg per day. For parenteral administration, a representative amount is from about 0.0001 mg/kg to about 10 mg/kg, about 0.0001 mg/kg to about 1 mg/kg, about 0.01 mg/kg to about 0.1 mg/kg or about 0.0001 mg/kg to about 0.01 mg/kg will be administered. For oral administration, a representative amount is from about 0.001 μg/kg to about 10 mg/kg, about 0.1 μg/kg to about 10 mg/kg, about 0.01 μg/kg to about 1 mg/kg or about 0.1 μg/kg to about 1 mg/kg. For administration in suppository form, a representative amount is from about 0.1 mg/kg to about 10 mg/kg or about 0.1 mg/kg to about 1 mg/kg. In some embodiments of the application, compositions are formulated for oral administration and the one or more compounds are suitably in the form of tablets containing 0.1, 0.25, 0.5, 0.75, 1.0, 5.0, 10.0, 20.0, 25.0, 30.0, 40.0, 50.0, 60.0, 70.0, 75.0, 80.0, 90.0, 100.0, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000 mg of active ingredient (one or more compounds of the application) per tablet. In some embodiments of the application the one or more compounds of the application are administered in a single daily, weekly or monthly dose or the total daily dose is divided into two, three or four daily doses. [00238] In some embodiments, the compounds of the application are used or administered in an effective amount which comprises administration of doses or dosage regimens that are devoid of clinically meaningful psychedelic/ psychotomimetic actions. In some embodiments, the compounds of the application are used or administered in an effective amount which comprises administration of doses or dosage regimens that provide clinical effects similar to those exhibited by a human plasma psilocin Cmax of 4 ng/mL or less and/or human 5-HT2A human CNS receptor occupancy of 40% or less or those exhibited by a human plasma psilocin Cmax of 1 ng/mL or less and/or human 5-HT2A human CNS receptor occupancy of 30% or less. In some embodiments, the compounds of the application are used or administered in an effective amount which comprises administration of doses or dosage regimens that provide clinical effects similar to those exhibited by a
human plasma psilocin Tmax in excess of 60 minutes, in excess of 120 minutes or in excess of 180 minutes. [00239] To be clear, in the above, the term “a compound” also includes embodiments wherein one or more compounds are referenced. Likewise, the term “compounds of the application” also includes embodiments wherein only one compound is referenced. V. Preparation of Compounds [00240] Compounds of the present application can be prepared by various synthetic processes. The choice of particular structural features and/or substituents may influence the selection of one process over another. The selection of a particular process to prepare a given compound of the application is within the purview of the person of skill in the art. Some starting materials for preparing compounds of the present application are available from commercial chemical sources or may be extracted from cells, plants, animals or fungi. Other starting materials, for example as described below, are readily prepared from available precursors using straightforward transformations that are well known in the art. In the Schemes below showing some embodiments of methods of preparation of compounds of the application, all variables are as defined in Formula I, unless otherwise stated. [00241] In some embodiments, when Q is (Q3) the compounds of Formula I are prepared as shown in Scheme 1: Scheme 1 [00242] Therefore, in some embodiments, compounds of Formula A, wherein R1, R2, R3, R4 and R5 are as defined in Formula I, are reacted under basic conditions using, for
example, pyridine with compounds of Formula B, wherein and R25-28 are as defined in Formula I, R29 and/or R30 are as defined in Formula I or are a suitable protecting group such as alkyloxycarbonyl or benzyloxycarbonyl protecting group and LG is a suitable leaving group, such as chloro, to provide compounds of Formula I. If R29 and/or R30 are a protecting group, it is removed in a separate step. [00243] In some embodiments, when Q is (Q4) and R31 and R32 are either H or D, the compounds of Formula I are prepared as shown in Scheme 2: Scheme 2 [00244] Therefore, in some embodiments, compounds of Formula A, wherein R1, R2, R3, R4 and R5 are as defined in Formula I, are reacted under basic conditions using, for example, pyridine with compounds of Formula C, wherein R33 and R35-R40 are as defined in Formula I, R34 is as defined in Formula I or is a suitable protecting group such as an alkyloxycarbonyl or benzyloxycarbonyl protecting group and LG’ is a suitable leaving group, such as chloro, to provide compounds of Formula D. Reduction of keto group in the compounds of Formula C, for example using Al-based reducing agents such as lithium borohydride lithium aluminum hydride or lithium aluminum deuteride provides the
compounds of Formula (I), wherein R31 and R33 are either H or D. If R34 is a protecting group, it is removed in a separate step or, wherein the protecting group is removed in the presence of Al-based reducing agents is removed during the reduction of the compounds of Formula D. [00245] A person skilled in the art would appreciate that a similar reaction sequence can be used to prepare compounds of Formula I, wherein Q is (Q5). [00246] In some embodiments, when Q is (Q2) and is a single bond, the compounds of Formula I are prepared as shown in Scheme 3: Scheme 3 [00247] Therefore, in some embodiments, the compounds of Formula A, wherein R1, R2, R3, R4 and R5 are as defined in Formula I, are coupled with compounds of Formula E, wherein and R15-18 and R20-24 are as defined in Formula I, R19 is as defined in Formula I or is a suitable protecting group such as an alkyloxycarbonyl or benzyloxycarbonyl protecting group and LG’’ is a suitable leaving group, such as iodo, bromo, tosyl group or mesyl group, under suitable conditions, for example, with sodium hydride (NaH) or sodium tertiary butoxide (t-BuONa) to provide compounds of Formula I. If R19 is a protecting group, it is removed in a sepa’’te step. A person skilled in the art would appreciate that a similar
reaction sequence can be used to prepare compounds of Formula I, wherein Q is (Q1) or (Q6) and is a single bond. [00248] In some embodiments, the compound of Formula I, wherein Q is (Q1), (Q2) or (Q6) and is a single bond are prepared using methods known in the art, for example, the methods described in JP 2015096495 A and WO2007102883 A2. [00249] In some embodiments, when Q is (Q2) the compounds of Formula I are prepared as shown in Scheme 4: Scheme 4 [00250] Therefore, in some embodiments, compounds of Formula A, wherein R1, R2, R3, R4 and R5 are as defined in Formula I are coupled with compounds of Formula F, wherein and R15-18 and R20-24 are as defined in Formula I, R19 is as defined in Formula I or is a suitable protecting group such as alkyloxycarbonyl or benzyloxycarbonyl protecting group under suitable conditions, such as Mitsunobu reaction conditions using, for example, triphenylphosphine (PPh3) in the presence of, for example, diethyl azodicarboxylate
(DEAD) or diisopropyl azodicarboxylate (DIAD) to provide compounds of Formula I. If R19 is a protecting group, it is removed in a separate step. [00251] A person skilled in the art would appreciate that a similar reaction sequence can be used to prepare compounds of Formula I, wherein Q is (Q1) and (Q6). [00252] In some embodiments, the compound of Formula I, wherein Q is (Q1) or (Q2) or (Q6) are prepared using methods known in the art, for example, the methods described in WO2010095663 A1 , WO2017007008 and WO2021127333 [00253] In some embodiments, when Q is (Q2) and is a double bond the compounds of Formula I are prepared as shown in Scheme 5: Scheme 5
[00254] Therefore, in some embodiments, compounds of Formula A, wherein R1, R2, R3, R4 and R5 are as defined in Formula I are coupled with compounds of Formula G, wherein and R15-18 and R20-24 are as defined in Formula I, R19 is as defined in Formula I or is a suitable protecting group such as alkyloxycarbonyl or benzyloxycarbonyl protecting group and Ra and Rb are independently selected from H or alkyl, or Ra and Rb are linked together to form –(CH2)1-2-, under suitable conditions such as in the presence of a copper catalyst such as copper acetate, a suitable base such as pyridine and a suitable inert solvent such as methylene chloride to provide compounds of Formula I. If R19 is a protecting group, it is removed in a separate step. [00255] A person skilled in the art would appreciate that a similar reaction sequence can be used to prepare compounds of Formula I, wherein Q is (Q1) and (Q6) and is a double bond. [00256] In some embodiments, the compound of Formula I, wherein Q is (Q1) or (Q2) or (Q6) and is a double bond are prepared using methods known in the art, for example, the methods described in WO2016112637A1 and JP 2016141632 A. [00257] In some embodiments, when Q is wherein Q is (Q1) and is a single bond, one of R7 and R8 is OH or protected OH and the other H and R14 is H, or is a double bond wherein R7 is H, the compounds of Formula I are prepared as shown in Scheme 6:
Scheme 6 [00258] Therefore, in some embodiments, compounds of Formula A, wherein R1, R2, R3, R4 and R5 are as defined in Formula I are reacted with compounds of Formula H, wherein and R9-10 and R12-13 are as defined in Formula I, R11 is as defined in Formula I or is a suitable protecting group such as alkyloxycarbonyl or benzyloxycarbonyl protecting group under suitable conditions such as in the presence of a base, for example, sodium hydride in a suitable inert solvent such as dimethylformamide (DMF) to provide compounds of Formula I (a) wherein is a single bond, one of R7 and R8 is OH and the other H. The compounds of Formula I(a) are protected with a suitable protecting group such as a mesylate group to provide compounds of Formula I(b) wherein PG is a suitable protecting group which is further reacted with a suitable base such as sodium methoxide (NaOMe) to provide a compound of Formula I wherein is a double bond and R7 is H. If R11 is a protecting group, it is removed in a separate step.
[00259] A person skilled in the art would appreciate that a similar reaction sequence can be used to prepare compounds of Formula I, wherein Q is (Q2) and (Q6). [00260] In some embodiments, when Q is wherein Q is (Q1) and is a single bond, one of R7 and R8 is OH or protected OH and the other H and R14 is H, or is a double bond wherein R7 is H, the compounds of Formula I are prepared as shown using methods known in the art, for example, the methods described in JP 2014224104 A [00261] A person skilled in the art would appreciate that specific enantiomers or diastereomers of the compounds of the application are available by using corresponding single enantiomers or diastereomers of the corresponding starting materials. [00262] In some embodiments, compounds of Formula I, wherein Q (Q6) and is a single bond, and the stereochemistry at the carbon to which R53 is bonded is either R or S are prepared using methods known in the art, for example, the methods described in WO 2007102883 A2.
[00263] In some embodiments, compounds of Formula I, wherein Q is (Q1), (Q2) or (Q6) and is a single bond, and the stereochemistry at the carbon to which R14, R24 or R53 is bonded is either R or S are prepared using methods known in the art, for example, the methods described in JP 2014224104 and WO 2018092047 A1. [00264] Throughout the processes described herein it is to be understood that, where appropriate, suitable protecting groups will be added to, and subsequently removed from, the various reactants and intermediates in a manner that will be readily understood by one skilled in the art. Conventional procedures for using such protecting groups as well as examples of suitable protecting groups are described, for example, in “Protective Groups in Organic Synthesis”, T.W. Green, P.G.M. Wuts, Wiley-Interscience, New York, (1999). [00265] It is also to be understood that a transformation of a group or substituent into another group or substituent by chemical manipulation can be conducted on any intermediate or final product on the synthetic path toward the final product, in which the possible type of transformation is limited only by inherent incompatibility of other functionalities carried by the molecule at that stage to the conditions or reagents employed in the transformation. Such inherent incompatibilities, and ways to circumvent them by carrying out appropriate transformations and synthetic steps in a suitable order, will be readily understood to one skilled in the art. Examples of transformations are given herein, and it is to be understood that the described transformations are not limited only to the generic groups or substituents for which the transformations are exemplified. References and descriptions of other suitable transformations are given in “Comprehensive Organic Transformations – A Guide to Functional Group Preparations” R.C. Larock, VHC Publishers, Inc. (1989). References and descriptions of other suitable reactions are described in textbooks of organic chemistry, for example, “Advanced Organic Chemistry”, March, 4th ed. McGraw Hill (1992) or, “Organic Synthesis”, Smith, McGraw Hill, (1994). [00266] Techniques for purification of intermediates and final products include, for example, straight and reversed phase chromatography on column or rotating plate, recrystallisation, distillation and liquid-liquid or solid-liquid extraction, which will be readily understood by one skilled in the art.
[00267] The products of the processes of the application may be isolated according to known methods, for example, the compounds may be isolated by evaporation of the solvent, by filtration, centrifugation, chromatography or other suitable method. [00268] Generally, the reactions described above are performed in a suitable inert organic solvent and at temperatures and for times that will optimize the yield of the desired compounds. Examples of suitable inert organic solvents include, but are not limited to, 2- propanol, dimethylformamide (DMF), 1,4-dioxane, methylene chloride, chloroform, tetrahydrofuran (THF), toluene, and the like. [00269] The formation of a desired compound salt is achieved using standard techniques. For example, the neutral compound is treated with an acid or base in a suitable solvent and the formed salt is isolated by filtration, extraction or any other suitable method. [00270] The formation of solvates of the compounds of the application will vary depending on the compound and the solvate. In general, solvates are formed by dissolving the compound in the appropriate solvent and isolating the solvate by cooling or using an antisolvent. The solvate is typically dried or azeotroped under ambient conditions. The selection of suitable conditions to form a particular solvate can be made by a person skilled in the art. [00271] Prodrugs of the compounds of the present application may be, for example, conventional esters formed with available hydroxy, thiol, amino or carboxyl groups. For example, available hydroxy or amino groups may be acylated using an activated acid in the presence of a base, and optionally, in inert solvent (e.g. an acid chloride in pyridine). [00272] One skilled in the art will recognize that where a reaction step of the present application is carried out in a variety of solvents or solvent systems, said reaction step may also be carried out in a mixture of the suitable solvents or solvent systems. EXAMPLES [00273] The following non-limiting examples are illustrative of the present application: Example 1: R-6-Methoxy-1-((1-methylpyrrolidin-2-yl)methyl)-1H-indazole ((R) I-111) –
Synthesis of (R)-2-(2-(6-methoxy-1H-indazole-1-carbonyl)pyrrolidine-1-yl)-1-phenyl-2λ2- ethan-1-one (2): [00274] A solution of ((benzyloxy)carbonyl)-D-proline (6.73 g, 26.99 mmol) in dry THF (80 mL) was treated with thionyl chloride (3.93 mL, 53.99 mmol) at room temperature and the resulting solution was refluxed for additional 2 h. The reaction was brought to room temperature and solvent was evaporated to obtain the crude acid chloride as pale-yellow oil. [00275] A solution of above crude acid chloride in CH2Cl2 (50 mL) was treated with a solution of 6-methoxy-1H-indazole (4.0 g, 26.99 mmol) in CH2Cl2 (30 mL), followed by pyridine (4.32 mL, 53.99 mmol) at 0 oC. The reaction was brought to room temperature and stirred overnight (16 h). The reaction was diluted with CH2Cl2 (100 mL), washed with water (2 x 100 mL), 1 N HCl solution (100 mL), brine (50 mL) and dried (Na2SO4). Solvent was evaporated and crude was purified by flash column chromatography (EtOAc: CH2Cl2, 1:9) on silica gel to obtain the title compound 2 (8.5 g, 83.4%) along with its positional isomer in 9:1 ratio as glassy solid. ESI-MS (m/z, %): 402 (M+Na), 380 (MH+, 100). Synthesis of (R)-6-methoxy-1-((1-methylpyrrolidin-2-yl)methyl)-1H-indazole ((R)I-111): [00276] A suspension of LiAlH4 (0.75 g, 19.76 mmol) in dry THF (40 mL) was treated with AlCl3 (3.16 g, 23.71 mmol) at 0 oC. The reaction was treated with I-2-(2-(6-methoxy- 1H-indazole-1-carbonyl)pyrrolidine-1-yl)-1-phenyl-2l2-ethan-1-one (1.5 g, 3.95 mmol) in dry THF (20 mL) over a period of 5 min. after stirring for 15 min. The reaction was brought to room temperature and stirred for additional 4 h. The reaction was cooled to 0 oC, quenched with water (1.0 mL), 2 N NaOH solution (1 mL) and water (1 mL). The reaction was brought to room temperature and stirred for additional 30 min. The reaction was diluted with THF (50 mL), filtered through a pad of Na2SO4, followed by a pad of silica gel. Solvent was evaporated and crude was purified by column chromatography (2 M NH3 in MeOH: CH2Cl2, 5:95) on silica gel to obtain the title compound (R) I-111 (0.15 g, 15%) as a brown oil.1H NMR (DMSO-d6): δ 8.24 (s, 1H), 7.56 (d, 1H, J = 6.0 Hz), 6.92 (d, 1H, J = 3.0 Hz), 6.68 (dd, 1H, J = 3.0, 6.0 Hz), 4.42-4.37 (m, 1H), 4.26-4.21 (m, 1H), 3.79 (s, 3H), 2.97-2.93 (m, 1H), 2.72-2.2.60 (m, 1H), 2.20-2.14 (m, 4H), 1.75-1.70 (m, 1H), 1.60-1.54 (m, 3H); ESI-MS (m/z, %): 246 (MH+, 100). Example 2: (S)-6-Methoxy-1-((1-methylpyrrolidin-2-yl)methyl)-1H-indazole ((S)-I-111)
Synthesis of (S)-2-(2-(6-methoxy-1H-indazole-1-carbonyl)pyrrolidine-1-yl)-1-phenyl-2l2- ethan-1-one (4): [00277] A solution of ((benzyloxy)carbonyl)-L-proline (1.6 g, 6.74 mmol) in dry THF (20 mL) was treated with thionyl chloride (1.0 mL, 13.49 mmol) at room temperature and the resulting solution was refluxed for additional 2 h. The reaction was brought to room temperature and solvent was evaporated to obtain the crude acid chloride as pale-yellow oil. [00278] A solution of above crude acid chloride in CH2Cl2 (25 mL) was treated with a solution of 6-methoxy-1H-indazole (1.0 g, 6.74 mmol) in CH2Cl2 (10 mL), followed by pyridine (1.09 mL, 13.49 mmol) at 0 oC. The reaction was brought to room temperature and stirred overnight (16 h). The reaction was diluted with CH2Cl2 (50 mL), washed with water (2 x 50 mL), 1 N HCl solution (50 mL), brine (25 mL) and dried (Na2SO4). Solvent was evaporated and crude was purified by flash column chromatography (EtOAc: CH2Cl2, 1:9) on silica gel to obtain the title compound 4 (2.3 g, 89.8%) along with its positional isomer in 93:7 ratio as glue. ESI-MS (m/z, %): 402 (M+Na), 380 (MH+, 100). Synthesis of (S)-6-methoxy-1-((1-methylpyrrolidin-2-yl)methyl)-1H-indazole ((S)-I-111): [00279] A suspension of LiAlH4 (1.0 g, 26.35 mmol) in dry THF (40 mL) was treated with AlCl3 (4.21 g, 31.62 mmol) at 0 oC. The reaction was treated with (S)-2-(2-(6-methoxy- 1H-indazole-1-carbonyl)pyrrolidine-1-yl)-1-phenyl-2l2-ethan-1-one (2.0 g, 5.27 mmol) in dry THF (20 mL) over a period of 5 min. after stirring for 15 min. The reaction was brought to room temperature and stirred for additional 4 h. The reaction was cooled to 0 oC, quenched with water (1.0 mL), 2 N NaOH solution (1 mL) and water (1 mL). The reaction was brought to room temperature and stirred for additional 30 min. The reaction was diluted with THF (50 mL), filtered through a pad of Na2SO4, followed by a pad of silica gel. Solvent was evaporated and crude was purified by column chromatography (2 M NH3 in MeOH: CH2Cl2, 5:95) on silica gel to obtain the title compound (S) I-111 (35 mg, 2.7%) as a pale-yellow oil. 1H NMR (DMSO-d6): δ 8.24 (s, 1H), 7.56 (d, 1H, J = 6.0 Hz), 6.92 (d, 1H, J = 3.0 Hz), 6.68 (dd, 1H, J = 3.0, 6.0 Hz), 4.41-4.37 (m, 1H), 4.25-4.20 (m, 1H), 3.79 (s, 3H), 2.96-2.93 (m,
1H), 2.73-2.2.69 (m, 1H), 2.23-2.14 (m, 4H), 1.76-1.69 (m, 1H), 1.62-1.56 (m, 3H); ESI-MS (m/z, %): 246 (MH+, 100). Example 3: (R)-6-Fluoro-1-((1-methylpyrrolidin-2-yl)methyl)-1H-indazole ((R)-I-52) Synthesis of (R)-2-(2-(6-fluoro-1H-indazole-1-carbonyl)pyrrolidine-1-yl)-1-phenyl-2l2- ethan-1-one (7): [00280] A solution of ((benzyloxy)carbonyl)-D-proline (5.0 g, 20.06 mmol) in dry THF (75 mL) was treated with thionyl chloride (2.93 mL, 40.19 mmol) at room temperature and the resulting solution was refluxed for additional 2 h. The reaction was brought to room temperature and solvent was evaporated to obtain the crude acid chloride as pale-yellow oil. A solution of above crude acid chloride in CH2Cl2 (50 mL) was treated with a solution of 6-fluoro-1H-indazole (2.73 g, 20.06 mmol) in CH2Cl2 (25 mL), followed by pyridine (3.24 mL, 40.19 mmol) at 0 oC. The reaction was brought to room temperature and stirred overnight (16 h). The reaction was diluted with CH2Cl2 (100 mL), washed with water (2 x 50 mL), 1 N HCl solution (50 mL), brine (25 mL) and dried (Na2SO4). Solvent was evaporated and crude was purified by flash column chromatography (EtOAc: CH2Cl2, 1:9) on silica gel to obtain the title compound 7 (6.5 g, 88.3%) along with its positional isomer in 7:3 ratio as pale-yellow glue. ESI-MS (m/z, %): 406 (M+K, 100), 390 (M+Na), 368 (MH+). Synthesis of (R)-6-fluoro-1-((1-methylpyrrolidin-2-yl)methyl)-1H-indazole ((R)-I-52): [00281] A suspension of LiAlH4 (0.775 g, 20.41 mmol) in dry THF (30 mL) was treated with AlCl3 (3.26 g, 24.49 mmol) at 0 oC. The reaction was treated with I-2-(2-(6- fluoro-1H-indazole-1-carbonyl)pyrrolidine-1-yl)-1-phenyl-2l2-ethan-1-one (1.5 g, 4.08 mmol) in dry THF (20 mL) over a period of 5 min. after stirring for 15 min. The reaction was brought to room temperature and stirred for additional 4 h. The reaction was cooled to 0 oC, quenched with water (1.0 mL), 2 N NaOH solution (1 mL) and water (1 mL). The reaction was brought to room temperature and stirred for additional 30 min. The reaction was diluted with THF (50 mL), filtered through a pad of Na2SO4, followed by a pad of silica gel. Solvent was evaporated and crude was purified by column chromatography (2 M NH3 in MeOH: CH2Cl2, 5:95) on silica gel to obtain the title compound (R)-I-52 (0.12 g, 12.6%) as light brown oil 1H NMR (DMSOd ): δ 843 (s 1H) 780776 (m 1H) 735731 (m 1H) 696
6.91 (m, 1H), 4.45 (dd, 1H, J = 3.0, 12.0 Hz), 4.30 (dd, 1H, J = 3.0, 9.0 Hz), 2.97-2.92 (m, 1H), 2.74-2.70 (m, 1H), 2.21-2.16 (m, 4H), 1.75-1.71 (m, 1H), 1.62-1.55 (m, 3H); ESI-MS (m/z, %): 234 (MH+, 100). Example 4: 2-(6-Methoxy-1H-indazol-1-yl)-N,N-dimethylethan-1-amine (12) Synthesis of ethyl 2-(6-methoxy-1H-indazol-1-yl)acetate (9): [00282] A solution of 6-methoxy-1H-indazole (4.0 g, 26.99 mmol) in dry DMF (50 mL) was treated with sodium hydride (1.76 g, 44.00 mmol, 60% in mineral oil) portion-wise over a period of 10 min. at 0 oC. The reaction was brought to room temperature and stirred for 30 min. Ethyl bromoacetate (5.39 mL, 48.60 mmol) was added drop-wise over a period of 30 min. at 0 oC and stirred for additional 24 h at room temperature. The reaction was quenched with water (300 mL) and product was extracted into diethyl ether (2 x 150 mL). Combined diethyl ether layer was washed with water (50 mL), brine (50 mL) and dried (Na2SO4). Solvent was evaporated and crude was purified by column chromatography (Hexanes: EtOAc, 1:4) on silica gel to obtain the title compound 9 (2.05 g, 32.4%) as a light-yellow solid.1H NMR (CDCl3): δ 7.97 (s, 1H), 7.62 (d, 1H, J = 6.0 Hz), 6.86 (dd, 1H, J =3.0, 6.0 Hz), 6.68 (s, 1H), 5.12 (s, 2H), 4.24 (q, 2H), 3.90 (s, 3H), 1.28 (t, 3H, J = 6.0 Hz); ESI-MS (m/z, %): 235 (MH+, 100). Synthesis of 2-(6-methoxy-1H-indazol-1-yl)ethan-1-ol (10): [00283] A solution of ethyl 2-(6-methoxy-1H-indazol-1-yl)acetate (2.0 g, 8.54 mmol) in dry THF (20 mL) was treated with DIBAL-H (23 mL, 34.15 mmol, 25% in toluene) drop- wise over a period of 20 min. at 0 oC. The reaction was brought to room temperature and stirred for additional 2 h. The reaction was quenched with sat. NH4Cl solution (25 mL) drop-
pad of celite and washed with ethyl acetate (2 x 50 mL). Combined ethyl acetate layer was evaporated and crude was purified through flash column chromatography (EtOAc) on silica gel to obtain the title compound 10 (1.64 g, 82%) as a beige solid.1H NMR (CDCl3): δ 7.91 (s, 1H), 7.60 (d, 1H, J = 6.0 Hz), 6.84 (dd, 1H, J = 1.5, 6.0 Hz), 6.77 (d, 1H, J = 3.0 Hz), 4.43-4.41 (m, 2H), 4.14-4.12 (m, 2H), 3.91 (s, 3H), 3.18 (brs, 1H); ESI-MS (m/z, %): 263 (100), 215 (M+Na), 193 (MH+). Synthesis of 2-(6-methoxy-1H-indazol-1-yl)ethyl methanesulfonate (11): [00284] A solution of 2-(6-methoxy-1H-indazol-1-yl)ethan-1-ol (1.6 g, 8.32 mmol) and Et3N (1.73 mL, 12.48 mmol) in dry CH2Cl2 (15 mL) was treated with MsCl (0.71 mL, 9.16 mmol) drop-wise over a period of 5 min. at 0 oC. The reaction was brought to room temperature and stirred for additional 1.5 h. The reaction was quenched with brine solution (25 mL) and product was extracted into CH2Cl2 (2 x 50 mL). Combined CH2Cl2 layer was dried (Na2SO4), solvent was evaporated to obtain the crude title compound 11 (2.2 g), which was used as such without any further purification. Synthesis of 2-(6-methoxy-1H-indazol-1-yl)-N,N-dimethylethan-1-amine (12): [00285] A solution of above crude 2-(6-methoxy-1H-indazol-1-yl)ethyl methanesulfonate (2.2 g, 8.14 mmol) in dry THF (30 mL) was treated with dimethyl amine (82 mL, 162.78 mmol) and stirred for additional 15 h at 100 oC in a sealed tube. The reaction was cooled to room temperature, solvent was evaporated and crude was purified by column chromatography (2 M NH3 in MeOH: CH2Cl2, 3:97) on silica gel to obtain the title compound 12 (1.66 g, 93% over two steps) as a pale-yellow glue.1H NMR (DMSO-d6): δ 7.91 (d, 1H, J = 1.5 Hz), 7.59 (dd, 1H, J = 1.5, 6.0 Hz), 7.12 (d, 1H, J = 3.0 Hz), 6.75 (dd, 1H, J = 1.5, 6.0 Hz), 4.43 (t, 2H, J = 6.0 Hz), 3.85 (s, 3H), 2.70 (t, 2H, J = 6.0 Hz), 2.18 (s, 6H). Example 5: 2-(6-Fluoro-1H-indazol-1-yl)-N,N-dimethylethan-1-amine (16)
[00286] Synthesis of ethyl 2-(6-fluoro-1H-indazol-1-yl)acetate (13): A solution of 6- fluoro-1H-indazole (4.0 g, 29.39 mmol) in dry DMF (50 mL) was treated with sodium hydride (1.92 g, 47.91 mmol, 60% in mineral oil) portion-wise over a period of 10 min. at 0 oC. The reaction was brought to room temperature and stirred for 30 min. Ethyl bromoacetate (5.87 mL, 52.90 mmol) was added drop-wise over a period of 30 min. at 0 oC and stirred for additional 24 h at room temperature. The reaction was worked-up and purified as described for compound 9 to obtain the title compound 13 (2.05 g, 31.4%) as a light-yellow solid.1H NMR (CDCl3): δ 8.05 (s, 1H), 7.71 (dd, 1H, J = 3.0, 6.0 Hz), 7.03-6.96 (m, 2H), 5.12 (s, 2H), 4.26 (q, 2H), 1.29 (t, 3H, J = 6.0 Hz); ESI-MS (m/z, %): 223 (MH+, 100). [00287] Synthesis of 2-(6-fluoro-1H-indazol-1-yl)ethan-1-ol (14): A solution of ethyl 2-(6-fluoro-1H-indazol-1-yl)acetate (2.04 g, 9.24 mmol) in dry THF (20 mL) was treated with DIBAL-H (24.8 mL, 36.88 mmol, 25% in toluene) drop-wise over a period of 20 min. at 0 oC. The reaction was brought to room temperature and stirred for additional 2 h. The reaction was worked-up and purified as described for compound 10 to obtain the title compound 14 (1.46 g, 88.5%) as pale-yellow solid.1H NMR (CDCl3): δ 8.00 (d, 1H, J = 1.5 Hz), 7.69 (dd, 1H, J = 3.0, 6.0 Hz), 7.11 (dd, 1H, J = 3.0, 6.0 Hz), 6.99-6.94 (m, 1H), 4.44- 4.41 (m, 2H), 4.13 (t, 2H, J = 6.0 Hz), 2.96 (brs, 1H); ESI-MS (m/z, %): 203 (M+Na), 181 (MH+, 100). Synthesis of 2-(6-fluoro-1H-indazol-1-yl)ethyl methanesulfonate (15): [00288] A solution of 2-(6-fluoro-1H-indazol-1-yl)ethan-1-ol (1.43 g, 7.94 mmol) and Et3N (1.65 mL, 11.91 mmol) in dry CH2Cl2 (15 mL) was treated with MsCl (0.68 mL, 8.73 mmol) drop-wise over a period of 5 min. at 0 oC. The reaction was brought to room temperature and stirred for additional 1.5 h. The reaction was worked-up as described for
compound 11 to obtain the crude title compound 15 (2.0 g), which was used as such without any further purification. [00289] Synthesis of 2-(6-fluoro-1H-indazol-1-yl)-N,N-dimethylethan-1-amine (16): A solution of above crude 2-(6-fluoro-1H-indazol-1-yl)ethyl methanesulfonate (2.0 g, 7.74 mmol) in dry THF (30 mL) was treated with dimethyl amine (77 mL, 154.87 mmol) and stirred for additional 15 h at 100 oC in a sealed tube. The reaction was cooled to room temperature, worked-up and purified as described for compound 12 to obtain the title compound 16 (1.4 g, 84.7% over two steps) as a pale-yellow glue.1H NMR (DMSO-d6): δ 8.07 (d, 1H, J = 1.5 Hz), 7.78 (dd, 1H, J = 3.0, 6.0 Hz), 7.60-7.56 (m, 1H), 7.03-6.98 (m, 1H), 4.45 (t, 2H, J = 6.0 Hz), 2.69 (t, 2H, J = 6.0 Hz), 2.16 (s, 6H). Example 6: 2-(6-Methoxy-1H-indazol-1-yl)-N,N-bis(methyl-d3)ethan-1-amine (I-6) Synthesis of 2-(6-methoxy-1H-indazol-1-yl)ethyl methanesulfonate (11): [00290] Title compound was prepared as described above starting from 2-(6- methoxy-1H-indazol-1-yl)ethan-1-ol (1.1 g, 5.72 mmol). Crude product was used in the next step without any purification. 2-(6-methoxy-1H-indazol-1-yl)-N,N-bis(methyl-d3)ethan-1-amine (I-6): [00291] A suspension of above crude 2-(6-methoxy-1H-indazol-1-yl)ethyl methanesulfonate, K2CO3 (2.37 g, 17.17 mmoL), bis(methyl-d3)amine hydrochloride (1.0 g, 11.45 mmol) and DMF (0.3 mL) in dry ACN (50 mL) was stirred at 70 oC in a sealed tube for overnight (16 h). The reaction was cooled to room temperature, worked-up and purified as described for compound 12 to obtain the title compound I-6 (0.8 g, 62% over two steps) as a pale-yellow glue.1H NMR (DMSO-d6): δ 7.91 (d, 1H, J = 1.5 Hz), 7.59 (d, 1H, J = 6.0 Hz), 7.12 (d, 1H, J = 1.5 Hz), 6.75 (dd, 1H, J = 1.5, 6.0 Hz), 4.42 (t, 2H, J = 6.0 Hz), 3.85 (s, 3H), 2.69 (t, 2H, J = 6.0 Hz); ESI-MS (m/z, %): 226 (MH+, 100). Example 7: 2-(6-Fluoro-1H-indazol-1-yl)-N,N-bis(methyl-d3)ethan-1-amine (I-119
Synthesis of 2-(6-fluoro-1H-indazol-1-yl)ethyl methanesulfonate (17): [00292] Title compound was prepared as described above starting from 2-(6-fluoro- 1H-indazol-1-yl)ethan-1-ol (0.92 g, 5.10 mmol). Crude product was used in the next step without any purification. Synthesis of 2-(6-fluoro-1H-indazol-1-yl)-N,N-bis(methyl-d3)ethan-1-amine (I-119 ): [00293] A suspension of above crude 2-(6-fluoro-1H-indazol-1-yl)ethyl methanesulfonate, K2CO3 (2.12 g, 15.32 mmoL), bis(methyl-d3)amine hydrochloride (0.89 g, 10.21 mmol) and DMF (0.3 mL) in dry ACN (50 mL) was stirred at 70 oC in a sealed tube for overnight (16 h). The reaction was cooled to room temperature, worked-up and purified as described for compound 12 to obtain the title compound I-119 (0.66 g, 60.5% over two steps) as a pale-yellow oil.1H NMR (DMSO-d6): δ 8.07 (d, 1H, J = 1.5 Hz), 7.77 (dd, 1H, J = 3.0, 6.0 Hz), 7.58 (dd, 1H, J = 1.5, 6.0 Hz), 7.03-6.98 (m, 1H), 4.44 (t, 2H, J = 6.0 Hz), 2.69 (t, 2H, J = 6.0 Hz); ESI-MS (m/z, %): 214 (MH+, 100). Example 8: (R)-6-Methoxy-1-(pyrrolidin-2-ylmethyl)-1H-indazole hydrochloride ((R)-I- 121.HCl) Synthesis of tert-butyl (R)-2-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate (20): [00294] Title compound was prepared as described for compound 11 starting from tert-butyl (R)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (5.43 g, 26.99 mmol). Crude product was used in the next step without any purification.
Synthesis of tert-butyl (R)-2-((6-methoxy-1H-indazol-1-yl)methyl)pyrrolidine-1-carboxylate (21): [00295] A solution of 6-methoxy-1H-indazole (2.0 g, 13.50 mmol) in dry DMF (50 mL) was treated with sodium hydride (2.16 g, 53.99 mmol, 60% in mineral oil) portion-wise over a period of 10 min. at 0 oC. The reaction was brought to room temperature and stirred for 30 min. Above crude tert-Butyl (R)-2-(((methylsulfonyl)oxy)methyl)pyrrolidine-1- carboxylate in dry DMF (25 mL) was added drop-wise over a period of 30 min. at 0 oC and stirred for additional 24 h at room temperature. The reaction was worked-up and purified as described for compound 9 to obtain the title compound 21 (1.5 g, 33.5% over two steps) as a pale-yellow oil. ESI-MS (m/z, %): 354 (M+Na), 332 (MH+, 100). Synthesis of (R)-6-methoxy-1-(pyrrolidin-2-ylmethyl)-1H-indazole hydrochloride ((R)-I- 121.HCl): [00296] A solution of tert-butyl (R)-2-((6-methoxy-1H-indazol-1- yl)methyl)pyrrolidine-1-carboxylate (1.5 g, 4.53 mmol) in dry diethyl ether (20 mL) was treated with 2 M HCl in diethyl ether (45.3 mL, 90.52 mmol) at room temperature. The reaction was stirred for additional 24 h at 50 oC in a sealed tube. The reaction was cooled to room temperature and solid was filtered off and washed with ether. Solid was dried under high vacuum to obtain the title compound (R)-I-121.HCl (1.11 g, 91.7%) as an off-white solid.1H NMR (DMSO-d6): δ 8.03 (d, 1H, J = 1.5 Hz), 7.64 (d, 1H, J = 6.0 Hz), 7.41 (d, 1H, J = 3.0 Hz), 6.80 (dd, 1H, J = 3.0, 6.0 Hz), 5.81 (brs, 2H), 4.82-4.68 (m, 2H), 3.94-3.91 (m, 1H), 3.88 (s, 3H), 3.31-3.09 (m, 2H), 2.10-1.71 (m, 4H); ESI-MS (m/z, %): 232 (MH+, 100, free base). Example 9: (R)-6-Fluoro-1-(pyrrolidin-2-ylmethyl)-1H-indazole hydrochloride ((R)-I- 120.HCl) Synthesis of tert-butyl (R)-2-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate (20):
[00297] Title compound was prepared as described for compound 11 starting from tert-butyl (R)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (5.9 g, 29.39 mmol). Crude product was used in the next step without any purification. Synthesis of tert-butyl (R)-2-((6-fluoro-1H-indazol-1-yl)methyl)pyrrolidine-1-carboxylate (23): [00298] A solution of 6-fluoro-1H-indazole (2.0 g, 14.69 mmol) in dry DMF (50 mL) was treated with sodium hydride (2.35 g, 58.78 mmol, 60% in mineral oil) portion-wise over a period of 10 min. at 0 oC. The reaction was brought to room temperature and stirred for 30 min. Above crude tert-Butyl (R)-2-(((methylsulfonyl)oxy)methyl)pyrrolidine-1- carboxylate in dry DMF (25 mL) was added drop-wise over a period of 30 min. at 0 oC and stirred for additional 24 h at room temperature. The reaction was worked-up and purified as described for compound 9 to obtain the title compound 23 (2.6 g, 55.4% over two steps) as a pale-yellow oil. ESI-MS (m/z, %): 320 (MH+, 100). Synthesis of (R)-6-fluoro-1-(pyrrolidin-2-ylmethyl)-1H-indazole hydrochloride ((R)-I- 120.HCl): [00299] A solution of tert-butyl (R)-2-((6-fluoro-1H-indazol-1-yl)methyl)pyrrolidine-1- carboxylate (1.6 g, 5.01 mmol) in dry diethyl ether (20 mL) was treated with 2 M HCl in diethyl ether (50.0 mL, 100.19 mmol) at room temperature. The reaction was stirred for additional 24 h at 50 oC in a sealed tube. The reaction was cooled to room temperature and solid was filtered off and washed with ether. Solid was dried under high vacuum to obtain the title compound (R)-I-120.HCl )(1.0 g, 78%) as an off-white solid.1H NMR (DMSO-d6): δ 8.20 (d, 1H, J = 1.5 Hz), 7.86-7.77 (m, 2H), 7.09-7.04 (m, 1H), 6.23 (brs, 2H), 4.85-4.70 (m, 2H), 3.96-3.92 (m, 1H), 3.31-3.25 (m, 1H), 3.16-3.11 (m, 1H), 2.08-1.69 (m, 4H); ESI- MS (m/z, %): 220 (MH+, 100, free base). B. Biological Testing Example 10: Human 5-HT2A: Functional FLIPR assay Objective: [00300] The potential excitatory effects of exemplary compounds of the application targeting on human 5-hydroxytryptamine receptor 2A (5-HT2A) under agonist mode was assessed.
1 Materials and Instrumentation 1.1 Cell line Cell line Name Target Host cell HTR2A&Gα15-HEK293 5HT2A Flp-In-293 1.2 Materials Regents Vendor Cat# DMEM Gibco 10569-010 Dialyzed FBS BIOSUN BS-0005-500 Penicillin-Streptomycin Invitrogen 15140 Hygromycin B Invivogen Ant-hg-5 Tetracycline Abcam ab141223 hydrochloride TrypLE™Express Gibco 12604-013 DPBS Gibco 14190250 DMSO Millipore 1029312500 Probenecid Sigma P8761 FLIPR Calcium 6 Molecular Device R8191 Assay Kit HEPES Invitrogen 15630 Hank’s Buffered Saline Invitrogen 14025 Solution Serotonin HCl Selleck S4244 1.3 Instrumentation and consumables Item Supplier Cat# Fluorometric Imaging Plate Reader (FLIPR) Molecular Device Tetra Countess Automated Cell Counter Invitrogen Countess Cell Counting Chamber Slides Invitrogen C10312 STERI-CYCLE CO2 Incubator Thermo 371
Item Supplier Cat# 1300 Series Class II Biological Safety Thermo 1389 Cabinet Table-type Large Capacity Low Speed Cence L550 Centrifuge Centrifuge Eppendorf 5702 Echo Labcyte 550 Echo Labcyte 655 Electro-thermal incubator Shanghai Yiheng DHP-9031 plate shaker IKA MS3 digital Water Purification System ULUPURE UPH-III- 20T Versatile and Universal pH and Mettler Toledo S220 Conductivity Meters 384-Well plate Corning 3764 384-Well LDV Clear microplate LABCYTE LP-0200 384-Well Polypropylene microplate LABCYTE PP-0200 384-well compound plate Corning 3657 T25 cell culture flask Corning 430639 50 mL Polypropylene Centrifuge Tube JET CFT01150 0 15 mL Polypropylene Centrifuge Tube JET CFT01115 0 2 Experimental Methods 2.1 Cell culture [00301] HTR2A&Gα15-HEK293 cells were cultured in DMEM medium containing 10% dialyzed FBS and 1× penicillin-streptomycin, 100 μg/mL Hygromycin B and 300 μg/mL G418. The cells were passaged about three times a week, maintained between ~30% to ~90% confluence. 2.2 Cell plating [00302] 1. The cell culture medium (DMEM medium containing 10% dialyzed FBS and 1× penicillin-streptomycin, 100 μg/mL Hygromycin B and 300 μg/mL G418),
[00303] 2. For induction, 1 μg/ml tetracycline (final concentration) was added to cell culture medium and incubated for 48 hours prior to seeding cells into plate at 37ºC, 5% (v/v) CO2. The cell culture medium was removed from flask. Cells were washed with DPBS. [00304] 3. 2 mL TrypLE™ Express was added to the flask, mixed well by gentle shaking and cells were incubated at 37oC for a few minutes. [00305] 4. The cells were checked for morphological change under microscope, the digestion was stopped by adding 4 mL cell culture medium to the flask when most of cells turned to round. [00306] 5. The cell suspension was transferred into a 15 mL centrifuge tube, and then centrifuged at 1,200 rpm for 5 minutes. [00307] 6. The supernatant was removed. The cell pellet was resuspended with 2 mL cell culture medium. [00308] 7. The cell density was counted using cell counter. Only cells with >85% viability were used for the assay. [00309] 8. Cells were diluted to 6.67×105/mL with cell culture medium. [00310] 9. 30 μL/well cell suspensions added into a 384-well cell plate (The cell density was 20,000 cells/well). [00311] 10. The cell plate was incubated overnight at 37oC, 5% (v/v) CO2. 2.3 Cell handling [00312] On the day of experiments, culture medium was removed from the cell plate. [00313] 10 μL of assay buffer (20 mM HEPES, in 1× HBSS, pH 7.4) was added to each well of the cell plate. [00314] 2×dye solution was prepared following the manual of the FLIPR® Calcium 6 Assay Kit: [00315] i. The dye was diluted with assay buffer. [00316] ii. Probenecid was added to the final concentration of 5 mM. [00317] iii. Vortexed vigorously for 1–2 minutes. [00318] 4. 10 μL of 2× dye solution was added to each well of the cell plate [00319] 5. The cell plate was placed on plate shaker, followed by shaking at 600 rpm for 2 minutes.
[00320] 6. The plate was incubated at 37oC for 2 hours followed by an additional 15-minute incubation at 25 oC. 2.4 Prepare 3×compound [00321] 1. Serotonin HCl was prepared to the concentration of 10 mM with DMSO. [00322] 2. The test compounds were prepared to the concentration of 10 mM with DMSO. [00323] 3. The compounds were added to a 384-well compound source plate. [00324] 4. 3-folds serial dilutions were performed with DMSO. [00325] 5. 90 nL/well of serial diluted compounds was transferred from source plate to a 384-well compound plate by using an Echo. [00326] 6. 30 μL/well of assay buffer (20mM HEPES in 1× HBSS, pH 7.4) was added to the compound plate. [00327] 7. The plate was mixed on-plate shaker for 2 minutes. 2.5 FLIPR assay [00328] 1. After the cells were incubated with dye solution, the cell plate, compound plate containing 3×compounds and FLIPR tips were placed into FLIPR. [00329] 2. 10 μL of 3×compounds transferred from the compound plate to the cell plate by FLIPR. [00330] 3. The plate was read for 160 sec with 1 sec interval and the data of agonist mode was obtained. 3 Data Analysis [00331] 1. The normalized fluorescence reading (RFU) was calculated as shown below, wherein Fmax and Fmin stand for maximum and minimum of calcium signal during defined time window: RFU = Fmax – Fmin [00332] 2. EC50 by fitting RFU against log of compound concentrations with Hill equation was calculated using XLfit. Results & Discussion [00333] The results of potential competition binding properties of the exemplary
HT2A) are summarized in Table 2. The results of exemplary compounds of the application are presented as IC50 is provided in Table 2. Table 2: Effect of exemplary compounds of Formula I using FLIPR functional assay on human 5-HT2A receptor Compound ID# h5-HT2A, EC50 [nM] RFU@10 μM (1) Psilocybin ND(2) 257 Psilocin 72.5 308 (R)-I-111 ND 251 (S)-I-111 ND 367 (R)-I-52 ND 534 12 ND 463 16 ND 491 I-6 ND 523 I-119 ND 599 (R)-I-121.HCl ND 306 (R)-I-120.HCl ND 280 (1) Curve fitting with activation (%) @ 10mM with RFU (2) ND: not detected [00334] Exemplary compounds of Formula I were evaluated using radioligand binding assay on human 5-HT2A receptor. EC50 (nM) concentrations are illustrated in Table 2. This assay confirms that exemplary compounds of the application are effective ligands of the target human 5-HT2A receptors. Example 11: Human 5-HT2A: Radioligand binding assay: Objective [00335] The objective of this study was to evaluate the binding properties of exemplary compounds of Formula I on 5-hydroxytryptamine receptor 2A (5-HT2A). 1 Materials and Instrumentation 1.1 Regents Items Vendor Cat#
Ketanserin Hydrochloride, [Ethylene- PerkinElmer NET791250UC 3H]- Ketanserin MedChemExpress HY-10562 Bovine Serum Albumin (BSA) Sigma A1933 Calcium chloride (CaCl2) Sigma C5670 Tris(hydroxymethyl)aminomethane Alfa Aesar A18494 (Tris) Polyethylenimine, branched (PEI) Sigma 408727 1.2 Instrumentation and Consumables Item Supplier Cat# Microbeta2 Microplate Counter PerkinElmer 2450-0060 UniFilter-96 GF/B PerkinElmer 6005177 TopSeal Biotss SF-800 MicroBeta Filtermate-96 PerkinElmer D961962 Seven Compact pH meter Mettler Toledo S220 Ultrapure Water Meter Sichuan Ulupure UPH-III-20T Benchtop Centrifuge Hunan Xiangyi L550 Microplate Shaker Allsheng MX100-4A 384-Well Polypropylene Labcyte PP-0200 Microplate 96 Round Well Plate Corning 3799 96 Round Deep Well Plate Axygen P-DW-11-C Echo LABCYTE 550 2 Experimental Methods [00336] 1. The assay buffer was prepared following the table below. Reagent Concentration
Tris 50 mM CaCl2 4 mM BSA 0.1% (w/v) Adjust pH to 7.4 followed by 0.2 μM sterile filtration [00337] 2. 8 doses of reference and test compounds starting from 10 mM stock solution as required was prepared by 5-fold serial dilutions with 100% (v/v) DMSO. [00338] 3. UniFilter-96 GF/B plate was pretreated: [00339] i. 50 μl/well of 0.5% (v/v) PEI was added to UniFilter-96 GF/C plates. The plates were sealed and incubated at 4ºC for 3 hrs. [00340] ii. After incubation, the plates were washed 3 times with ice-cold wash buffer (50 mM Tris, pH7.4). [00341] 4. The assay plate was prepared: [00342] i. Cell membrane was diluted with assay buffer and 330 μl/well was added to 96 round deep well plates to reach a concentration of 20 μg/well. [00343] ii.8 concentrations of reference or test compounds were prepared and 110 μl/well was added to 96 round deep well plates. [00344] iii. [3H]-ketanserin was diluted with assay buffer to 5 nM (5X final concentration) and 110 μl/well was added to 96 round deep well plates. [00345] 5. The plate was centrifuged at 1000 rpm for 30 secs and then agitated at 600 rpm, R.T. for 5 min. [00346] 6. The plates were sealed and the plate incubated at 27ºC for 90 min. [00347] 7. The incubation was stopped by vacuum filtration onto GF/B filter plates followed by 4 times washing with ice-cold wash buffer (50 mM Tris, pH7.4). [00348] 8. The plates were dried at 37ºC for 45 min. [00349] 8. The filter plates were sealed and 40 μl/well of scintillation cocktail was added. [00350] 10. The plate was read by using a Microbeta2 microplate counter.
3 Data Analysis [00351] 1. For reference and test compounds, the results were expressed as % Inhibition, using the normalization equation: N = 100-100×(U-C2)/(C1-C2), where U is the unknown value, C1 is the average of high controls, and C2 is the average of low controls. [00352] 2. The IC50 was determined by fitting percentage of inhibition as a function of compound concentrations with Hill equation using XLfit. Results and Discussion [00353] The results of potential competition binding properties of the exemplary compounds of the application targeting the human 5-hydroxytryptamine receptor 2A (5- HT2A) are summarized in Table 3. The results of exemplary compounds of the application are presented as IC50 provided in Table 3. Table 3: Effect of exemplary compounds of Formula I using Radioligand binding assay on human 5-HT2A receptor Compound ID# h5-HT2A, IC50 [nM] Psilocybin 4248 Psilocin 187.2 (R)-I-111 >30000 (S)-I-111 >30000 (R)-I-52 19429.6 12 5208.41 16 3403.52 I-6 5170.01 I-119 3582.94 (R)-I-121.HCl 2192.39 II. Results & Discussion [00354] Exemplary compounds of Formula I were evaluated using radioligand binding assay on human 5-HT2A receptor. IC50 (nM) concentrations are illustrated in Table
3. This assay confirms that the compounds of the application are effective ligands of the target human 5-HT2A receptors. Example 12: Human 5-HT1A: Functional FLIPR assay 1 Objective [00355] The potential excitatory effects of exemplary compounds of the application targeting on 5-hydroxytryptamine receptor 1A (5-HT1A) under agonist mode was assessed. 2 Materials and Instrumentation 2.1 Cell line Cell line Name Target Host cell HTR1A&Gα15-CHO 5HT1A Flp-in CHO 2.2 Materials Regents Vendor Cat# DMEM/F12 Gibco 11330057 Dialyzed FBS BIOSUN BS-0005-500 Penicillin-Streptomycin Invitrogen 15140 Hygromycin B Invivogen Ant-hg-5 TrypLE™Express Gibco 12604-013 DPBS Gibco 14190250 DMSO Millipore 1029312500 Probenecid Sigma P8761 FLIPR Calcium 6 Assay Molecular Device R8191 Kit HEPES Invitrogen 15630 Hank’s Buffered Saline Invitrogen 14025 Solution Serotonin HCl Selleck S4244
2.3 Instrumentation and consumables Item Supplier Cat# Fluorometric Imaging Plate Reader Molecular Tetra (FLIPR) Device Countess Automated Cell Counter Invitrogen Countess Cell Counting Chamber Slides Invitrogen C10312 STERI-CYCLE CO2 Incubator Thermo 371 1300 Series Class II Biological Safety Thermo 1389 Cabinet Table-type Large Capacity Low Speed Cence L550 Centrifuge Centrifuge Eppendorf 5702 Echo Labcyte 550 Echo Labcyte 655 Electro-thermal incubator Shanghai DHP-9031 Yiheng plate shaker IKA MS3 digital Water Purification System ULUPURE UPH-III-20T Versatile and Universal pH and Mettler Toledo S220 Conductivity Meters 384-Well plate Corning 3764 384-Well LDV Clear microplate LABCYTE LP-0200 384-Well Polypropylene microplate LABCYTE PP-0200 384-well compound plate Corning 3657 T25 cell culture flask Corning 430639 50 mL Polypropylene Centrifuge Tube JET CFT011500 15 mL Polypropylene Centrifuge Tube JET CFT011150
3 Experimental Methods 3.1 Cell culture [00356] HTR1A&Gα15-CHO cells were cultured in DMEM/F12 medium containing 10% dialyzed FBS, 1× penicillin-streptomycin and 600 μg/mL Hygromycin B. The cells were passaged about three times a week, maintained between ~30% to ~90% confluence. 3.2 Cell plating [00357] 1. The cell culture medium (DMEM/F12 medium containing 10% dialyzed FBS, 1× penicillin-streptomycin and 600 μg/mL Hygromycin B), TrypLE™ Express and DPBS was warmed to R.T. in advance. [00358] 2. The cell culture medium was removed from flask. Washed cells with DPBS. [00359] 3. 1 mL TrypLE™ Express was added to the flask, mixed well by gentle shaking and cells were incubated at 37oC for a few minutes. [00360] 4. The cells were checked for morphological change under microscope, the digestion was stopped by adding 2 mL cell culture medium to the flask when most of cells turned to round. [00361] 5. The cell suspension was transferred into a 15 mL centrifuge tube, and then centrifuged at 1,200 rpm for 5 minutes. [00362] 6. The supernatant was removed. The cell pellet were resuspended with 2 mL cell culture medium. [00363] 7. The cell density were counted using cell counter. Only cells with >85% viability were used for the assay. [00364] 8. Cells were diluted to 4×105/mL with cell culture medium. [00365] 9. 30 μL/well cell suspensions were added into a 384-well cell plate (The cell density was 12,000 cells/well). [00366] 10. The cell plate was incubated overnight at 37oC, 5% (v/v) CO2. 3.3 Cell handling [00367] 1. On the day of experiments, culture medium was removed from the cell plate. [00368] 2. 10 μL of assay buffer (20 mM HEPES, in 1× HBSS, pH 7.4) was added to each well of the cell plate.
[00369] 3. 2× dye solution was prepared following the manufacture’s instruction of the FLIPR® Calcium 6 assay kit: [00370] i. The dye was diluted with assay buffer. [00371] ii. probenecid was added to the final concentration of 5 mM. [00372] iii. Vortexed vigorously for 1–2 minutes, adjust pH to 7.4. [00373] 4. 10 μL of 2× dye solution was added to each well of the cell plate. [00374] 5. The cell plate was placed on plate shaker, followed by shaking at 600 rpm for 2 minutes. [00375] 6. The plate was incubated at 37oC for 2 hours followed by an additional 15-minute incubation at 25 oC. 3.4 Prepare 3×compounds. [00376] 1. Serotonin was prepared to the concentration of 10 mM with DMSO, 3-folds serial dilutions were performed with DMSO. [00377] 2. Prepare the test compound to the concentration of 10 mM with DMSO, preform 3-folds serial dilutions with DMSO. [00378] 3. The compounds were added to a 384-well compound source plate. [00379] 4. 90 nL/well of serial diluted compounds were transferred from source plate to a 384-well compound plate by using an Echo. [00380] 5. 30 μL/well of assay buffer was added to the compound plate. [00381] 6. The plate was mixed on-plate shaker for 2 minutes. 3.5 FLIPR assay [00382] 1. After the cells incubate with dye solution, the cell plate, compound plate containing 3×compounds and FLIPR tips were placed into FLIPR. [00383] 2. 10 μL of 3×compounds were transferred from the compound plate to the cell plate by FLIPR. [00384] 3. The plate was read for 160 sec with 1 sec interval to obtain the data of agonist mode.
4 Data Analysis [00385] 1. The normalized fluorescence reading (RFU) was calculated as shown below, wherein Fmax and Fmin stand for maximum and minimum of calcium signal during defined time window: RFU = Fmax – Fmin [00386] 2. EC50 was calculated by fitting RFU against log of compound concentrations with Hill equation using XLfit. Results & Discussion [00387] The results of potential competition binding properties of the exemplary compounds of the application targeting the human 5-hydroxytryptamine receptor 1A (5- HT1A) are summarized in Table 4. The results of exemplary compounds of the application are presented as EC50 provided in Table 4. Table 4: Effect of exemplary compounds of Formula I using FLIPR functional assay on human 5-HT1A receptor Compound ID# h5-HT1A, EC50 [nM] RFU@10 μM (1) Psilocybin ND(2) 143 Psilocin ND 140 (R) I-111 ND 76 (R)-I-52 ND 87 12 ND 1164 16 ND 268 I-6 3288 2486 I-119 ND 162 (R)-I-121.HCl ND 1165 (R)-I-120.HCl ND 170 (1) Curve fitting with activation (%) @ 10mM with RFU (2) Not detected
[00388] Exemplary compounds of Formula I were evaluated using functional FLIPR assay on human 5-HT1A receptor. EC50 (nM) concentrations are illustrated in Table 4. This assay confirms that compounds of the application have moderate functional activity at the target human 5-HT1A receptors. Example 13: Human 5-HT1A: Radioligand binding assay: 1 Objective [00389] The objective of this study was to evaluate the binding properties of test compounds on 5-hydroxytryptamine receptor 1A (5-HT1A). 2 Materials and Instrumentation 2.1 Regents Items Vendor Cat# [3H]-8-Hydroxy-DPAT PE NET929250UC Serotonin HCl Selleck S4244 Bovine Serum Albumin (BSA) Sigma A1933 Calcium chloride (CaCl2) Sigma C5670 MgCl2 Sigma M1028 Tris(hydroxymethyl)aminomethane Alfa Aesar A18494 (Tris) Polyethylenimine, branched (PEI) Sigma 408727 2.2 Instrumentation and Consumables Item Supplier Cat# Microbeta2 Microplate Counter PerkinElmer 2450-0060 UniFilter-96 GF/B PerkinElmer 6005177 TopSeal Biotss SF-800 MicroBeta Filtermate-96 PerkinElmer D961962 Seven Compact pH meter Mettler Toledo S220 Ultrapure Water Meter Sichuan Ulupure UPH-III-20T Benchtop Centrifuge Hunan Xiangyi L550
Item Supplier Cat# Microplate Shaker Allsheng MX100-4A 384-Well Polypropylene Labcyte PP-0200 Microplate 96 Round Well Plate Corning 3799 96 Round Deep Well Plate Axygen P-DW-11-C Echo LABCYTE 550 3 Experimental Methods [00390] 1. The assay buffer was prepared following the table below. Reagent Concentration Tris 25 mM MgCl2 10 mM CaCl2 1 mM BSA 0.5% (w/v) Adjust pH to 7.4 followed by 0.2 μM sterile filtration [00391] 2. 8 doses of reference and test compounds were prepared starting from 10 mM stock solution as required by 5-fold serial dilutions with 100% (v/v) DMSO. [00392] 3. UniFilter-96 GF/B plate was pretreated: [00393] i. 50 μl/well of 0.5% (v/v) PEI was added to UniFilter-96 GF/B plates. The plates were sealed and incubated at 4℃ for 3 hrs. [00394] ii. After incubation, the plates were washed 3 times with ice-cold wash buffer (50 mM Tris, pH7.4). [00395] 4. Assay plate was prepared: [00396] i. Cell membrane was diluted with assay buffer and 100 μl/well was added to 96 round well plates to reach a concentration of 20 μg/well. [00397] ii. 8 concentrations of reference or test compounds were prepared and 50 μl/well was added to 96 round deep well plates.
[00398] iii. [3H]-8-Hydroxy-DPAT was diluted with assay buffer to 2 nM (4X final concentration) and 50 μl/well was added to 96 round well plates. [00399] 5. The plate was centrifuged at 1000 rpm for 30 secs and then agitated at 600 rpm, R.T. for 5 min. [00400] 6. The plates were sealed and the plate was incubated at 27ºC for 90 min. [00401] 7. The incubation was stopped by vacuum filtration onto GF/B filter plates followed by 4 times washing with ice-cold wash buffer (50 mM Tris, pH7.4). [00402] 8. The plates were dried at 37ºC for 45 min. [00403] 9. The filter plates were sealed and 40 μl/well of scintillation cocktail was added. [00404] 10. The plate was read by using a Microbeta2 microplate counter. 4 Data Analysis [00405] 1. For reference and test compounds, the results were expressed as % Inhibition, using the normalization equation: N = 100-100×(U-C2)/(C1-C2), where U is the unknown value, C1 is the average of high controls, and C2 is the average of low controls. [00406] 2. The IC50 was determined by fitting percentage of inhibition as a binding of compound concentrations with Hill equation using XLfit. Results and Discussion [00407] The results of potential competition binding properties of the exemplary prodrug compounds application targeting the human 5-hydroxytryptamine receptor (5- HT1A) are summarized in Table 5. The results of exemplary compounds of the application are presented as IC50 provided in Table 5. Table 5: Effect of exemplary compounds of Formula I using Radioligand binding assay on human 5-HT1A receptor Compound ID# h5-HT1A, IC50 [nM] Psilocybin 4785 Psilocin 195.7 (R) I-111 419.78 (R) I-52 924.39
12 46.81 16 616.50 I-6 23.79 I-119 486.50 (R)-I-121.HCl 33.57 (R)-I-120.HCl 668.21 Results & Discussion [00408] Exemplary compounds of Formula I were evaluated using radioligand binding assay on human 5-HT1A receptor. IC50 (nM) concentrations are illustrated in Table 5. This assay confirms that compounds of the application are effective ligands of the target human 5-HT1A receptors. Example 14: Human, Rat and Mouse Liver Microsomes Stability Objective [00409] The objective of this study was to estimate in vitro metabolic stability of exemplary compounds of the application in pooled human, male rat and male mouse liver microsomes. The concentrations of compounds in reaction systems were evaluated by LC- MS/MS for estimating the stability in pooled human, male rat and male mouse liver microsomes. The in vitro intrinsic clearances of test compounds were determined as well. Protocol [00410] A master solution in the “Incubation Plate” containing phosphate buffer, ultra-pure H2O, MgCl2 solution and liver microsomes was made according to Table 6. The mixture was pre-warmed at 37 ^C water bath for 5 minutes. Table 6: Preparation of master solution Reagent Stock Concentration Volume Final Concentration Phosphate buffer 200 mM 200 μL 100 mM Ultra-pure H2O - 106 μL - MgCl2 solution 50 mM 40 μL 5 mM Microsomes 20 mg/mL 10 μL 0.5 mg/mL
[00411] 40 μL of 10 mM NADPH solution was added to each well. The final concentration of NADPH was 1 mM. The negative control samples were prepared by replacing NADPH with 40 μL of ultra-pure H2O. Samples were prepared in duplicate. Negative controls were prepared in singlet. [00412] The reaction was started with the addition of 4 μL of 200 μM exemplary test compounds of the application or control compounds to each master solution to get the final concentration of 2 μM. This study was performed in duplicate. [00413] Aliquots of 50 µL were taken from the reaction solution at 0, 15, 30, 45 and 60 minutes. The reaction solutions were stopped by the addition of 4 volumes of cold methanol with IS (100 nM alprazolam, 200 nM imipramine, 200 nM labetalol and 2 μM ketoprofen). Samples were centrifuged at 3,220 g for 40 minutes. Aliquot of 90 µL of the supernatant was mixed with 90 µL of ultra-pure H2O and then was used for LC-MS/MS analysis. [00414] LC/MS analysis was performed for all samples from this study using a Shimadzu liquid chromatograph separation system equipped with degasser DGU-20A5R,; solvent delivery unit LC-30AD; system controller SIL-30AC; column oven CTO-30A; CTC Analytics HTC PAL System;. Mass spectrometric analysis was performed using a Triple QuadTM 5500 instrument. [00415] All calculations were carried out using Microsoft Excel. Peak area ratios of test compound to internal standard (listed in the below table) were determined from extracted ion chromatograms. [00416] All calculations were carried out using Microsoft Excel. Peak areas were determined from extracted ion chromatograms. The slope value, k, was determined by linear regression of the natural logarithm of the remaining percentage of the parent drug vs. incubation time curve. [00417] The in vitro half-life (in vitro t1/2) was determined from the slope value: [00418] Conversion of the in vitro t1/2 (min) into the in vitro intrinsic clearance (in vitro CLint, in µL/min/mg proteins) was done using the following equation (mean of duplicate determinations):
[00419] For the exemplary compounds of the application or control compound that showed an initial fast disappearance followed by a slow disappearance, only the time points that were within the initial rate were included in the calculation. Results & Discussion [00420] Human, rat and mouse liver microsomes contain a wide variety of drug metabolizing enzymes and are commonly used to support in vitro ADME (absorption, distribution, metabolism and excretion) studies. These microsomes are used to examine the potential first-pass metabolism by-products of orally administered drugs. Exemplary compounds of the application were evaluated for their stability in human, rat and mouse liver microsomes. [00421] A majority of the exemplary compounds of the application in two species, human and rat liver microsomes were recovered within a 60-minute time period indicating that the compounds were not rapidly cleared (see Table 7 for Exemplary compounds of Formula I). Table 7: Metabolic stability of exemplary compounds of Formula I and control compound diclofenac in human and rat with NADPH CLint Scaled-up Predicted Compound T1/2 Species (µL/min/mg CLint hepatic CL ID (min) protein) (mL/min/Kg) (mL/min/kg) Human 10.35 133.92 167.95 18.43 Diclofenac Rat 15.73 88.12 157.91 40.90 Human 110.55 12.54 15.72 8.94 I-6 Rat 7.10 195.17 349.75 47.68 (R)-I- Human 446.85 3.10 3.89 3.27 121.HCl Rat 42.62 32.52 58.27 28.35 Note: 1. For the compounds that showed an initial fast disappearance followed by a slow disappearance, only the time points that were within the initial rate i l d d i th l l ti
2. If % remaining at 30 minutes was lower than 1%, then CLint and t1/2 will be reported as “>307.01” and “<4.51”, respectively. Table 8: Metabolic stability of exemplary compounds of Formula I and control compound diclofenac in human, rat and mouse liver microsomes Example Remaining Percentage (%) Species Assay Format ID 0 min 30 min 60 min With Cofactors 100.00 5.38 1.80 Human Without Cofactors 100.00 99.36 95.90 Diclofenac With Cofactors 100.00 13.12 7.11 Rat Without Cofactors 100.00 100.63 97.86 With Cofactors 100.00 82.16 68.65 Human Without Cofactors 100.00 96.80 89.50 I-6 With Cofactors 100.00 5.35 0.51 Rat Without Cofactors 100.00 96.12 94.40 With Cofactors 100.00 92.80 91.11 Human (R)-I- Without Cofactors 100.00 98.12 96.49 121.HCl With Cofactors 100.00 52.52 37.70 Rat Without Cofactors 100.00 97.92 102.34 Discussion: [00422] The results demonstrate the exemplary compounds showed a spectrum of stability at 30 min and 60 min timepoints. Example 15: Human, Rat, Mouse and Dog: Plasma stability [00423] 1. Preparation of Stock Solutions [00424] The stock solution of test compound is prepared in DMSO and diluted at the final concentration of 200 µM.1 mM lovastatin and propantheline working solution is pre- pared in DMSO and acetonitrile, respectively. Lovastatin is used as positive control for rat and dog plasma stability assay. Propantheline is used as positive control in human, mouse and monkey plasma stability assay
[00425] 2. Procedures for Plasma Stability [00426] a.2.5 µL of 200 µM or 1 mM test compound or control compound solution is spiked to 497.5 µL plasma to reach a final concentration of 1 µM or 5 µM. The final concentration of organic solvents is 0.5 %. The assay is performed in duplicated. [00427] b. The reaction samples are incubated at 37°C at approximately 60 rpm in a water bath. [00428] c. Aliquots of 50 µL are taken from the reaction samples at 0, 30, 60, 120, 180 and 240 minutes. The reaction is stopped by the addition of 7 volumes of cold acetonitrile containing internal standards (IS: 100 nM alprazolam, 200 nM imipramine, 200 nM labetalol and 2 µM ketoprofen). [00429] d. All samples are vortexed for 2 minutes, followed by centrifugation at 3,220 g for 30 minutes to precipitate proteins.100 µL of the supernatant is transferred to a new plate. The supernatant is diluted with ultrapure water according to the LC-MS signal response and peak shape. [00430] 3. Sample Analysis [00431] Samples are analyzed by LC-MS/MS. • LC system: Shimadzu • MS analysis: Triple QuadTM 6500+ from AB Inc (Canada) with an ESI interface • Column temperature: 40 °C • Column: Xselect® Hss T32.5 µ (2.1×30 mm) coupled with preguard column • Mobile phase: 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B) Time (min) 0 0.1 0.5 0.8 0.81 1.0 % B 5 5 100 100 5 5 [00432] 4. Data Analysis [00433] All calculations are carried out using Microsoft Excel. Remaining percentages of parent compounds at each time point are estimated by determining the peak area ratios from extracted ion chromatograms.
[00434] While the present application has been described with reference to examples, it is to be understood that the scope of the claims should not be limited by the embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole. [00435] All patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the application described and claimed herein.
Claims
CLAIMS: 1. A compound of Formula I: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, 5 wherein: R1 is selected from H, halo, NH2, C1-6alkyl, C1-6alkoxyl, NH(C1-6alkyl) and N(C1-6alkyl)2; Q is selected from Q1, Q2, Q3, Q4, Q5 and Q6: (Q1), (Q2), (Q3), (Q4) (Q5), and (Q6) 10 is a single bond or a double bond provided that when in Q1 is a double bond then R8 and R14 are not present, when in Q2 is a double bond then R16 and R24 are not present, and when in Q6 is a double bond then R53 and R62 are not present; R2 and R5 are independently selected from H, halo, OH, C1-6alkyl and C1-6alkoxy; one or both of R3 and R4 is independently selected from H, halo, C1-6alkyl and C1-6alkoxy, or 15 R3 and R4 are linked together to form O-(CH2)1-2O, or one of R3 and R4 is selected from X-L-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy; X is selected from a direct bond, O, C(O), NRa, NRaC(O), C(O)NRa, OC(O), C(O)O, OC(O)O, NRaC(O)O OC(O)NRa and NRaC(O)NRa; 20
L is selected from a direct bond, C1-6alkylene, C2-6alkenylene, C1-6alkyleneO, C2- 6alkenyleneO, C1-6alkyleneC(O), C2-6alkenyleneC(O), C1-6alkyleneNRbC(O), C2- 6alkenyleneNRbC(O), C1-6alkyleneC(O)NRb, C2-6alkenyleneC(O)NRb, C1-6alkyleneOC(O), C2- 6alkenyleneOC(O), C1-6alkyleneC(O)O, C2-6alkenyleneC(O)O, C1-6alkyleneOC(O)NRb, C2- 6alkenyleneOC(O)NRb, C1-6alkyleneNRbC(O)O C2-6alkenyleneNRbC(O)O, C1- 5 6alkyleneOC(O)O, C2-6alkenyleneOC(O)O, C1-6alkyleneNRbC(O)NRb and C2- 6alkenyleneNRbC(O)NRb; Ra is selected from H and C1-6alkyl; Rb is selected from H, C1-6alkyl and A; A is selected from H, C1-30alkyl, C2-30alkenyl, phenyl, C3-6cycloalkyl, 3- to 6-membered 10 heterocycloalkyl comprising 1 to 4 heteromoeities independently selected from O, S, S(O), SO2, N and NR53 and 5- to 6-membered heteroaryl comprising 1 to 4 heteromoeities independently selected from O, S, S(O), SO2, N and NR63, wherein the phenyl, C3- 10cycloalkyl, 3- to 6-membered heterocycloalkyl and 5- to 6-membered heteroaryl are optionally substituted with one or more substituents independently selected from halo, OH, 15 C1-4alkyl and OC1-4alkyl; R7, R8, R9, R10, R12, R13, R14, R15, R16, R17, R18, R20, R21, R22, R23, R24, R25, R26, R27, R28, R31, R32, R33, R35, R36, R37, R38, R39, R40, R41, R42, R43, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R57, R58, R59, R60, R61, and R62 are independently selected from H, halo and C1- 6alkyl; 20 R11, R19, R34, R44 and R56 are independently selected from H, C1-6alkyl and C(O)C1-6alkyl; R29 and R30 are independently selected from H and C1-6alkyl; or one of R29 and R30 is C(O)-A’ and the other is selected from H and C1-6alkyl; wherein A' is selected from Y, O-Y and O-C1-4alkylene-O-C(O)-Y; and Y is selected from C7-30alkyl and C7-30alkenyl; or 25 R29 and R30, together with the N atom to which they are bound, form a 3- to 6-membered heterocyclic ring which optionally comprises one or two additional heteromoieties independently selected from O, S, S(O), SO2, N, and NR64 and which is optionally substituted with one or more substituents independently selected from halo, OH, C1-4alkyl and OC1-4alkyl; R63 and R64 are independently selected from H and C1-6alkyl; and 30
all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof, provided when Q is Q3; at least one of R2, R3, R4, R5, R25, R26, R27, R28, R29 and R30 is D or comprises D, or at least one of R2, R3, R4, R5 is alkyl substituted with one or more fluorine 5 and/or chlorine atoms; or at least three of R2, R3, R4, R5 are not H; or when Q is Q3; R3 and R4 are linked together to form O-(CH2)1-2O; or when Q is Q3; one of R3 and R4 is selected from X-L-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy; and A is not H, C1-6alkyl or C2-6alkenyl; when Q is Q1 or Q4 then R7-R14 or R31- R40 respectively are not all H, when one of R3 and 10 R4 is halo and the other of R3 and R4 is H. 2. The compound of claim 1, wherein R7, R8, R9, R10, R12, R13, R14, R15, R16, R17, R18, R20, R21, R22, R23, R24, R25, R26, R27, R28, R31, R32, R33, R35, R36, R37, R38, R39, R40, R41, R42, R43, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R57, R58, R59, R60, R61 and R62 are independently selected from H and D. 15 3. The compound of claim 1, wherein Q is selected from one of the following groups:
D
wherein R11, R19, R29, R30, R34, R44 and R56 are independently selected from H, D, C1-6alkyl, C1-6fluoroalkyl, C1-6deuteroalkyl and C(O)-A’. 4. The compound of claim 3, wherein R11, R19, R29, R30, R34, R44 and R56 are independently selected from H, C1-4alkyl, C1-4fluoroalkyl and C1-4deuteroalkyl. 5 5. The compound of claim 3, wherein R29 and R30, together with the N atom to which they are bound, form a 3- to 6-membered heterocyclic ring which optionally comprises one or two additional heteromoieties independently selected from O, N and NR64 and which is optionally substituted with one or more substituents independently selected from halo, OH, C1-4alkyl and OC1-4alkyl. 10 6. The compound of claim 3, wherein Q is selected from one of the following groups: , wherein R34 is selected from H D C16alkyl C16fluoroalkyl C16deuteroalkyl and C(O)A’
7. The compound of claim 6, wherein R34 is selected from H, CH3, CD3, CF2H and CF3. 8. The compound of claim 1 or claim 3, wherein R11, R19, R29, R30, R34, R44 and R56 are independently selected from C(O)-A’. 9. The compound of claim 1 or claim 3, wherein one of R29 and R30 is C(O)-A’ and the other is selected from H and C1-6alkyl. 5 10. The compound of claim 8 or claim 9, wherein A' is selected from Y, O-Y and O- C1alkylene-O-C(O)-Y, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom. 11. The compound of claim 10, wherein Y is C10-25alkyl, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom. 10 12. The compound of claim 10, wherein Y is C10-25alkenyl, wherein all available hydrogen atoms are optionally and independently replaced with a fluorine atom or deuterium atom. In 13. The compound of claim 12, wherein Y is an alkenyl group present in a fatty acid, wherein all available H atoms are optionally substituted with deuterium. 14. The compound of claim 11, wherein Y is an alkyl group present in a fatty acid wherein all 15 available H atoms are optionally substituted with deuterium. 15. The compound of claim 10, wherein Y is an alkyl or alkenyl group present in linoleic acid, eicosadienoic acid or decosahexanoic acid. 16. The compound of claim 10, wherein Y is the alkyl or alkenyl group of a fatty acid wherein 1-10, 2-8, 2-6 or 2-4 H atoms are substituted with deuterium. 20 17. The compound of claim 10, wherein Y is (CH2)7CH=CH(CH2)7CH3, (CH2)7CH=CHCH2CH=CH(CH2)4CH3, (CH2)8CH=CHCH2CH=CH(CH2)4CH3, (CH2)7CH=CHCH2CH=CHCH2CH=CH(CH2)1CH3, (CH2)3CH=CHCH2CH=CH(CH2)1CH=CHCH2CH=CH(CH2)3CH3, or (CH2)2CH=CHCH2CH=CHCH2CH=CHCH2CH=CHCH2CH=CHCH2CH=CH(CH2)1CH3. 25 18. The compound of any one of claims 1 to 17, wherein R1 is selected from H, halo, NH2, C1-4alkyl, C1-4alkoxy, NH(C1-4alkyl) and N(C1-4alkyl)2. 19. The compound of any one of claims 1 to 17, wherein R1 is selected from H, D, Cl, F, OH, C1-2alkyl, C1-2alkoxy, C1-2fluoroalkyl, C1-2deuteroalkyl, NH(C1-2alkyl), NH(C1-2deuteroalkyl), NH(C1-2flouroalkyl), N(C1-2alkyl)2, N(C1-2fluoroalkyl)2, N(C1-2deuteroalkyl)2, N(C1- 30 2fluoroalkyl)(C1-2alkyl), N(C1-2fluoroalkyl)(C1-2deuteroalkyl) and N(C1-2deuteroalkyl)(C1-2alkyl).
20. The compound of any one of claims 1 to 19, wherein R1 is H. 21. The compound of any one of claims 1 to 20, wherein R2 and R5 are independently selected from H, D, Cl, F, OH, C1-4alkyl, C1-4alkoxy, C1-4fluoroalkyl and C1-4deuteroalkyl. 22. The compound of claim 21, wherein R2 and R5 are independently selected from H, D, Cl, F, OH, C1-2alkyl, C1-2alkoxy, C1-2fluoroalkoxy, C1-2deuteroalkoxy, C1-2fluoroalkyl and C1- 5 2deuteroalkyl. 23. The compound of claim 22, wherein R2 and R5 are independently selected from H and D. 24. The compound of any one of claims 1 to 23, wherein one or both of R3 and R4 is independently selected from H, D, F, Cl, C1-6alkyl, C1-6fluoroalkyl, C1-6deuteroalkyl, C1- 6alkoxy, C1-6fluoroalkoxy and C1-6deuteroalkoxy. 10 25. The compound of any one of claims 1 to 23, wherein both of R3 and R4 are independently selected from D, F, Cl, C1-6alkyl, C1-6fluoroalkyl, C1-6deuteroalkyl, C1-6alkoxy, C1-6fluoroalkoxy and C1-6deuteroalkoxy. 26. The compound of any one of claims 1 to 23, wherein R3 is H or D and R4 is selected from H, D, F, Cl, C1-6alkyl, C1-6fluoroalkyl, C1-6deuteroalkyl, C1-6alkoxy, C1-6fluoroalkoxy and C1- 15 6deuteroalkoxy. 27. The compound of any one of claims 1 to 23, wherein R4 is H or D and R3 is selected from H, D, F, Cl, C1-6alkyl, C1-6fluoroalkyl, C1-6deuteroalkyl, C1-6alkoxy, C1-6fluoroalkoxy and C1- 6deuteroalkoxy. 28. The compound of any one of claims 1 to 23, wherein R3 and R4 are linked together to 20 form O-CH2O. 29. The compound of any one of claims 1 to 23, wherein one of R3 and R4 is selected from X-L-A and the other of R3 and R4 selected from H, halo, C1-6alkyl and C1-6alkoxy. 30. The compound of claim 29, wherein X is a direct bond and one of R3 and R4 is selected from L-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy. 25 31. The compound of claim 29, wherein X is selected from O, C(O), NRa, NRaC(O), C(O)NRa, OC(O), C(O)O, OC(O)O, NRaC(O)O, OC(O)NRa and NRaC(O)NRa. 32. The compound of claim 29, wherein X is selected from O, NRa, NRaC(O), C(O)NRa, NRaC(O)O, OC(O)NRa and NRaC(O)NRa. 33. The compound of any one of claims 29 to 32, wherein L is selected from a direct bond, 30 C1-4alkylene, C2-4alkenylene, C1-4alkyleneO, C2-4alkenyleneO, C1-4alkyleneC(O), C2-
4alkenyleneC(O) C1-4alkyleneNRbC(O), C2-4alkenyleneNRbC(O), C1-4alkyleneC(O)NRb, C2- 4alkenyleneC(O)NRb, C1-4alkyleneOC(O), C2-4alkenyleneOC(O), C1-4alkyleneC(O)O, C2- 4alkenyleneC(O)O, C1-4alkyleneOC(O)NRb, C2-4alkenyleneOC(O)NRb, C1- 4alkyleneNRbC(O)O C2-4alkenyleneNRbC(O)O, C1-4alkyleneOC(O)O, C2- 4alkenyleneOC(O)O, C1-4alkyleneNRbC(O)NRb and C2-4alkenyleneNRbC(O)NRb. 5 34. The compound of any one of claims 29 to 33, wherein the other of R3 and R4 is selected from H, F, Cl, C1-4alkyl, C1-4haloalkyl, C1-4deuteroalkyl and C1-4alkoxy. 35. The compound of any one of claims 29 to 34, wherein A is H. 36. The compound of any one of claims 29 to 34, wherein A is selected from C1-30alkyl, C2- 30alkenyl, phenyl, C3-6cycloalkyl, 3- to 6-membered heterocycloalkyl comprising 1 to 3 10 heteromoeities independently selected from O, S, S(O), SO2, N and NR63 and 5- to 6- membered heteroaryl comprising 1 to 3 heteromoeities independently selected from O, S, S(O), SO2, N and NR53, wherein the phenyl, C3-10cycloalkyl, 3- to 6-membered heterocycloalkyl and 5- to 6-membered heteroaryl are optionally substituted with one or two substituents independently selected from F, Cl, OH, C1-4alkyl, C1-4deuteroalkyl, C1- 15 4fluoroalkyl, OC1-4alkyl, OC1-4deuteroalkyl and OC1-4fluoroalkyl, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. 37. The compound of claim 36, wherein A is selected from phenyl, C3-6cycloalkyl, 5- to 6- membered heterocycloalkyl comprising 1 to 2 heteromoeities independently selected from 20 O, S, S(O), SO2, N and NR63 and 5- to 6-membered heteroaryl comprising 1 to 3 heteromoeities independently selected from O, S, S(O), SO2, N and NR53, wherein the phenyl, C3-10cycloalkyl, 3- to 6-membered heterocycloalkyl and 5- to 6-membered heteroaryl are optionally substituted with one or two substituents independently selected from F, Cl, OH, C1-4alkyl, C1-4deuteroalkyl, C1-4fluoroalkyl, OC1-4alkyl, OC1-4deuteroalkyl and OC1- 25 4fluoroalkyl. 38. The compound of claim 37, wherein R63 is selected from H, D, C1-4alkyl, C1-4fluoroalkyl and C1-4deuteroalkyl. 39. The compound of claim 36, wherein A is selected from C1-30alkyl and C2-30alkenyl, wherein all available hydrogen atoms are optionally and independently substituted with a 30 fluorine atom or deuterium atom. 40. The compound of claim 39, wherein A is C10-25alkyl, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom
41. The compound of claim 39, wherein A is C10-25alkenyl, wherein all available hydrogen atoms are optionally and independently substituted with a fluorine atom or deuterium atom. 42. The compound of claim 41, wherein A is an alkenyl group present in a fatty acid, wherein all available H atoms are optionally substituted with deuterium. 43. The compound of claim 40, wherein A is an alkyl group present in a fatty acid wherein all 5 available H atoms are optionally substituted with deuterium. 44. The compound of claim 36, wherein A is an alkyl or alkenyl group present in linoleic acid, eicosadienoic acid or decosahexanoic acid. 45. The compound of claim 36, wherein A is an alkyl or alkenyl group of a fatty acid wherein 1-10, 2-8, 2-6 or 2-4 H atoms are substituted with deuterium. 10 46. The compound of claim 36, wherein A is (CH2)7CH=CH(CH2)7CH3, (CH2)7CH=CHCH2CH=CH(CH2)4CH3, (CH2)8CH=CHCH2CH=CH(CH2)4CH3, (CH2)7CH=CHCH2CH=CHCH2CH=CH(CH2)1CH3, (CH2)3CH=CHCH2CH=CH(CH2)1CH=CHCH2CH=CH(CH2)3CH3, or (CH2)2CH=CHCH2CH=CHCH2CH=CHCH2CH=CHCH2CH=CHCH2CH=CH(CH2)1CH3. 15 47. The compound of claim 1, wherein the compound of Formula I is defined as follows: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, wherein: R1 is H; 20 Q is selected from Q1, Q2, Q3, Q4, Q5 and Q6: (Q1), (Q2) (Q3),
(Q4) (Q5), and (Q6); is a single bond or a double bond provided that when in Q1 is a double bond then R8 and R14 are not present, when in Q2 is a double bond then R16 and R24 are not present, and when in Q6 is a double bond then R53 and R62 are not present; R2 and R5 are independently selected from H, D and F; 5 one or both of R3 and R4 is selected from H, C1-4alkoxy, C1-4fluoralkoxy and C1- 4deuteroalkoxy, or R3 and R4 are linked together to form O-(CH2)1-2O; R7, R8, R9, R10, R12, R13, R14, R15, R16, R17, R18, R20, R21, R22, R23, R24, R25, R26, R27, R28, R31, R32, R33, R35, R36, R37, R38, R39, R40, R41, R42, R43, R45, R46, R47, R48, R49, R50, R51 and R52 are 10 independently selected from H and D; and R11, R19, R29,R30, R34 and R44 are independently selected from H, C1-4alkyl, C1-4fluoroalkyl and C1-4deuteroalkyl, provided when Q is Q3; at least one of R2, R3, R4, R5, R25, R26, R27, R28, R29 and R30 is D or comprises D, or at least one of R2, R3, R4, R5 is alkyl substituted with one or more fluorine 15 and/or chlorine atoms; or at least three of R2, R3, R4, R5 are not H, or when Q is Q3; R3 and R4 are linked together to form O-(CH2)1-2O. 48. The compound of claim 1, wherein the compound of Formula I is defined as follows: I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, 20 R1 is selected from H, halo, NH2, C1-6alkyl, C1-6alkoxy, NH(C1-6alkyl) and N(C1-6alkyl)2; Q is selected from Q1, Q2, Q3, Q4, Q5 and Q6:
(Q1), (Q2), (Q3), (Q4) (Q5) and (Q6) is a single bond or a double bond provided that when in Q1 is a double bond then R8 and R14 are not present, when in Q2 is a double bond then R16 and R24 are not present, and when in Q6 is a double bond then R53 and R62 are not present; 5 R2 and R5 are independently selected from H, halo, OH, C1-6alkyl and C1-6alkoxy; one or both of R3 and R4 is independently selected from H, halo, C1-6alkyl and C1-6alkoxy, or R3 and R4 are linked together to form O-(CH2)1-2O, or one of R3 and R4 is selected from X-L-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy, 10 X is selected from a direct bond, O, C(O), NRa, NRaC(O), C(O)NRa, OC(O), C(O)O, OC(O)O, NRaC(O)O, OC(O)NRa and NRaC(O)NRa; L is selected from a direct bond, C1-6alkylene, C2-6alkenylene, C1-6alkyleneO, C2- 6alkenyleneO, C1-6alkyleneC(O), C2-6alkenyleneC(O), C1-6alkyleneNRbC(O), C2- 6alkenyleneNRbC(O), C1-6alkyleneC(O)NRb, C2-6alkenyleneC(O)NRb, C1-6alkyleneOC(O), C2- 15 6alkenyleneOC(O), C1-6alkyleneC(O)O, C2-6alkenyleneC(O)O, C1-6alkyleneOC(O)NRb, C2- 6alkenyleneOC(O)NRb, C1-6alkyleneNRbC(O)O C2-6alkenyleneNRbC(O)O, C1- 6alkyleneOC(O)O, C2-6alkenyleneOC(O)O, C1-6alkyleneNRbC(O)NRb and C2- 6alkenyleneNRbC(O)NRb; Ra is selected from H and C1-6alkyl; 20 Rb is selected from H, C1-6alkyl, and A; A is selected from H, C1-30alkyl, C2-30alkenyl, phenyl, C3-6cycloalkyl, 3- to 6-membered heterocycloalkyl comprising 1 to 4 heteromoeities independently selected from O, S, S(O),
independently selected from O, S, S(O), SO2, N and NR63, wherein the phenyl, C3- 10cycloalkyl, 3- to 6-membered heterocycloalkyl and 5- to 6-membered heteroaryl are optionally substituted with one or more substituents independently selected from halo, OH, C1-4alkyl and OC1-4alkyl; R7, R8, R9, R10, R12, R13, R14, R15, R16, R17, R18, R20, R21, R22, R23, R24, R25, R26, R27, R28, R31, 5 R32, R33, R35, R36, R37, R38, R39, R40, R41, R42, R43, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R57, R58, R59, R60, R61 and R62 are independently selected from H, halo and C1-6alkyl; R11, R19, R34, R44 and R56 are independently selected from H, C1-6alkyl and C(O)-A’; R29 and R30 are independently selected from H and C1-6alkyl; or one of R29 and R30 is C(O)-A’ and the other is selected from H and C1-6alkyl; 10 wherein A' is selected from Y, O-Y and O-C1-4alkylene-O-C(O)-Y; and Y is selected from C7-30alkyl and C7-30alkenyl; or R29 and R30, together with the N atom to which they are bound, form a 3- to 6-membered heterocyclic ring which optionally comprises one or two additional heteromoieties independently selected from O, S, S(O), SO2, N, and NR64 and which is optionally substituted 15 with one or more substituents independently selected from halo, OH, C1-4alkyl and OC1-4alkyl; R63 and R64 are independently selected from H and C1-6alkyl; and all available hydrogen atoms are optionally and independently substituted with a fluorine atom or chlorine atom and all available atoms are optionally substituted with alternate isotope thereof, 20 provided one of R11, R19, R29, R30 R34, R44 and R56 is C(O)-A’; or one of R3 and R4 is selected from X-L-A and the other of R3 and R4 is selected from H, halo, C1-6alkyl and C1-6alkoxy provided A is not H, C1-6alkyl or C1-6alkeynyl when X and L are both direct bonds. 49. The compound of claim 1 selected from: Compound I.D. Chemical Structures I-1
I-44 I-45 I-46 (R)-I-47 (R)-I-48 (R)-I-49 (R)-I-50 (R)-I-51
(R)-I-52 (S)-I-53 (R)-I-53 (R)-I-54 (R)-I-55 (R)-I-56 (R)-I-57 (S)-I-57
(R)-I-58 (R)-I-59 (R)-I-60 (R)-I-61 (R)-I-62 (R)-I-63 (R)-I-64 (R)-I-65 (R)-I-66
(R)-I-67 (R)-I-68 (R)-I-69 (R)-I-70 (R)-I-71 (R)-I-72 (R)-I-73 (R)-I-74
(R)-I-75 (R)-I-76 (R)-I-77 (R)-I-78 (R)-I-79 (R)-I-80 (R)-I-81 (R)-I-82 (R)-I-83
(R)-I-84 (R)-I-85 (R)-I-86 (R)-I-87 (R)-I-88 (R)-I-89 (R)-I-90 (R)-I-91 (R)-I-92
(R)-I-93 (R)-I-94 (R)-I-95 (R)-I-96 (R)-I-97 (R)-I-98 (R)-I-99 (R)-I-100
(R)-I-101 (R)-I-102 (R)-I-103 (R)-I-104 I-105 I-106 I-107
I-108 I-109 I-110 (R)-I-111 (S)-I-111 (R)-I-112 I-113
I-114 (S)-I-115 (S)-I-116 (S)-I-117 (R)-I-118 I-119
(R)-I-120.HCl .HCl, and (R)-I-121.HCl .HCl or a pharmaceutically acceptable salt, solvate and/or prodrug thereof. 50. A compound selected from compound 12 and compound 16, 12 and 16 or a pharmaceutically acceptable salt, solvate and/or prodrug thereof. 51. A composition comprising one or more compounds of any one of claims 1 to 50 and a carrier. 5 52. A pharmaceutical composition comprising one or more compounds of any one of claims 1 to 50 and pharmaceutically acceptable carrier. 53. A composition comprising one or more compounds of any one of claims 1 to 50 and one or more components of a nano-carrier system. 54. The composition of claim 51, wherein the nano-carrier system is selected from 10 liposomes, micelles, nanoparticles, nano-emulsions and lipidic nano-systems. 55. A method of treating a disease, disorder or condition by activation of a serotonin receptor comprising administering a therapeutically effective amount of one or more compounds of any one of claims 1 to 50 to a subject in need thereof.
56. A method of treating a mental illness comprising administering a therapeutically effective amount of one or more compounds of any one of claims 1 to 49 to a subject in need thereof. 57. The method of claim 56, wherein the mental illness is selected from anxiety disorders; depression; mood disorders; psychotic disorders; impulse control and addiction disorders; drug addiction; obsessive-compulsive disorder (OCD); post-traumatic stress disorder 5 (PTSD); stress response syndromes; dissociative disorders; depersonalization disorder; factitious disorders; sexual and gender disorders; and somatic symptom disorders and combinations thereof. 58. A method of treating psychosis or psychotic symptoms comprising administering a therapeutically effective amount of one or more compounds of any one of claims 1 to 50 to 10 a subject in need thereof. 59. A method of treating a CNS disease, disorder or condition and/or a neurological disease, disorder or condition comprising administering a therapeutically effective amount of one or more compounds of any one of claims 1 to 50 to a subject in need thereof. 60. The method of claim 59, wherein the CNS disease, disorder or condition and/or a 15 neurological disease, disorder or condition is selected from neurological diseases including neurodevelopmental diseases and neurodegenerative diseases such as Alzheimer’s disease; presenile dementia; senile dementia; vascular dementia; Lewy body dementia; cognitive impairment, Parkinson’s disease and Parkinsonian related disorders such as Parkinson dementia, corticobasal degeneration, and supranuclear palsy; epilepsy; CNS 20 trauma; CNS infections; CNS inflammation; stroke; multiple sclerosis; Huntington’s disease; mitochondrial disorders; Fragile X syndrome; Angelman syndrome; hereditary ataxias; neuro-otological and eye movement disorders; neurodegenerative diseases of the retina amyotrophic lateral sclerosis; tardive dyskinesias; hyperkinetic disorders; attention deficit hyperactivity disorder and attention deficit disorders; restless leg syndrome; Tourette's 25 syndrome; schizophrenia; autism spectrum disorders; tuberous sclerosis; Rett syndrome; cerebral palsy; disorders of the reward system including eating disorders such as anorexia nervosa (“AN”) and bulimia nervosa (“BN”); and binge eating disorder (“BED”), trichotillomania, dermotillomania, nail biting; migraine; fibromyalgia; and peripheral neuropathy of any etiology, and combinations thereof. 30 61. A method of treating a behavioral problem comprising administering a therapeutically effective amount of one or more compounds of any one of claims 1 to 50 to a non-human subject in need thereof.
62. The method of claim 61, wherein the non-human subject is a canine or feline suffering from neurological diseases, behavioral problems, trainability problems and/or a combination thereof. 63. The method of claim 62, wherein the neurological diseases, behavioral problems, trainability problems are selected from anxiety, fear, stress, sleep disturbances, cognitive 5 dysfunction, aggression, excessive noise making, scratching, biting, and/or a combination thereof. 64. A method of treating a disease, disorder or condition by activation of a serotonin receptor comprising administering a therapeutically effective amount of one or more compounds of any one of claims 1 to 50 in combination with another known agent useful for treatment of a 10 disease, disorder or condition by activation of a serotonin receptor to a subject in need thereof. 65. A pharmaceutical composition comprising a compound of any one of claims 1 to 50 and an additional therapeutic agent. 66. The pharmaceutical composition of claim 65, wherein the additional therapeutic agent is 15 a psychoactive drug.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263401856P | 2022-08-29 | 2022-08-29 | |
US63/401,856 | 2022-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024044848A1 true WO2024044848A1 (en) | 2024-03-07 |
Family
ID=90100091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2023/051144 WO2024044848A1 (en) | 2022-08-29 | 2023-08-29 | Indazole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024044848A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998030548A1 (en) * | 1997-01-13 | 1998-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | 5-HT2c RECEPTOR AGONISTS AND AMINOALKYLINDAZOLE DERIVATIVES |
WO2000038677A1 (en) * | 1998-12-23 | 2000-07-06 | Allelix Biopharmaceuticals Inc. | Indole and indolizidine derivatives for the treatment of migraine |
WO2013085957A1 (en) * | 2011-12-06 | 2013-06-13 | Janssen Pharmaceutica Nv | Substituted piperidinyl-pyridazinyl derivatives useful as scd 1 inhibitors |
CA2869143A1 (en) * | 2012-04-10 | 2013-10-17 | Sumitomo Dainippon Pharma Co., Ltd. | Novel 1-substituted indazole derivative |
CN116478145A (en) * | 2022-04-13 | 2023-07-25 | 杭州邦顺制药有限公司 | ALK2 kinase inhibitors |
-
2023
- 2023-08-29 WO PCT/CA2023/051144 patent/WO2024044848A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998030548A1 (en) * | 1997-01-13 | 1998-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | 5-HT2c RECEPTOR AGONISTS AND AMINOALKYLINDAZOLE DERIVATIVES |
WO2000038677A1 (en) * | 1998-12-23 | 2000-07-06 | Allelix Biopharmaceuticals Inc. | Indole and indolizidine derivatives for the treatment of migraine |
WO2013085957A1 (en) * | 2011-12-06 | 2013-06-13 | Janssen Pharmaceutica Nv | Substituted piperidinyl-pyridazinyl derivatives useful as scd 1 inhibitors |
CA2869143A1 (en) * | 2012-04-10 | 2013-10-17 | Sumitomo Dainippon Pharma Co., Ltd. | Novel 1-substituted indazole derivative |
CN116478145A (en) * | 2022-04-13 | 2023-07-25 | 杭州邦顺制药有限公司 | ALK2 kinase inhibitors |
Non-Patent Citations (1)
Title |
---|
PAGANO M A, ET AL: "The selectivity of inhibitors of protein kinase CK2: an update", BIOCHEMICAL JOURNAL, PUBLISHED BY PORTLAND PRESS ON BEHALF OF THE BIOCHEMICAL SOCIETY., GB, vol. 415, no. 3, 1 November 2008 (2008-11-01), GB , pages 353 - 365, XP002579522, ISSN: 0264-6021, DOI: 10.1042/BJ20080309 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11591353B2 (en) | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | |
US11453689B2 (en) | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | |
CA3229361A1 (en) | 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto | |
US20240166630A1 (en) | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto | |
WO2024044848A1 (en) | Indazole derivatives as serotonergic agents useful for the treatment of disorders related thereto | |
CA3201080A1 (en) | 3-cyclic amine-indole derivatives as serotonergic agents for the treatment of cns disorders | |
WO2024044847A1 (en) | Indoline derivatives as serotonergic agents useful for the treatment of disorders related thereto | |
WO2024026573A1 (en) | 3-ethylamino-indole dimers as serotonergic agents useful for the treatment of disorders related thereto | |
WO2024026574A1 (en) | 3-pyrrolidine-indole dimers as serotonergic agents useful for the treatment of disorders related thereto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23858491 Country of ref document: EP Kind code of ref document: A1 |